

CURRICULUM VITAE

ALEXANDER G.G. TURPIE

MB, FRCP (Glasg., Lond.), FACP, FACC, FRCPC

Professor of Medicine

McMaster University

Hamilton, Ontario, Canada

and

Internist

Hamilton Health Sciences - General Hospital

Hamilton, Ontario, Canada

Business Address:
Hamilton Health Sciences, General Hospital
237 Barton Street East
Hamilton, Ontario, Canada
L8L 2X2
Telephone: (905) 528-9946
Fax: (905) 521-1551
e-mail: turpiea@mcmaster.ca

CURRICULUM VITAE

NAME: Alexander Graham Grierson Turpie

HOME ADDRESS: 1127 Sulphur Springs Road, Dundas, ON, Canada L9H 5R3

TELEPHONE: (905) 628-4534

BUSINESS ADDRESS: McMaster Clinic, Hamilton Health Sciences
General Hospital, 237 Barton Street East, Hamilton,
Ontario, Canada L8L 2X2

BUSINESS TELEPHONE: (905) 527-1710/(905) 528-9946
(905) 527-0271 extension 4484, 4486
(905) 521-1551 - Fax machine
turpiea@mcmaster.ca - email

DATE OF BIRTH: February 23, 1939. Glasgow, Scotland

NATIONALITY: British, Canadian Citizen

CIVIL STATUS: Married with three children

EDUCATION: University of Glasgow; Glasgow, Scotland
1956-1962

UNDERGRADUATE HONOURS: Ure Prize, Systematic Medicine,
1959
West of Scotland R.A.M.C. Memorial Prize, 1962
Macewan Medical, 1962
Herkless Prize for Clinical Surgery, 1962
Final Examination: Distinctions in Medicine
in Surgery, 1962

UNDERGRADUATE BURSARIES: William Gardiner Bursary,
1961
John McFarlane Bursary, 1962

QUALIFICATIONS: M.B., Ch.B. (with Honours)
University of Glasgow, 1962
E.C.F.M.G. Certificate, 1964

M.R.C.P. (Glasg.)
Royal College of Physicians and Surgeons
Glasgow, 1967

M.R.C.P. (Lond.)
Royal College of Physicians
London, 1969

F.R.C.P. (C)
Royal College of Physicians and Surgeons
of Canada, 1972

F.A.C.P.
American College of Physicians, 1975

F.R.C.P. (Glasg.)
Royal College of Physicians and Surgeons
Glasgow, 1976

Licentiate
Medical Council of Canada, 1976

F.R.C.P. (Lond.)
Royal College of Physicians
London, 1981

F.A.C.C.
American College of Cardiology, 1990.

F.A.H.A.
Fellow of the American Heart Association

APPOINTMENTS:

Scotland
RESIDENT HOUSE SURGEON Royal Infirmary, Glasgow,
August 1962 - January 1963

Glasgow, Scotland
RESIDENT HOUSE PHYSICIAN Stobhill General Hospital,
February 1963 - July 1963

University Medical REGISTRAR
FAULDS CLINICAL RESEARCH Department of Materia Medica
FELLOW AND MEDICAL University of Glasgow and
Unit, Stobhill General Hospital
Glasgow, Scotland
August 1963 - February 1965.

HONORARY CLINIC University of East Africa Medical School
LECTURER Extension. Kenyatta National Hospital
SENIOR REGISTRAR IN Nairobi, Kenya
MEDICINE March 1965 - March 1966 (On secondment from
University of Glasgow)
LECTURER Department of Materia Medica and
Therapeutics
University of Glasgow and University Medical
Unit, Stobhill General Hospital
May 1967 - June 1968

MEDICAL REGISTRAR
Department of Medicine, Royal Infirmary
Glasgow, Scotland
July 1968 - August 1969

SENIOR MEDICAL REGISTRAR
Department of Medicine, Royal Infirmary
Glasgow, Scotland
August 1969 - February 1972

(From October 1970 - on leave of absence)

POST DOCTORAL FELLOW Canadian Medical Research Council
Department of Pathology, McMaster University
Hamilton, Ontario
October 1970 - December 1972

ASSISTANT PROFESSOR
Department of Medicine, McMaster University
Hamilton, Ontario
January 1973 - June 1978

ASSOCIATE CLINICAL Hamilton General Hospital
TEACHING UNIT January 1974 - June 1981
DIRECTOR

ASSOCIATE PROFESSOR Department of Medicine
McMaster University, Hamilton, Ontario
July 1978 - June 1983

(Acting Chief of Medicine)
Hamilton General Hospital
January 1981 - September 1981

MCFARLANE VISITING University of Glasgow
PROFESSOR Royal Infirmary
Glasgow, Scotland
January 1988 - March 1988.

PRESENT APPOINTMENT

PROFESSOR Department of Medicine
McMaster University
Hamilton, Ontario
July 1983 - present.

INTERNIST Active Staff
Hamilton Civic Hospitals
Hamilton, Ontario
January 1973 - present.

CHIEF OF MEDICINE Hamilton General Hospital
January 1985 - 1993.

EXTERNAL EXAMINER MD Examination
MB, BS Examination
University of the West Indies
June 1990 - present

LEARNED SOCIETIES Medical Research Society, London,
U.K.

Canadian Society for Clinical Investigation

International Society on Thrombosis and

Hemostasis

Central Society for Clinical Research

American Federation for Clinical Research

Canadian Cardiovascular Society

COMMITTEES Member, Scientific Review Committee
Canadian Heart Foundation
1978 - 1983

Member, Examination Board in Internal Medicine
Royal College of Physicians and Surgeons
1982 - 1988

Chairman, Hamilton Civic Hospitals Research
and Ethics Committee
1982 - 1987

Member, Hamilton Civic Hospitals Institutional
Review Board
1973 - present

Member, Hamilton Civic Hospitals Education
Committee
1976 - 1982

Member, Department of Medicine Education
Committee
McMaster University
1975 - 1982

Member, Department of Medicine Resident
Appointments Committee
1975 - present

Member, Hamilton Civic Hospitals Redevelopment
Committee
1977 - present

Member, Committee for Scientific Development
McMaster University
1981 - 1986

Member, Presidents Ethics Committee
McMaster University
1976 - 1987

Elected Member, Board of Management
Regional Medical Associates
1977 - 1978

Elected Member, Department of Medicine
Executive Committee, McMaster University
1976 - 1978

Elected Member, Promotions and Tenure
Committee, Department of Medicine
McMaster University
1978 - 1980.

Member, Department of Medicine Executive
Committee
1981 - 1989

Elected Member, Faculty of Health Sciences
Appointments Committee
1984 - 1986

Elected Member, Faculty of Health Sciences
Promotions and Tenure Committee
1984 - 1988

Member, Hamilton General Hospital
Planning Subcommittee
1982 - present

Member, Medical Staff Advisory Committee
Hamilton General Hospital
1982-present

Member, Special Review Committee
NIH
1988 - present

Elected Member, Senate
McMaster University
1988 - present

Member, Editorial Advisory Committee
Touchstone - Journal of the
Hamilton Civic Hospitals
1986 - present

Elected Member
The Committee of Honorary Degrees
1991

Appointed Member
Senate Committee on Honorary Degrees
1992

Member
Thrombosis Interest Group (Canada)
1990 - present

Member
Thrombosis Forum
1990 - present

Member
Anticoagulation Forum
1990 - present

Member
Asociacion Colombiana de Angiologia y
Cirugia Vasular
2002

Honorary Member
Korean Society of Phlebology
2002

JOURNAL REVIEWER

Annals of Internal Medicine
Circulation
Thrombosis Research
Canadian Medical Association Journal
New England Journal of Medicine
Clinical and Investigative Medicine
Atherosclerosis
Thrombosis and Haemostasis
Drugs

EDITORIAL BOARD

Vascular Medicine Review
Blood Coagulation and Fibrinolysis
Acute Coronary Syndromes
HeartDrug (Co-editor)

PUBLICATIONS

1. Turpie AGG, Thomson TJ: Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side effects. *Gut* 6:591-594, 1965.
2. Forbes CD, Turpie AGG, McNicol GP: The anticoagulant action of puff adder (B. Arietans) venom. *East African Medical Journal* 42:566-574, 1965.
3. Forbes CD, Turpie AGG, McNicol GP: Enhancement of the activity of optimum concentrations of urokinase by the venom of *Echis Carinata*. *Nature* 211:989-990, 1966.
4. Forbes CD, Turpie AGG, McNicol GP, Douglas AS: Studies on East African Snakes: mode of action of *Echis Carinatus* venom. *Scottish Medical Journal* 11:168-175, 1966.
5. Forbes CD, Turpie AGG: A simple method of urea estimation. *East Africa Medical Journal* 44:163-168, 1967.
6. Turpie AGG, Forbes CD, McNicol GP: Idiopathic gangrene in African children. *British Medical Journal* 3:646-648, 1967.
7. Turpie AGG: Platelets and Thrombosis. *Scottish Medical Journal* 13:430-433, 1968.
8. Forbes CD, Turpie AGG, Ferguson JG, McNicol GP, Douglas AS: The effect of gaboon viper (*Bitis Gabonica*) venom on blood coagulation, platelets and the fibrinolytic enzyme system. *Journal of Clinical Pathology* 22:312-316, 1969.
9. Prentice CRM, Turpie AGG, Hassanein AA, McNicol GP, Douglas AS: Changes in platelet behaviour during Arvin therapy. *Lancet* i:644-647, 1969.
10. Turpie AGG, Runcie J, Thomson TJ: Clinical trial of deglycyrrhizinised liquorice in gastric ulcer. *Gut* 10:299-302, 1969.
11. Hassanein AA, Turpie AGG, McNicol GP, Douglas AS: Effect of RA 233 on platelet function in vitro. *British Medical Journal* 2:83-86, 1970.
12. McDougall AI, Addis GJ, Turpie AGG, MacArthur JG: Treatment of hypertension with Clonidine. *British Medical Journal* 3:440-442, 1970.
13. Turpie AGG, Prentice CRM, McNicol GP, Douglas AS: In vitro studies with Ancrod (Arvin). *British Journal of Hematology* 20:217-224, 1971.
14. Hassanein AA, Turpie AGG, McNicol GP, Forbes CD, Douglas AS: Action of pyrimido-pyrimidine compounds on platelet behaviour in vitro. Platelet adhesion and aggregation in thrombosis. Countermeasures. FK Shattauer, Verlag-Stuttgart, New York, 1971.
15. Turpie AGG, McNicol GP, Douglas AS: Platelet electrophoresis: effect of defibrination by Ancrod (Arvin). *Cardiovascular Research* 6:101-108, 1972.
16. Slater SD, Turpie AGG, Douglas AS, McNicol GP: Effect in vitro on platelet function on two compounds developed from the pyrimido-pyrimidines. *Journal of Clinical Pathology* 25:427-432, 1972.
17. Prentice CRM, Turpie AGG, McNicol GP, Douglas AS: Urokinase therapy: dosage schedules and coagulant side effects. *British Journal of Hematology* 22:567-577, 1972.

18. Turpie AGG, Chernesky MA, Larke RPB, Packham MA, Mustard JF: Effect of Newcastle disease virus on human or rabbit platelets. Aggregation and loss of constituents. *Laboratory Investigation* 28:575-583, 1973.
19. Chernesky MA, Larke RPB, Turpie AGG: Interaction between viruses and platelets. Requirement of haemolytic activity for platelet aggregation induced by paramyxoviruses. *Journal of General Virology* 21:205-213, 1973.
20. Gallus AS, Hirsh J, Cade JF, Turpie AGG, Walker IR, Gent M: Thrombolysis with a combination of small doses of streptokinase and small doses of heparin. *Seminars in Thrombosis and Haemostasis* 2:14-32, 1975.
21. Hull R, vanAken WG, Hirsh J, Gallus AS, Hoicka G, Turpie AGG, Walker IR, Gent M: Impedance plethysmography using the occlusive cuff technique in the diagnosis of venous thrombosis. *Circulation* 53:696-700, 1976.
22. Turpie AGG, Gallus AS, Beattie WS, Hirsh J: Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. *Neurology* 5:435-438, 1977.
23. Hull R, Hirsh J, Sackett DL, Powers P, Turpie AGG, Walker I: Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. *The New England Journal of Medicine* 296:1497-1500, 1977.
24. Larke RPB, Turpie AGG, Scott S, Chernesky MA: Paramyxovirus-induced platelet aggregation. Requirement for neuraminic acid receptors on platelets. *Laboratory Investigation* 37:150-157, 1977.
25. Turpie AGG, Hirsh J: Antiplatelet drugs: Their role in prevention of atherosclerosis. *Modern Medicine* 50-57, 1977.
26. Turpie AGG: La Pathogenie des Thromboses. *L'Union Medicale du Canada*, 107:151-161, 1978.
27. Turpie AGG: Les Methodes Physiques de Prevention des Thrombo-Embolies Veineuses. *L'Union Medicale du Canada* 107:227-231, 1978.
28. Turpie AGG, Hirsh J: Platelet suppressant therapy. *British Medical Bulletin* 34:183-190, 1978.
29. Hull R, Taylor DW, Hirsh J, Sackett DL, Powers P, Turpie AGG, Walker I: Impedance plethysmography. The relationship between venous filling and sensitivity and specificity for proximal vein thrombosis. *Circulation* 58:898-902, 1978.
30. Turpie AGG, Hirsh J: Prophylaxis and therapy of venous thromboembolism. *Critical Reviews in Clinical Laboratory Science* 10:247-274, 1979.
31. Hull R, Hirsh J, Sackett DL, Powers P, Turpie AGG, Walker I, McBride J: The value of adding impedance plethysmography to ¹²⁵I-fibrinogen leg scanning for the detection of deep vein thrombosis in high risk surgical patients: A comparative study between patients undergoing general surgery and hip surgery. *Thrombosis Research* 15:227-234, 1979.
32. Turpie AGG, Hirsh J: When and how to use heparin prophylaxis and treatment. *Geriatrics* 34:59-70, 1979.
33. Turpie AGG, Hirsh J: Heparin. *Nova Scotia Medical Bulletin*, 58:25-29, 1979.

34. Turpie AGG, Delmore T, Hirsh J, Hull R, Genton E, Hiscoe C, Gent M: Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. *Thrombosis Research* 15:611-616, 1979.
35. Han P, Turpie AGG, Genton E: Plasma B-thromboglobulin: Differentiation between intravascular and extravascular platelet destruction. *Blood* 54:1192-1196, 1979.
36. Turpie AGG, Hirsh J: Venous thrombosis and pulmonary embolism: Guide to detection and prevention. (Part I) *Hospital Medicine* 1:32-47, 1980.
37. Turpie AGG, Hirsh J: Venous thrombosis and pulmonary embolism: Guide to detection and prevention. (Part II) *Hospital Medicine* 2:22-34, 1980.
38. Han P, Butt RW, Turpie AGG, Walker WHC, Genton E: B-thromboglobulin radioimmunoassay - A laboratory characterization and evaluation. *The Journal of Radioimmunoassay* 1 (2):211-227, 1980.
39. deBoer AC, Butt R, Turpie AGG, Genton E: The use of the evacuated blood collection tube in the determination of plasma betathromboglobulin. *Thrombosis Research* 20:693-695, 1980.
40. Hull R, Hirsh J, Sackett DL, Taylor DW, Carter C, Turpie AGG, Zielinsky A, Powers P, Gent M: Replacement of venography in suspected venous thrombosis with impedance plethysmography and ¹²⁵I-fibrinogen leg scanning: A less invasive approach. *Annals of Internal Medicine* 94:12-15, 1981.
41. Turpie AGG: The effectiveness of drugs that modify platelet function in peripheral venous thrombosis and pulmonary embolism. (Proceedings of the First World Conference) *Clinical Pharmacology and Therapeutics* 224-233, 1981.
42. Hirsh J, Turpie AGG, Kelton J, Hull R, Carter C: Unresolved issue in the use of heparin for management of venous thromboembolism. *Chemistry and Biology of Heparin*. Lundblat RL, Brown WV, Mann KG, Roberts HR (eds) Elsevier North Holland Inc. New York 513-528, 1981.
43. deBoer AC, Han P, Turpie AGG, Butt R, Zielinsky A, Genton E: Plasma and urine betathromboglobulin concentration in patients with deep vein thrombosis. *Blood* 58:693-698, 1981.
44. Zielinsky A, Hirsh J, Straumanis A, Carter C, Gent M, Sackett DL, Hull R, Kelton JG, Powers P, Turpie AGG: The diagnostic value of fibrinogen/fibrin Fragment E assay in clinically suspected deep vein thrombosis. *Blood* 59:346-350, 1982.
45. Turpie AGG: Antiplatelet therapy. *Clinics in Haematology* 10 (2):497-520, 1981.
46. Hull R, Hirsh J, Sackett DL, Taylor DW, Carter C, Turpie AGG, Powers P, Gent M: Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. *Circulation* 64 (3):622-625, 1981.
47. Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, Turpie AGG, McLaughlin D: Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis. *New England Journal of Medicine* 306 (4):189-234, 1982.
48. deBoer AC, Turpie AGG, Butt RW, Duke RJ, Bloch RF, Genton E: Plasma betathromboglobulin and serum Fragment E in acute partial stroke. *British Journal of Haematology* 50:327-334, 1982.
49. deBoer AC, Genton E, Turpie AGG: Chemistry, measurement and clinical significance of platelet specific proteins. *C.R.C. Critical Reviews* 18 (2):183-211, 1982.

50. deBoer AC, Turpie AGG, Butt RW, Johnston RV, Genton E: Platelet release and thromboxane synthesis in symptomatic coronary artery disease. *Circulation* 66:327-333, 1982.
51. Turpie AGG, deBoer AC, Genton E: Platelet consumption in cardiovascular disease. *Seminars in Thrombosis and Hemostasis* 8:157-181, 1982.
52. Rosenfeld J, Devereaux D, Buchanan MR, Turpie AGG, High-performance liquid chromatographic determination of dipyridamole. *Journal of Chromatography* 231:216-221, 1982.
53. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AGG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P: Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. *New England Journal of Medicine* 307:1676-1681, 1982.
54. Buchanan MR, Rischke JA, Butt RW, Turpie AGG, Hirsh J, Rosenfeld J: The sex related differences in platelet function and aspirin pharmacokinetics in rabbits and man. *Thrombosis Research* 29:125-129, 1983.
55. deBoer AC, Han P, Turpie AGG, Butt RW, Gent M, Genton E: Platelet tests and antiplatelet drugs in coronary artery disease. *Circulation* 67:500-504, 1983.
56. Hull R, Carter C, Jay R, Ockelford P, Hirsh J, Turpie AGG, Zielinsky A, Gent M, Powers P: The diagnosis of acute recurrent deep vein thrombosis. A diagnostic challenge. *Circulation* 67:901-906, 1983.
57. Duke RJ, Turpie AGG, Bloch RF, Trebilcock RG: Natural history of acute partial stroke and stroke-in-evolution: A clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression. *Cerebrovascular Diseases* 399-405, 1983.
58. Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, Coates G, Gill GJ, Turpie AGG, Doyle DJ, Buller HR, Raskob GE: Pulmonary angiography, ventilation lung scanning and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. *Annals of Internal Medicine* 98:891-899, 1983.
59. Rosenfeld J, Buchanan MR, Reilly PA, Turpie AGG: Dipyridamole disposition after chronic administration: Effect of aspirin. *Thrombosis Research (Supp 14)*:137-143, 1983.
60. Genton E, Turpie AGG: Anticoagulant therapy following acute myocardial infarction. *Modern Concepts of Cardiovascular Disease* 52 (9):45-48, 1983 September (Part I).
61. Genton E, Turpie AGG: Anticoagulant therapy following acute myocardial infarction. *Modern Concepts of Cardiovascular Disease* 52 (10):49-51, 1983 October (Part II).
62. Kelton JG, Brain H, Sheridan D, Powers PJ, Turpie AGG, Carter CJ: The clinical usefulness of testing for a heparin-dependent platelet aggregating factor in patients with suspected heparin-associated thrombocytopenia. *Journal of Laboratory and Clinical Medicine* 103 (4):607-612, 1984.
63. Turpie AGG, Gent M, deBoer AC, Giroux M, Kinch D, Butt R, Gunstensen J, Saerens E, Genton E: Effect of suloctidil on platelet function in patients with shortened platelet survival time. *Thrombosis Research* 35:397-406, 1984.

64. Jay R, Hull R, Carter C, Ockelford P, Buller H, Turpie AGG, Hirsh J: Outcome of abnormal impedance plethysmography results in patients with proximal vein thrombosis. Frequency of return to normal. *Thrombosis Research* 36:259-263, 1984.
65. Turpie AGG, Hirsh J: Venous thromboembolism: Current Concepts (Part I) *Hospital Medicine* 151-166, October 1984.
66. Turpie AGG, Hirsh J: Venous thromboembolism: Current Concepts (Part II) *Hospital Medicine* 13-41, November 1984.
67. Butt RW, deBoer AC, Turpie AGG, Evaluation of a commercial kit for the radioimmunoassay of fibrinopeptide A. *Journal of Immunoassay* 5 (3 & 4):245-266, 1984.
68. Turpie AGG, Gent M, Doyle DJ, Saerens E, deBoer AC, Talbot C, McNamee J, Hirsh J: An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients. *Thrombosis Research* 39:173-181, 1985.
69. Gent M, Blakely JA, Hachinski V, Roberts RS, Barnett HJM, Bayer NH, Carruthers SG, Collins SM, Gowel MG, Giroux-Klimek M, Hopkins MB, Jain P, Lamy M, Meloche JP, Saerens E, Sicurella J, Turpie AGG: A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. *Stroke* 16 (3):416-424, 1985.
70. Hull RD, Hirsh J, Carter CJ, Jay RM, Ockelford P, Buller H, Turpie AGG, Powers P, Kinch D, Dodd P, Gill GJ, LeClerc JR, Gent M: Diagnostic efficacy of impedance plethysmography for clinically suspected deep vein thrombosis. *Annals of Internal Medicine* 102 (1):21-28, 1985.
71. Turpie AGG: Platelet release proteins. *Laboratory Management* 23 (8):43-51, 1985.
72. Turpie AGG: Thrombolytic therapy in myocardial infarction. *Perspectives in Cardiology* 2 (2):46-51, 1986.
73. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay R, Powers P, Andrew M, Hull R, Gent M: A randomized controlled trial of PK 10169 low-molecular weight heparin (Enoxaparin) for the prevention of deep vein thrombosis in patients undergoing elective hip surgery. *New England Journal of Medicine* 315 (15):925-929, 1986.
74. Turpie AGG, Levine MN, Hirsh J: Response to "Letter to the Editor" *New England Journal of Medicine* 316 (15):pp 949, 1987.
75. Duke RJ, Bloch RF, Turpie AGG, Trebilcock R, Bayer N: Intravenous heparin for the prevention of stroke progression in acute partial stable stroke: A randomized controlled trial. *Annals of Internal Medicine* 105:825-828, 1986.
76. Duke RJ, Bloch RF, Turpie AGG: Response to "Letter to the Editor", *Annals of Internal Medicine* 106:781-782, 1987.
77. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani HN, Hull RD, Gent M: A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep vein thrombosis in patients with thrombotic stroke. *Lancet* i:523-526, 1987.
78. Buchanan MR, Butt RW, Turpie AGG: Effect of Nafazatrom on platelet function and release: Relationship to symptomatic episodes in patients with peripheral vascular disease. *American Heart Journal* 113 (5):1033-1137, 1987.
79. Doyle DJ, Turpie AGG, Hirsh J, Best C, Kinch D, Levine MN, Gent M: A randomized trial of adjusted subcutaneous heparin versus continuous intravenous heparin in patients with acute deep vein thrombosis. *Annals of Internal Medicine* 107 (4):441-445, 1987.

80. Turpie AGG: Clinical Studies: Evidence for intervention with specific antiplatelet drugs in arterial thromboembolism. *Seminars in Thrombosis and Hemostasis* 14 (1):41-49, 1988.
81. Turpie AGG: Recent advances in thrombolytic therapy. *Ontario Medicine*, pp. 8, February 1988.
82. Turpie, AGG: Subcutaneous versus continuous intravenous heparin for deep vein thrombosis. *Cardiology Board Review*, 5 (7) 103-114, 1988.
83. Turpie AGG: The relationship between ex-vivo anti-Factor Xa levels and efficacy/safety of low molecular weight heparin. *Br J of Clin Practice* 43 (1) Supp 65:18-25, 1988.
84. Turpie AGG, Hirsh J, Gent M, Julian D, Johnson J: Prevention of deep vein thrombosis in potential neurosurgical patients: A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. *Archives of Internal Medicine* 149:679-681, 1989.
85. Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M: A randomized trial comparing two intensities of oral anticoagulant therapy following tissue heart valve replacement. *Lancet* i:1242-1245, 1988
86. ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Journal of the American College of Cardiology* 12 (6): 3A-12A, 1988.
87. Turpie AGG: Low molecular weight heparins: Deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. *Acta Chir Scand Suppl* 543:85-86, 1988.
88. ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* ii:349-360, 1988.
89. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Streptokinase for Acute Myocardial Infarction: Results and Implications of the Major Clinical Studies. Proceedings of a satellite symposium held in Vienna, Austria, P. Sleight (ed) August 31, 1988. pp 51-73.*
90. M. Gent, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, J. Sicurella J, Turpie AGG: The Canadian American Ticlopidine Study (CATS) in Thromboembolic Stroke. *Stroke* 19 (10):1203-1210, 1988
91. Turpie AGG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA, Hirsh J, Skingley L, Gent M: Prevention of left ventricular mural thrombosis in acute transmural anterior myocardial infarction: A double blind trial comparing high dose with low dose subcutaneous calcium heparin. *N Engl J Med* 320 (6):352-357, 1989.
92. Turpie AGG, Gent M, Hirsh J: Letter to the Editor, *N Engl J Med* 321:259-260, 1989.
93. Powers PJ, Gent M, Jay R, Julian D, Turpie AGG, Levine MN, Hirsh J: A randomized trial of post-operative less-intense warfarin or acetylsalicylic acid in the prevention of venous thromboembolism after surgery for fractured hip. *Archives of Internal Medicine*, 149 (4):771-774, 1989.

94. Turpie AGG, Bloch R, Duke R: Heparin in the treatment of thromboembolic stroke. *Annals of New York Academy of Sciences* 556:406-415, 1989.
95. Dormandy J, Mahir M, Ascady G, Balsano F, DeLeeuw P, Blombery P, Bousser MG, Clement D, Coffman J, Deutshinoff A, Bletry O, Hampton J, Mahler F, Ohlin P, Rieger H, Stranden E, Turpie AGG, Urai L, Verstraete M: Fate of the patient with chronic leg ischaemia. A review article. *J of Cardiovasc Surg* 30 (2): 50-57, 1989.
96. Prevention of Atherosclerotic Complications with Ketanserin Trial Group: Prevention of atherosclerotic complications: controlled trial of ketanserin. *Brit J Med* 298:424-430, 1989.
97. Turpie AGG: Thrombolytic therapy. *Medicine, North America* 30: 5549-5554, 1989.
98. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG and the CATS Group. The Canadian American Ticlopidine Study (CATS) in Thromboembolic Stroke. *Lancet* i:1215-1220, 1989.
99. Turpie AGG: Examining the role of anticoagulants in post-AMI. *Perspectives in Cardiology* 5 (5):31-41, 1989.
100. Turpie AGG: Therapy of deep vein thrombosis. *Herz (Kardiovaskulare Erkankungen)* 14 (6) 341-347, 1989.
101. Ginsberg JS, Shin A, Turpie AGG, Hirsh J: Detection of previous proximal venous thrombosis with doppler ultrasonography and photoplethysmography. *Archives of Internal Medicine* 149:2255-2257, 1989.
102. Cruickshank MK, Levine MN, Hirsh J, Turpie AGG, Powers P, Jay R, Gent M: An evaluation of impedance plethysmography and ¹²⁵I-fibrinogen leg scanning in patients following hip surgery. *Thrombosis and Haemostasis* 62 (3) 830-834, 1989.
103. Turpie AGG, Robinson JG, Doyle DD, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA, Skingley L, Hirsh J, Gent M: Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. *N Engl J Med* 320:352-357, 1989.
104. Turpie AGG, Hirsh J, Gent M, Julian D, Johnson J: Prevention of deep vein thrombosis in potential neurosurgical patients. *Arch of Int Med* 149:679-681, 1989.
105. Turpie AGG: Prevention of left ventricular mural thrombosis. *Am J Cardiol* 64:41B-43B, 1989.
106. Turpie AGG: Anticoagulant therapy after acute myocardial infarction. *Am J of Cardiol* 65:20C-23C, 1990.
107. Turpie AGG, Levine MN, Hirsh J, Ginsberg JS, Cruickshank M, Jay R, Gent M: Tissue plasminogen activator (rt-PA) versus heparin in deep vein thrombosis: results of a randomized trial. *Chest* 97: 172S-175S, 1990.
108. Levine MN, Weitz J, Turpie AGG, Andrew M, Cruickshank M, Hirsh J: A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. *Chest* 97: 168S-171S, 1990.
109. Turpie AGG: Thrombolytic agents in venous thrombosis. *J of Vasc Surg* August: 196-197, 1990.

110. Turpie AGG: Enoxaparin prophylaxis in elective hip surgery. *Acta Chirurgica Scandinavica* 156 (Supp 556) 1990.
111. Turpie AGG: Low-dose or high-dose heparin to prevent left ventricular mural thrombosis. *LeMonde Medical Magazine* 25-29, 1990.
112. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AGG, Gent M: A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. *Chest* 98 (6) 1473-1479, 1990.
113. Hirsh J, Turpie AGG: Use of plasminogen activators in venous thrombosis. *World J of Surg* 14: 688-693, 1990.
114. Turpie AGG: Thrombolytic agents in venous thrombosis. *J of Vasc Surg* 12: 196-197, 1990.
115. Levine MN, Hirsh J, Gent M, Turpie AGG et al: Prevention of deep vein thrombosis in patients undergoing elective hip surgery: A randomized trial comparing Enoxaparine low molecular weight heparin with standard unfractionated heparin. *Annals of Int Med* 114 (7) 545-551, 1991.
116. Turpie AGG: Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. *Am J of Surg* 161:532-536, 1991.
117. Prins MH, Turpie AGG: Clinical and laboratory diagnosis of deep vein thrombosis: current status. *Current Medical Literature - Thrombosis (Scientific and Clinical Perspectives)* 1: (3) 67-74, 1991.
118. Turpie AGG: Atrial Fibrillation: Helping patients get into the rhythm of life. *Perspectives in Cardiology* March: 41-48, 1991.
119. Connolly S, Laupacis A, Gent M (for the CAFA Study Coinvestigators): Canadian Atrial Fibrillation Anticoagulation (CAFA Study). *JACC* 18 (2):349-355, 1991.
120. ISIS-4 Collaborative Group: Fourth International Study of Infarct Survival: Protocol for a large simple study of the effects of oral mononitrate, of oral captopril and of intravenous magnesium. *Am J of Cardiol* 68:87D-100D, 1991.
121. ISIS-3: Third International Study of Infarct Survival Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. *The Lancet* 339:753-781, 1992.
122. Turpie AGG: Orgaran in the prevention of deep vein thrombosis in stroke patients. *Haemostasis* 22:92-98, 1992.
123. Turpie AGG, Gent M, Cote R, Levine MN, Ginsberg JS, Powers PJ, Leclerc J, Geerts W, Jay R, Neemeh J, Klimek M, Hirsh J. A low-molecular weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. *Annals of Internal Medicine* 117 (5):353-357, 1992.
124. European Consensus Group. Prevention of venous thromboembolism. *International Angiology* 11 (3)151:159, 1992.
125. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. *Chest (Suppl)* 102 (4):445S-455S, 1992.

126. Stein PD, Dalen JE, Goldman S, Schwartz L, Turpie AGG, Theroux P: Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts following percutaneous transluminal coronary angioplasty. *Chest (Suppl)* 102 (4):508S-515S, 1992.
127. Turpie A, Graham G, Rosenbloom David: Ticlopidine: A new antiplatelet agent for stroke prevention. *Pharmacy Times* 69-79, September 1992.
128. Turpie AGG: Heparin alternative called efficacious to stop thrombosis. *Anesthesiology News*, pp 1 and 26, 1992.
129. Turpie AGG: Ischemic heart disease and anticoagulants. *Medicine, North America* 4719-4724, 1992.
130. Turpie AGG: Thromboprophylaxis in orthopedic surgery. *Thrombosis-Clinical Practice and Perspectives* 5:1-16, 1992.
131. Turpie AGG: Long-term warfarin RX safe for elderly with atrial fibrillation. *Medical Post* March 23, 1993.
132. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. *N Engl J Med* 329:524-529, 1993.
133. Turpie AGG: Acknowledgement of Scientific Reviewers. *Cdn Med Assoc J* 149(5) pp 661, 1993.
134. Heijboer H, Buller HR, Lensing AWA, Turpie AGG, Colly LP, ten Cate, JW: A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. *New Eng J Med* 329 (19) 1365-1369, 1993.
135. Turpie AGG: Thromboprophylaxis in orthopaedic surgery. *Orthopaedics International Edition* 1 (5):396-401, 1993.
136. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *Brit Med J* 308:81-106, 1994.
137. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft of arterial patency by antiplatelet therapy. *Brit Med J* 308:159-168, 1994.
138. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *Brit Med J* 308:235-246, 1994.
139. Levine MN, Hirsh J, Gent M, Turpie AGG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. *Arch Int Med* 154:49-56, 1994.
140. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. Aspirin and warfarin after heart-valve replacement. *ACP Journal Club*, Jan/Feb, 1994.

141. Turpie AGG, Gent M, Laupacis A, Hirsh J: Warfarin and aspirin after heart-valve replacement (Letter to the Editor) *N Engl J Med* 330 (7)507-509, 1994.
142. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. *The Lancet* 343:311-322, 1994.
143. Turpie AGG: Preventing thromboembolism in patients with prosthetic heart valves. *Cardiology Clinics* 12 (3), 487-493, 1994.
144. Turpie AGG: Thrombolytic therapy in venous thrombosis and pulmonary embolism. *Fibrinolysis* 8 (1):237-244, 1994.
145. The Stile Investigators: Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. *Annals of Surgery* 220 (3) 251-268, 1994.
146. Bolus Alteplase Pulmonary Group: Reduced dose bolus Alteplase vs conventional Alteplase infusion for pulmonary embolism thrombolysis. *Chest* 106:718-724, 1994.
147. Ginsberg J, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, Levine MN, Panju AA, Powers P, Stevens P, Turpie AGG et al: Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. *Circulation* 90 (5):2385-2389, 1994.
148. Turpie AGG: Acknowledgement of Scientific Reviews. *Cdn Med Assoc J* February 15, 1995, pp 552.
149. Turpie AGG: Ticlopidine in cardiovascular and peripheral vascular conditions. Does it have a role in event prevention. A Special Report. *Proceedings of a Symposium*. February 1995, 49:52.
150. Turpie AGG. Pathogenesis, diagnosis and treatment of deep vein thrombosis. *Current Concepts in Venous Thromboembolic Disorder* 1:4-7, 1994.
151. Andrew M, Brigden M, Bormanis J, Cruickshank M, Geerts W, Giles A, Hirsh J, Hull R, Johnson J, Johnston M, Leclerc J, Mant M, Pineo G, Robinson S, Robitaille D, Rutledge Harding S, Scully MF, Turpie AG et al: INR reporting in Canadian Medical Laboratories. *Am J of Hematol* 48:237-239, 1995.
152. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. *Archives of Internal Medicine* 154:1449-1457, 1994.
153. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. *Lancet* 345 (8951):669-685, 1995.
154. Turpie AGG. The role of antiplatelet agents in cerebrovascular disease. *Consultation on Stroke* 4:1, 1995.
155. Turpie AGG. Management of deep vein thrombosis: Prevention and treatment. *P & T (Excerpta Medica)* June Supplement, 1995.
156. Turpie AGG. Anticoagulation in cardiovascular disease. Concluding remarks. *European Heart Journal* 16 (Supp D):38-39, 1995.

157. Turpie AGG. DVT prophylaxis in the outpatient setting: Preventing complications following hospital discharge. *Orthopedics* 18, July 1995.
158. Turpie AGG. Antithrombotic therapy in acute coronary ischaemia. *Biomedical Progress* 8:49-51, 1995.
159. Levine MN, Hirsh J, Gent M, Turpie AGG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemen J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. *Thrombosis and Haemostasis* 74 (2):606-611, 1995.
160. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischaemia of the lower extremity. *Annals of Surgery* 220 (3):251-268, 1995.
161. Parish S, Collins R, Peto R, Youngman L, Barton J, Jayne K, Clarke R, Appleby P, Lyon V, Cederholm-Williams S, Marshall J, Sleight P for the International Studies of Infarct Survival (ISIS) Collaborators. *British Medical Journal* 311:471-477, 1995.
162. Turpie AGG: Danger of using antithrombotics postoperatively. *Vessels* 1 (3)25-29, 1995.
163. Turpie AGG: Terapeutica antiplaquetaria en la prevencion primaria y secundaria del accidente cerebrovascular. *Revista Argentina de Cardiologia, Noviembre-Diciembre* 63 (6):597, 1995.
164. Turpie AGG: Heparina en el accidente cerebrovascular isquemico. *Revista Argentina de Cardiologia, Noviembre-Diciembre* 63 (6):601, 1995.
165. Turpie AGG, Weitz JI, Hirsh J. Advances in antithrombotic therapy: Novel agents. *Thromb & Haemost* 74 (1):565-571, 1995.
166. Connolly SJ, Turpie AGG. Antithrombotic therapy in atrial fibrillation. *The Canadian Journal of Cardiology* 12 A:17A-20A, 1996.
167. Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, Jay RM, Leclerc J, Neemeh JA, Turpie AGG. Low-molecular-weight heparinoid Orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. *Circulation* 93 (1):80-84, 1996.
168. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AGG. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. *New England Journal of Medicine* 334 (11):677-681, 1996.
169. Turpie AGG. Hirudin and thrombosis prophylaxis. *The Lancet* 347:632-633, 1996.
170. Nurmohamed MT, van Riel AM, Henkens CMA, Koopman MMW, Que GTH, d'Azemar P, Buller HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AGG, Haley S, Sicurella J, Gent M. Low molecular-weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. *Thromb & Haemost* 75 (2):233-238, 1996.
171. Levine MN, Gent M, Hirsh J, Weitz J, Turpie AG et al. Ardeparin (Low molecular weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. *Arch Intern Med* 156:851-856, 1996.

172. Turpie AGG. New therapeutic opportunities for heparins: What does low molecular weight heparin offer? *Journal of Thrombosis and Thrombolysis* 3:145-149, 1996.
173. Turpie AGG, Connolly SJ. Antithrombotic therapy in atrial fibrillation. *Canadian Family Physician* 42:1341-1345, 1996.
175. Altman R, Rouvier J, Gurfinkel E, Scazziota A, Turpie AGG. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulants. *Circulation* 94 (9) 2113-2116, 1996.
176. Kearon C, Turpie AGG. Diagnosis of deep venous thrombosis. *Thrombosis - Scientific and Clinical Perspectives. Current Medical Literature*, 6 (4):95-98 1996.
177. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *The Lancet* 348:1329-1339, 1996.
178. Turpie AGG. Prevention and treatment of venous thromboembolism. *Orthopedic (Special Edition)* 2 (2):22-25, 1996.
- 178a. Tirone ED, Gott VL, Harker LA, Miler GE, Naftel DC, Turpie AGG. Letter to the Editor. Mechanical Valves. *Annals of Thoracic Surgery* 62:1565-1570, 1996.
179. Turpie AGG. Diagnosis and treatment of deep vein thrombosis. *Surgical Technology International V*, pg 377-381, 1997.
180. Turpie AGG. Low molecular weight heparin: From the bench to the orthopaedic patient. *Orthopedics (February supplement)* 10-13, 1997.
181. Turpie AGG. Safer anticoagulant therapy heart valve replacement. Recommendations for less intense regimens. *Postgraduate Medicine* 101 (3):85-94, 1997.
182. Lensing AWA, Doris CI, MNCGrath FP, Cogo A, Sabine MJ, Ginsberg J, Prandoni P, Turpie AGG, Hirsh J. A comparison of compression ultrasound with color Doppler ultrasound for the diagnosis of symptomless postoperative deep vein thrombosis. *Archives of Internal Medicine* 157 (7):765-768, 1997.
183. Turpie AGG. Prophylaxis of venous thromboembolism in stroke patients. *Seminars in Thrombosis and Hemostasis* 23:155-157, 1997.
184. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, van der Meer J, Olaisson E, Undeland S, Ludwig K for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. *Circulation* 96 (1):61-68, 1997.
185. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmureur J, Bigonzi F. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. *N Engl J Med* 337 (7):447-452, 1997.
186. Turpie AGG. New frontiers in the management of unstable coronary artery disease. *Am J of Cardiol* 89 (5A):21E-24E, 1997.
187. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, van der Meer J, Olaisson E, Undeland S, Ludwig K for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6

- weeks in the management of unstable coronary artery disease. *Am J of Cardiol* 89 (5A):21E-24E, 1997.
188. Ginsberg JS, Kearon C, Douketis J, Turpie AGG et al. The use of D-dimer and impedance plethysmographic examinations in patients with clinical indications for deep vein thrombosis. *Arch of Intern Med* 157:1077-1081, 1997.
189. The COLUMBUS Investigators. Low molecular weight heparin in the treatment of patients with venous thromboembolism. *N Engl J Med* 337 (10):657-662, 1997.
190. Lengyel M, Fuster V, Keltai M, Roudaut R, Schulte HD, Seward JB, Chesebro JH, Turpie AGG. Guidelines for management of left-sided prosthetic valve thrombosis: A role for thrombolytic therapy. *JACC* 30 (6):1521-1526, 1997.
191. Ray JG, Turpie AGG. Survey of cardiac surgeons' perceptions of the addition of ASA to warfarin for patients with mechanical heart valves. *Canadian Journal of Cardiology* 13 (12):1162-1165, 1997.
192. Turpie AGG. Antithrombotic therapy: The expanding role of low molecular weight heparin. *Indian Heart J* 49:489-492, 1997.
193. Cogo A, Lensing AWA, Koopman MMW, Piovela F, Siragusa S, Wells PS, Villalta S, Buller HR, Turpie AGG, Prandoni P. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. *BMJ* 316:17-20, 1998.
194. Turpie AGG. Thrombolysis in prosthetic valve thrombosis: When - and for which patients? *Clinical Update. J of Critical Illness* 13 (2):132-133, 1998.
195. Turpie AGG. Antithrombotic therapy in acute non-ST segment elevation coronary ischaemia. *Cardiology Today II* (1):46-48, Jan-Feb 1998.
196. Kearon C, Julian JA, Math M et al. Noninvasive diagnosis of deep venous thrombosis. *Annals of Internal Medicine* 128 (8) 663-677, 1998.
197. Turpie AGG, Weart CW, White R. Anticoagulation; Promises and Pitfalls, *Patient Care* April 106-125, 1998
198. Caprini JA, Barie PS, Comerota AJ, Turpie AGG. Symposium: DVT prophylaxis in high risk general surgery patients. *Contemporary Surgery* 52 (4):279-298, 1998
199. ISIS-3 Collaborative Group. Comparisons of early mortality and major morbidity among 26,480 men and 9,600 women with suspected acute myocardial infarction treated with fibrinolytic therapy in the ISIS-3 study. *N Engl J Med* (accepted for publication) 1997.
200. Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AGG et al. Economic assessment of low-molecular-weight heparin (Enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE Randomized trial. *Circulation* 1998; 97:1702-1707.
201. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS for the Canadian Collaborative Group. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin. *Arch of Intern Med* 158:873, 1998.
202. Brigden M, Johnston MJ (for the Thrombosis Interest Group). INR reporting in Canadian Medical Laboratories. *Am J of Clin Path* 109 (5):589-594, 1998.

203. Campbell RWF, Wallelin L, Verheugt FWA, Turpie AGG, Maseri A, Klein W, Cleland JGF, Bode C, Becker R, Anderson J, Bertrand ME, Conti CR. Management strategies for a better outcome in unstable coronary artery disease. *Clin Cardiol* 21:314-322, 1998.
204. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. on behalf of the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both or neither. *Br Med J* 316:1337-1343, 1998.
205. Ageno W, Turpie AGG. Aspirin and ticlopidine. *Rev Soc Cardiol Estado de Sao Paulo* 7 (3):406-417, 1997.
206. Ageno W, Turpie AGG. Anticoagulation in surgical patients. *Rev Soc Cardiol Estado de Sao Paulo* 7 (3):372-382, 1997.
207. Turpie AGG. Clinical potential of antithrombotic drugs in coronary syndromes. *Am J Cardiol* 1998; 82:11L-14L.
208. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmreur J, Bigonzi F for the ESSENCE Study Group. Low-molecular-weight heparins in non-ST-segment elevation ischaemia: The ESSENCE Trial. *Am J Cardiol* 1998; 82:19S-24L.
209. Kearon C, Julian JA, Math M et al (for the McMaster Diagnostic imaging Practice Guidelines Initiative). Noninvasive diagnosis of deep venous thrombosis. *Annals of Intern Med* 128:663-677, 1998.
210. Wells PS, Ginsberg JS, Anderson DR, Kearon C, Gent M, Turpie Alexander G, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Use of a clinical model for safe management of patients with suspected pulmonary embolism. *Annals of Intern Med* 129:997-1005, 1998.
211. Johnston M, Brigden M (for the Thrombosis Interest Group of Canada). A cross-Canada survey of prothrombin time testing. *Am J Clin Path* 110:683-690, 1998.
212. Ginsberg JS, Wells P, Kearon C, Anderson D, Crowther M, Weitz JI, Bormanis J, Brill-Edwards P, Turpie AG, MacKinnon B, Gent M, Hirsh J. Sensitivity and specificity of a rapid whole-blood assay for D-Dimer in the diagnosis of pulmonary embolism. *Ann Intern Med* 129:1006-1011, 1998.
213. Turpie AGG. Antithrombotic therapy in coronary ischaemia: The expanding role of low molecular weight heparin. *Haemostasis* 1998; 28 (Suppl 3):35-42.
214. Ageno W, Turpie AGG. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. *Thrombosis Research* 91:237-240, 1998.
215. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AGG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *N Engl J Med* 340 (12)901-907, 1999.
216. Turpie AGG, Kher A. Prevention of venous thrombosis after elective hip surgery. *Orthopaedics Review* pp 1275-1281, 1999
217. Turpie AGG. *Orthopaedics (Letter to the Editor)*:477-478, 1999

218. Lowe GDO, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AGG, Mannucci PM. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study. *Thromb Haemost* 81:879-886, 1999.
219. Turpie AGG. The ten most commonly asked questions about chronic anticoagulant use in cardiology. *Cardiology in Review* 7 (3):125-126, 1999.
220. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AGG, Weisslinger N for the prophylaxis in medical patients with enoxaparin study group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. *N Engl J Med* 341:793-800, 1999.
221. Haas S, Turpie AGG. Introduction. *Blood Coagulation and Fibrinolysis* 10 (suppl 2):S1-S3, 1999.
222. Turpie AGG. Customizing our approach in deep vein thrombosis and pulmonary embolism treatment: overview of our clinical experience. *Blood Coagulation and Fibrinolysis* 10 (suppl 2):S107-S115, 1999.
223. Turpie AGG. Antithrombotic therapy in the new millennium - the role of low molecular weight heparin. *South African Medical Journal* 89: (Cardiovascular suppl 3):C151-C155.
224. Turpie AGG. Anticoagulants in acute coronary syndromes. *Am J Cardiol* 84:2M-6M, 1999.
225. Antman EM, McCabe CH, Gurfinkle EP, Turpie AGG, Bernink PJLM, Salein D, Bayes de luna A, Fox K, Lablanche J-M, Radley D, Premmereur J, Braunwald for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction (TIMI) 11B trial. *Circulation* 100:1593-1601, 1999.
226. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E for the TIMI 11B (Thrombolysis in myocardial infarction) and ESSENCE (Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events) Investigators Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE Meta-analysis. *Circulation* 199: 1602-1608, 1999.
227. Verheugt FW, Becker RC, Bertrand ME, Bode C, Chesebro JH, Cleland JG, Conti R, Hillis WS, Klein W, Maqseri A, Turpie AGG, Wallentin L, Waters DD. Management strategies in unstable coronary artery disease - current problems and future directions. The UCAD Council. *Clin Cardiol* Sept 22 (9): 551-553, 1999.
228. Haas S, Turpie AG. Building a new era in DVT management. Introduction. *Blood Coagulation and Fibrinolysis* Aug: 10 Suppl 2:S1-S3, 1999.
229. Toal CB, Motr M, Baird MG, Klinke P, Sclarowski S, Zilberman A, Marmor A, Kostuk WJ, Lotan C, Weiss A, Erne P, Palant A, Stolero, Belanger L, Turpie AGG. Effectiveness of nifedipine GITS I combination with atenolol in chronic stable angina. *Can J Cardiol* 15 (10):1103-1109, 1999.
230. Ageno W, Turpie AGG. Exaggerated initial response to warfarin following heart valve replacement. *Am J Cardiol* 84: 905-908, 1999.
231. Turpie AGG. Clinical trials of low molecular weight heparins. *Europ Heart J* 1 (Suppl R); 418-427, 1999.

232. Ageno W, Turpie AGG. Prevention and treatment of venous thromboembolism. *General Surgery News* June 13-16, 1999.
233. Ageno W, Turpie AGG. Prevention and treatment of venous thromboembolism. *Pharmacy Practice News* June 11-14, 1999.
234. Ageno W, Turpie AGG. The use of antiplatelet agents in the secondary prevention of stroke. *Leading Article. Stroke*, 1999.
235. Sosis MB. Enoxaparin for the prevention of venous thromboembolism. *N Engl J Med* 342: 136, 2000 (Correspondence).
236. Turpie, AGG. Low molecular weight heparins in acute unstable coronary artery disease. An update. *Haemostasis* 29 (Suppl 1):72-75, 1999.
237. Ageno W, Turpie AGG. The use of glycoprotein IIb/IIIa receptor inhibitors in unstable angina. *G Ital Cardiol* 29:1357-1365, 1999.
238. Turpie AGG. Is lung scanning necessary in all patients with confirmed DVT? *J of Critical Illness* 15: (2): 2000
239. Turpie AGG. Can we differentiate the low-molecular weight heparins? *Clin Card* 23 (Suppl I):I-4-I-7, 2000.
240. Antman EM, Fox KM for the International Cardiology Forum. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisions. *Am Heart J* 2000; 139:461-475.
241. Huber K, Gaul G, Glogar D, Kaliman J und Miczoch J for the International Cardiology Forum. Richtlinien zur Diagnostik und Therapie der instabilen Angina pectoris und des Non-Q-Wave-Myokardinfarktes: vorgeschlagene Revisionen. *J Kardiol* 2000; 7:60-72.
242. Turpie AGG. Management of deep vein thrombosis and pulmonary embolism. *Scot Med J* 2000; 45:40-42.
243. Turpie AGG. Prophylaxis for venous thromboembolism in medical patients. *J Critical Illness* (Supplement) July 2000:S24-S30.
244. Turpie AGG, Elliot G, Fernandez B. Suspensions and subtleties in venous thromboembolism. Are clinical models and strategies effective? *Medical Crossfire* 2(8):35-46, 2000.
245. Wells PS, Anderson DR, Rodger M, Ginsbert JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-Dimer. *Thromb Haemost* Mar 83 (3):416-420m 2000.
246. Ageno W, Turpie AGG. Low molecular weight heparin in the treatment of pulmonary embolism. *Seminars in Vasc Surg* 13 (3):189-193, 2000.
247. Turpie AGG. Deep vein thrombosis (DVT) and pulmonary embolism (PE) post significant diagnostic and management challenges to clinicians. "DVT often arises in primary-care settings and crosses many subspecialty borders" noted Victor Tapson MD, Associate Professor of Medicine in the Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, in Durham, North Carolina. "We need to emphasize that, whatever the setting, there is much to consider in treating venous thrombosis and pulmonary embolism. *Medical Crossfire* 2 (8):35-45, 2000.

248. Cohen M, Elliot EM, Gurfinkel E, Turpie AGG, Furst J, Bigonzi F, Radley D. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction. *Am J Cardiol* 86: 553-556, 2000.
249. Turpie AGG. Prevention of venous thromboembolism in medical patients. *Turkish Journal of Haematology (Suppl)* 17 (3):96-101, 2000.
250. Cohen M, Turpie AGG. Management of unstable angina and myocardial infarction. (letter). *Lancet* 356: 119, 2000.
251. Cohen M, Antman EM, Gurfinkel E, Turpie AGG, Furst J, Bigonzi F and Radley D. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction. *Am J Cardiol* 86; Sept 1; p553-556, 2000.
252. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson C-G, Turpie AG, Weisslinger N. Hastalarda Enoksaparin ile profilaksi Calisma Grubu. Akut Meeical Hastalarda Venoz Tromboemboli Profilaksisinde Enoksaparin ile Plasebonun Karsilastirilmesi. *N Engl J med* 341:793-800, 1999.
253. Ageno W, Johnson J, Nowacki B, Turpie AGG. A computer generated induction system for hospitalised patients starting on oral anticoagulant therapy. *Thromb Haemost* 83: 849-852, 2000.
254. Turpie AGG. Antithrombotics and anticoagulants in coronary syndromes and stroke. *Seminars in Thromb and Hemost* 26 (Suppl 1) 79-83, 2000.
256. Cohen M, Turpie AGG. Management of unstable angina and myocardial infarction. *The Lancet (Correspondence)* 356:1193-1194, 2000.
257. Goodman SG, Cohen M, Bigonzi F, Gurfinkel EP, Radley DR, LeIouer V, Fromell GJ, Demers C, Turpie AGG, Califf RM, Fox KAA, Langer A for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events (ESSENCE) Study Group. Randomized trial of low molecular weight heparin (Enoxaparin) versus unfractionated heparin for unstable coronary artery disease. *JACC* 36 (3):693-698, 2000.
258. Buchanan MR, Schwartz L, Bourassa MG, Brister SJ, Peniston CM on behalf of the BRAT Investigators. Results of the BRAT Study - A pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. *Can J Cardiol* 16 (11):1385-1390, 2000.
259. Turpie AGG. Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice. *Am Heart J* 142S9-S15, 2001.
260. Turpie AGG. Thrombosis prophylaxis in the acutely ill medical patient: Insights from the prophylaxis in MEDical patients with ENOXaparin (Medenox) Trial. *Am J Cardiol* 86 (Suppl) 48M-52M, 2000.
261. Ageno W, Turpie AGG. Therapy of unstable angina with the low molecular weight heparins. *Vascular Medicine* 5:217-223, 2000
262. Ageno Walter, Turpie Alexander GG. Glycoprotein IIb/IIIa receptor antagonists in the treatment of unstable angina. *JICC* 1 (1): 26-31, 2000.

263. Turpie AGG, Gallus AS, Hoek JA for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. *N Engl J Med* 334 (9):619-625, 2001.
264. Ageno W, Turpie AGG. Outpatient treatment of deep vein thrombosis. *Emergency Medicine* April 74-81, 2001.
265. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. *Chest* 119:220S-227S, 2001.
266. Turpie AGG. Looking forward in the treatment of deep vein thrombosis. *Sem in Hematol* 38 2 (5): 49-57, 2001.
267. Turpie AGG, Antman EM. Low-molecular-weight heparins in the treatment of acute coronary syndromes. *Arch Intern Med* 161:1484-1490, 2001.
268. Ageno W, Turpie AGG, Steidl L, Ambrosini F, Cattaneo R, Codari RL, Nardo B, Venco A. Comparison of a daily fixed 2.5 mg warfarin dose with a 5 mg, International Normalized Ratio adjusted, warfarin dose initially following heart valve replacement. *Am J of Cardiol* 88:40-44, 2001.
269. Bath PMW, Lindenstrom E, Goysen G, De Deyn Peter, Friis P, Leys D, Marttila R, Olsson J-E, O'Neill D, Orgogozo J-M, Ringelstein B, van der Sande J-J, Turpie AGG for the TAIST Investigators. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. *The Lancet* 358:702-710, 2001.
270. Holper EM, Antman EM, McCabe CH, Premmereur J, Gurfinkel E, Bernink PJ, Turpie AG, Bayes de Luna A, Lablanche JM, Fox KM, Salein D, Radley DR, Braunwald E. A simple readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction. *Am J Cardiol* April 15; 87 (8): 1008-1010, 2001,
271. Becker RC, Eisenberg P, Turie AG. Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: fundamental principles and the contribution of platelets and thrombin. *Am Heart J* 14 (6):1025-1037, 2001.
272. Ginsberg JS, Turpie AG. Thromboembolism and pregnancy. *Int Angiol* 20 (2):103-109, 2001.
273. Turpie AG. Setting a standard for venous thromboembolism prophylaxis. *Am j Health Syst Pharm* 58 (Suppl 2)S18-S23m 2991,
274. Turpie AGG. Pentasaccharide Org31540/SR90107A clinical trials update Lessons for practice. *American Heart Journal (Supplement)* 142 (2):S9-S15, 2001
275. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist. *J South Orthop Assoc* 11 (4):197-202, 2002.
276. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG for the Steering Committee of the Pentasaccharide in hip fracture surgery study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. *N Engl J Med* 345: 1298-1304, 2002.
277. Bauer KA, Eriksson BI, Lassen MR. Turpie AGG for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for

- the prevention of venous thromboembolism after elective major knee surgery. *N Engl J Med* 345: 1305-1310, 2002.
278. Turpie AG. Overview of the clinical results of pentasaccharide in major orthopedic surgery. *Haematologica* 86 (Supp 2):59-62, 2001.
279. Ageno W, Turpie AG. New advances in the management of acute coronary syndromes: Low-molecular weight heparins. *CMAJ* 166 (7):919-924, 2002.
280. Turpie AGG. New data on long-term antiplatelet therapy. *Hematologia* 5 (2):47-48, 2001.
281. Turpie AGG. New strategies in the prevention and treatment of venous thromboembolism. *Hematologia* 5 (2): 45-46, 2001.
282. Bath PMW, Linderstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J-E, O'Neill D, Orgogozo J-M, Ringelstein B, van der Sande J-J, Turpie AGG for the TAIST investigators. Tinzaparin in acute ischaemic stroke (TAIST): A randomised aspirin-controlled trial. *Lancet* 358 (983):703-710, 2001.
283. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med* 345: 1444-1451, 2001.
284. Turpie AGG. Is new antithrombotic agent superior? *The Medical Post* January 2002, pp59.
285. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA and Braunwald E for the TIMI11B and ESSENCE Investigators. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1 year follow-up of TIMI 11B and ESSENCE. *European Heart Journal* 23:308-314, 2002.
286. Turpie AGG, Mason JA. Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. *Expert Opin Pharmacother* 3 (5):575-598, 2002.
287. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip replacement surgery: a randomised double-blind trial. *The Lancet* 359:1721-1726, 2002.
288. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. *The Lancet* 359:1715-1720, 2002.
289. Turpie AGG, Bauer KA, Eriksson BI, Lassen. Major Ortopedik Cerrahide Venöz Tromboembolizm Onlenmesinde Fondaparinux ile Enoxaparinin Karşılaştırılması: Randomize, Cift-kor 4 Calismanin Metaanalizi. *Arch Intern Med* 162: 1833-1840, 2002.
290. Turpie AGG, Buller HR. New standards in antithrombotic therapy: concepts, clinical evidence, and applications. *Semin in Thromb and Hemost* 28 (Supp 2):1 2002.

291. Turpie AGG: Optimizing prophylaxis of venous thromboembolism. *Semin in Thromb and Hemost* 28 (Supp 2):25-32, 2002.
292. Turpie AGG, Buller HR. Benefit of selective factor inhibition. *Semin in Thromb and Hemost* 28 (Supp 2):49-50, 2002.
293. Turpie AGG. Introduction: unstable angina- its pathogenesis and management. *Semin in Thromb and Hemost* 28 (Suppl 2) 1-3, 2002.
294. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *Brit Med J* 324;71-86, 2002.
295. Turpie AGG. Pentasaccharides. *Seminars in Hematology* 39 (3):July, 2002 pp 158-171.
296. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. *J South Orthop Assoc* 11 (4):182-188, 2006.
297. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery. *Arch Intern Med* 162:1833-1840, 2002.
298. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: a randomised double-blind comparison. *The Lancet* 359 (9319):1715-1720, 2002.
299. Simoons ML, Krzeminska-Pakula M, Alonso A, Goodman SG, Kali A, Loos U, Gosset F, Louer V, Bigonzi F for the AMI-SK Investigators. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. *Eur Heart J* 23:1282-1290, 2002
300. Turpie AGG, Buller HR. New standards in antithrombotic therapy: concepts, clinical evidence and applications. Introduction. *Seminars in Thromb and Hemost* 28 (Suppl2), 2002
301. Turpie AGG. State of the Art - A Journey through the world of antithrombotic therapy. *Thromb and Hemost* 28 (Suppl 2):3-11, 2002.
302. Turpie AGG, Lassen MR, Eriksson BI, Bauer KA. Factor Xa inhibitors in the prevention and treatment of venous thromboembolism - The role of fondaparinux, first of a new class of antithrombotic agents. *Today's Therapeutic Trends*. 253-267. 2002.
303. Turpie AGG, Chin BSP, Lip GYH. ABC of antithrombotic therapy. Venous thromboembolism: pathophysiology, clinical features, and prevention. *Brit Med J* 325: 887-890, 2002.
304. Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features and prevention. *BMJ* 325: 887-890, 2002
305. Ageno W, Turpie AG. low molecular weight heparins in the treatment of unstable angina. *Minerva Cardioangiol* 50 (6):643-651, 2002.

306. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the Steering Committee of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch Intern Med 162:1833-1840, 2002.
307. Turpie AGG. Use of selective factor Xa inhibitors in special populations. Supplement to American Journal of Orthopedics. XXXI (11S) November 2002.
308. Goldsmith I, Turpie AGG, Lip GYH. ABC of antithrombotic therapy. Valvular heart disease and prosthetic heart valves. Brit Med J 325:1228-1231, 2002.
309. Turpie AGG, Eriksson BI, Lassen MR, Bauer KA. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. JSOA 11 (4):182-188, 2002.
310. Ageno W, Turpie AGG. Deep venous thrombosis in the medically ill. Current Hematology Reports 1:73-78, 2002.
311. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. for the Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2):146-153, July 2003.
312. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol 10 (5):327-332, 2003.
313. Cannon CP, Turpie AGG. Unstable angina and non-ST-elevation myocardial infarction. Circulation 107:2640-2645, 2003.
314. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AGG et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631-639, 2003.
315. Turpie AGG, Bauer K, Eriksson B, Lassen M on behalf of the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Thromb Haemost 90:364-366, 2003.
316. Eriksson BI, Lassen MR for the PENTasaccharide in Hip-FRActure Surgery Plus (PENTHIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. Arch Intern Med 163:1337-1342, 2003.
317. Ageno W, Turpie AGG. Breathing life into pulmonary embolism. Perspectives in Cardiology 19 (10):36-39, 2003.
318. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M. Extended low-intensity anticoagulation for Thrombo-Embolic Investigators. Comparison of low intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349 (7):631-639, 2003.
319. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Prevention of venous thromboembolism in medical

- patients with enoxaparin: a subgroup analysis of the MEDENOX Study. *Blood Coagul Fibrinolysis* 14 (4):341-346, 2003.
320. The MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. *N Engl J Med* 349:1695-1702, 2003.
321. Topol EJ for the APPCR panel. Amtocpagi;atopm wotj [rpstjetoc cardiac va;ves/ *Arch Intern Med* 163:3251-3252, 2003.
322. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Letter to the Editor, *The Lancet* 362: 1582-1583. 2003.
323. Turpie AGG. Future therapeutic directions for factor Xa inhibitor in the prophylaxis and treatment of thrombotic disorders. *Am J Health-Syst Pharm*, 60 (Suppl) S20-S24, 2003.
324. Data Safety Monitoring Board - Member - Colwell CW, Berkowitz D, Davidson BL, Lotke PA, Ginsberg G, Lieberman JR, Naubauer J, mcElhattan JL, Peters GR and Francis CW. Comparison of Ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomised, double-blind study. *Journal of Thrombosis and Haemostasis* 1:2119-2130, 2003.
325. Turpie A, Bauer K, Eriksson B, Lassen M on behalf of the Steering Committee of the Pentasaccharide Orthopedic Prophylaxis Studies. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. *Thromb Haemost* 90:364-366, 2003.
326. Turpie AG. Choice of low molecular weight heparins. *J Thromb Haemost* 2 (3):598, 2003.
327. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systemic review. *Arch Intern Med* 163 (8):901-908, 2003
328. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery. *Lancet* 362:1582-1583, 2003.
329. Turpie Alexander G.G.: Fondaparinux (Arixtra) in the future: exploring new horizons. *Thromb & Haemost* (Suppl) Sept 13-14, 2004, Prague.
330. Turpie AGG. Proven strategies for preventing thromboembolism in heart failure. *Cardiology Special Edition* (based on the American Heart Association Scientific sessions, 2003), March 2004.
331. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, MacKinnon B, Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kahn R, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M and the SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. *J Thromb and Haemo* 2:743-749, 2004.
332. Turpie AG. Venous thromboembolism prophylaxis: role of factor Xa inhibition by fondaparinux. *Surg Technol Int* 13:261-267, 2004

333. Turpie AGG. The design of venous thromboembolism prophylaxis trials: Fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. *Int J Clin Pract* 58:483-493, May 2004.
334. Turpie AGG. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. *Expert Opin Pharmacother* 5 (6): 1373-1384, 2004.
335. Douketis JD, Johnson JA, Turpie AG. Low molecular weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. *Arch Intern Med* 164:1319-1326, 2004.
336. Ageno W, Crotti S, Turpie AG. The safety of antithrombotic therapy during pregnancy. *Expert Opin Drug Saf* 3 (2):113-118, 2004.
337. Turpie AGG, Norris TM. Thromboprophylaxis in medical patients: the role of low-molecular weight heparin. *Thromb Haemost* 92:3-12, 2004.
338. Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vitkus PT, Goldhaber SZ for the PREVENT Medical Thromboprophylaxis Study Group. Randomised, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation* 110:874-879, 2004.
339. Lee, AYY, Gent M, Julian J, Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Bilateral vs ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review. *J Thromb and Haemost* 2:1-8, 2004.
340. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy endpoints. *Chest* 126:501-508, 2004.
341. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor , Janbon C, Leizorovicz A, Olsson CG, Turpie AG: MEDENOX Study. *Arch intern Med* 164 (9):963-968, 2004
342. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA Mackinnon B, Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kayhn SR, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M; SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. *J Thromb Haemost* 2 (5):743-749, 2004.
343. Desjardins L, Bara I, Boutitie F, Samama MM, Cohen AT, Combe S, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics and outcome in the MEDENOX Study. *Arch Pathol lb Med* 128 (5):519-526, 2004.
344. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C. Csiba L, Kaste M, Leys D, matias-Guiu J, Rupprecht HJ on behalf of the MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *The Lancet* 394 (9431):331-337, 2004.
345. Leizorovicz A, Turpie AGG, Cohen AT, Wong W, Yoos MC, Dans A for the SMART Study Group. Epidemiology of venous thromboembolism in Asian patients undergoing major

- orthopedic surgery without thromboprophylaxis. The SMART Study. *J Thromb Haemost* 2:1-7, 2004.
346. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Goldhaber for the PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. *Thromb Haemost* 93: 76-79, 2005.
347. Turpie AGG, Eriksson BI, Bauer KA, Lassen MR. Fondaparinux. *J Am Acad Orthop Surg* 12:371-375, 2004.
348. Kovacs MJ, Kearon C, Rodger m, Anderson DR, Turpie AG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S, Wells PS. Single-arm study of bridging therapy with low molecular weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. *Circulation* 10 (12):1658-1663, 2004.
349. O'Donnell M, Turpie AGG. Low-molecular-weight heparin in acute coronary syndromes. *Heart/Drug* 4:111-118, 2004.
350. Leizorovicz A, Turpie AGG, cohen AT, Dhillon KS, Angchaisuksiri P, Wang C-J for the SMART Study Group. Epidemiology of post-operative venous thromboembolism in Asian Countries. *Int'l J of Angiology* 13:101-108, 2004.
351. Turpie AGG, Norris TM. Thromboprophylaxis in medical patients: the role of low molecular weight heparin. *Thromb Haemost* 92: 3-12, 2004,
352. Leizorovicz A, Turpie AGG, Cohen AT, Wong L, Yoo MC, Dans A for the SMART Study Group. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. *J Thromb Haemost* 3:28-34, 2005.
353. Turpie AGG. Venous thromboembolism prophylaxis: Role of Factor Xa inhibition by fondaparinux. *Surg Tech Int'l XIII*:261-267, 2005.
354. Kearon C, Ginsbert JS, Douketis J, Crowther MA, Turpie AG, Bates SM, Lee A, Brill-Edwards P, Finch T, Gent M. A randomised trial of diagnostic strategies after normal proximal vein ultrasonography for suspected deep venous thrombosis: D-dimer testing compared with repeated ultrasonography. *Ann Intern med* 142:490-496, 2005.
355. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Major Ortopedik Cerrahie Venoz Tromboembolinin Onlenmesinde Fonaparinux ile Enoksaparinin Karsilastirilmesi. *Archives of Internal Medicine (Turkce tipkibasim)* 162:1883-1840, 2005.
356. Abramson BL, Huckell V, Anand S, Forbes T, Gupta A, Harris K, Junaid A, Lindsay T, McAlister F, Roussin A, Sar J, Teo KK, Turpie AG, Verma S. Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease - executive summary. *Can J Cardiol* 21 (12):997-1006, 2005.
357. Spyropoulos AC, Turpie AG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. *Curr Opin Pulm Med* 11 (5)373-379, 2005.
358. Turpie AG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. *Expert Opin Drug Saf* 4 (4)707-721, 2005
359. Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, Barone M, Piovela F, Turpie AG, Middeldorp S, van Nguyen P, Prandoni P, Wells PS, Kovacs MJ, MacGillavry MR, Constantini L, Ginsberg. Does the type of hormone replacement therapy

influence the risk of deep vein thrombosis? A prospective case-control study. *J Thromb Haemost* 3 (5):943-948, 2005.

360. Kovacs MJ, Kearon C, Julian JA, Douketis jD, Demers C, Wells PS, turpie AG, Anderson DR, Kahn SR, Nguyen PV, Green D, Kassis J, Geerts W, Mackinnon B, Ginsberg JS. Influence of warfarin on symptoms of fatigue: findings of a randomised trial. *Ann Pharmacother* 39 (5):840-842, 2005.

361. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KAA, Sharma , Chew P, Braunwald E for the EXTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction treatment-thrombolysis in Myocardial Infarction study 25 (ExTRACT-TIMI 25). *American Heart Journal* 149:217-226, 2005.

362. Turpie AGG. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. *Expert Opinion Pharmacother* 5:1-12, 2004.

363. Ageno W, Turpie AGG. What's new for DVT prophylaxis for the medically ill. *Disease of the Month* 51:194-199, 2005.

364. Turpie AGG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. *Expert Opinion. Drug Safety.* 4 (4):707-721, 2005.

365. Turpie AG. Multidetector-row computed tomography in suspected pulmonary embolism. *N Engl j Med* 353 (6):630-631. 2005.

366. Kucher N, Leizorovicz A, Vaitkus PT Cohen AT, Turpie AG et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or eoderly hospitalised patients: a subgroup analysis of the PREVENT trial. *Arch Intern Med* 165 (3):341-345, 2005.

367. Goldhaber SZ, Turpie AGG. Prevention of venous Thromboembolism among hospitalised medical patients. *Circulation* 111:e1-e3, 2005.

368. Leizorovicz A, Turpie AG, Cohen AT Wong L, Yoo MC, Dans A. SMART study. *J Thromb Haemost* 3 (1) 28-34, 2005.

369. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ. PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. *Thromb Haemostst* 93 (1):76-79, 2005.

370. Cohen, AT, Alikhan R, Arcelus I, bergmann J-F, Haas S, Merli GJ, Spyropolous AC, Tapson VP, Turpie AGG. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medicalpatients. *Thromb Haemost* 94:750-759, 2005.

371. Turpie AGG, Fisher WD, Bauer KA, kwong M, Irwin MW, Kalebo P, Misselwitz F, Gent M for the ODIXa-Knee Study Group. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. *J Thromb & Haemost* 3: 2479-2486, 2005.

372. Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M for the ODIXa-Knee Study Group. Bay 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. *J Thromb & Haemost* 3:2479-2486, 2005.

373. Anand SS, Turpie AGG. Medical Treatment. *Can J Cardiol* 21 (12):1002-1003, 2005.
374. Piovela F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, Turpie AGG, Gallus AS, Planes A, Passera R, Rouillon A for the AIDA investigators. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. *J Thromb Haemost* 3:2664-2670, 2005.
375. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low molecular weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction. A meta-analysis of the randomised trials. *Circulation* 112:3855-3867, 2005.
376. Seshadri N, Goldhaber SZ, Elkayam U, Grimm RA, Groce JB, Heit JA, Spinler SA, Turpie AG, Bosker G, Klein AL. The clinical challenge of bridging anticoagulation with low molecular weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. *Am Heart J* 50 (s):27-34, 2005.
377. Ageno W, Turpie AG. Clinical trials of deep vein thrombosis prophylaxis in medical patients. *Clin Cornerstone* 7 (4):16-22, 2005.
378. Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins I, Turpie AGG, Glezer S, Thabane L, Sebaldt for the CURVE Study Investigators. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. *Thromb Res* March 1; 2006.
379. Natarajan MK, Velianou JL, Turpie AG, Mehta SR, Raco D, Goodhart DM, Afzal R, Ginsberg JS. A randomised pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. *Am Heart J* 151 (1):175, 2006
380. Gray LJ, Sprigg N, Bath PMW, Sorensen P, Lindenstrom E, Boysen G, De Deyn PP, Frils P, Leys D, Marttila R, Olsson J-E, O'Neill D, Ringelstein B, van der Sande J-J, Turpie AGG for the TAIST Investigators. *J Neurol Neurosurg Psychiatry* 77:327-333, 2006.
381. Colwell CW, Kwong LM, Turpie AGG, Davidson B. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. *J of Arthroplasty* 21 (1) 36-45, 2006.
382. Cohen AT, Davidson BI, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA for the ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *BMJ* 10:1-5, 2006.
383. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KAA, Braunwald E for the ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. *N Eng J Med* 354:1477-1488, 2006
384. Spyropoulos AC, Turpie AGG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ for the REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low molecular weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN Registry. *J Thromb Haemost*; 2006; 4:1246-1252.
385. Kearon C, Ginsberg JS, Douketis J, Turpie AG, Bates SM, Lee AY, Crowther MA, Weitz JI, Brill-Edwards P, Wells P, Anderson D, Kovacs MJ, Linkins L-A, Julian JA, Bonilla LR,

386. Gent M for the Canadian Pulmonary Embolism Diagnosis Study (CANPEDS) Group. An evaluation of D-Dimer in the Diagnosis of Pulmonary Embolism. A Randomized Trial. *Ann Intern Med* 144:812-821, 2006.
387. Turpie AGG. Clinical efficacy and safety of fondaparinux: an emphasis on results in the elderly. *Aging Health* 2 (5) 1-13, 2006.
388. Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M. Comparison of fixed-dose weight-adjusted unfractionated heparin and low molecular weight heparin for acute treatment of venous thromboembolism. *JAMA* 296:935-942, 2006.
389. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AG, Wildgoose P, Yusen RD. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study. *J Thromb Thrombolysis* 22 (1):31-38, 2006.
390. Schellong SM, Beyer J, Kakkar AK, Schmidt B, Halbritter K, Eriksson B, Turpie AGG, Misselwitz F, Kalebo P. Validierung von zentral befundetem venösen Ultraschall bei Patienten eine Woche nach orthopädischem Gelenkersatz: Die VENUS-Studie. *VASA* 35 (Suppl 69): 18, 2006.
391. Turpie AGG, Leizorovicz A. Prevention of venous thromboembolism in medically ill patients: a clinical update. *Postgraduate Medical Journal* (Accepted for publication).

ABSTRACTS AND COMMUNICATIONS

1. The anticoagulant action of puff adder (*B. arietans*) venom. (Jointly) Association of Physicians of East Africa, Nairobi, July 1965.
2. Mode of action of *Echis Carinatus* venom. (Jointly) Association of the Physicians of East Africa, Kampala, April 1966.
3. The role of the fibrinolytic enzyme in spontaneous gangrene in African children. (Jointly) Royal Medico-Chirurgical Society, Glasgow, November 1966.
4. Snake venom - friend of foe? (Jointly) Royal Medico-Chirurgical Society, Glasgow, November 1966.
5. Spontaneous gangrene in African children. Medical Research Society, London, February 1967.
6. Effect of gaboon viper (*Bitis Gabonica*) venom on blood coagulation, platelet aggregation and the fibrinolytic enzyme. (Jointly) Scottish Society for Experimental Medicine, Glasgow, June 1967.
7. Trial of deglycyrrhizinised liquorice in gastric ulcer. (Jointly) European Society of Gastroenterology, Prague, July 1968.
8. Changes in platelet behaviour associated with Arvin therapy. (Jointly) Medical Research Society, March, 1969.
9. Action of pyrimido-pyrimidine compounds on platelet behaviour in vitro. (Jointly) Vth Congress of Asian and Pacific Society of Haematology, Istanbul, September, 1969.
10. Platelets. Vascular Surgical Society of Great Britain and Ireland. Glasgow, November, 1969.
11. Action of pyrimido-pyrimidine compounds on platelet behaviour in vitro. (Jointly) 18th Annual Symposium on Blood. Wayne State University School of Medicine, Detroit, 1970.
12. Platelets. Association of Surgeons of Great Britain and Ireland. Glasgow, April, 1970.
13. Platelet electrophoresis: Effect of defibrination by ancrod. Thirteenth International Congress of Haematology, Munich, August, 1970.
14. The effect of cigarette smoking on blood coagulation, platelet aggregation and fibrinolysis. (Jointly) Scottish Society for Experimental Medicine, Dundee, January, 1971.
15. Interaction of Newcastle Disease Virus (NDV) with blood platelets. (Jointly) American Society of Microbiology, Minneapolis, May, 1971.
16. Interaction of Newcastle Disease Virus (NDV) with platelets. (Jointly) Federation of American Societies of Experimental Biology, Atlantic City, April, 1972.
17. Contrasting effects of human and rabbit platelets in Chikungunya Virus (CV) infectivity. (Jointly) American Society for Microbiology, Philadelphia, April, 1972.

18. Requirement for hemolytic activity in virus-induced platelet aggregation. (Jointly) Canadian Federation of Biological Societies, Quebec City, June, 1972.
19. Thrombocytopenia and vasculitis induced in rabbits by Newcastle Disease Virus. (Jointly) III Congress, International Society on Thrombosis and Hemostasis, Washington, D.C., August, 1972.
20. Effect of bacteria on platelet aggregation and the platelet release reaction. (Jointly) Federation of American Societies of Experimental Biology, Atlantic City, April, 1973.
21. Haematological and vascular changes in rabbits inoculated with Newcastle Disease Virus. (Jointly) American Society for Microbiology, May, 1973.
22. Thrombolysis with a combination of small doses of subcutaneous heparin. (Jointly) IV Congress, International Society on Thrombosis and Hemostasis, Vienna, June, 1973.
23. Prevention of venous thrombosis with small doses of subcutaneous heparin. (Jointly) IV Congress, International Society on Thrombosis and Hemostasis, Vienna, June, 1973.
24. Virus-induced platelet aggregation: Requirement for sialic acid receptors. (Jointly) Canadian Society of Microbiologists, Edmonton, June 1973.
25. ¹²⁵I-fibrinogen leg scanning after cardiac revascularization surgery. OMA Tri-City Meeting, Toronto, June, 1974.
26. Prevention of venous thrombosis in neurosurgical patients by intermittent calf compression. (Jointly) Vth Congress, International Society on Thrombosis and Hemostasis, Paris, July 1975.
27. Failure of aspirin and dipyridamole to influence the incidence of leg scan-detected venous thrombosis after elective hip surgery. (Jointly) Vth Congress, International Society on Thrombosis and Hemostasis, Paris, July 1975.
28. The role of the platelet in thrombosis. Symposium on the Detection and Treatment of Thromboembolism. Royal College of Physicians and Surgeons of Glasgow, April, 1976.
29. Impedance Plethysmography. Symposium on the Detection and Treatment of Thromboembolism. Royal College of Physicians and Surgeons of Glasgow, April, 1976.
30. Diagnosis of venous thrombosis. Invited participant. American College of Chest Physicians, Atlanta, October, 1976.
31. Physical methods of venous thrombosis prophylaxis. Plenary session. American Heart Association, Miami Beach, November, 1976.
32. Pathogenesis of Thrombosis. Symposium on the Prevention and Treatment of Human Thromboembolism. Laval University School of Medicine, Quebec City, March, 1976.
33. Venous Thromboembolism. Prevention by physical methods. Symposium on the Prevention and Treatment. Symposium on the Prevention and Treatment of Human Thromboembolism. Laval University School of Medicine, Quebec City, March, 1977.

34. Prevention of venous thrombosis by intermittent sequential calf compression in neurological and neurosurgical patients. International Society of Haematology, Paris, July, 1978.
35. Platelet Suppressant Therapy. Interstate Postgraduate Medical Association, Washington, D.C., October, 1978.
36. Turpie AGG, Hirsh J, Genton E, Han P, Gent M: Comparative effects of sodium and calcium heparin on plasma heparin concentration, partial thromboplastin time, platelet count and bleeding. Circulation II 58, #801, 1978.
37. Han P, Turpie AGG, Genton E, Hirsh J, Gent M: Negative correlation between platelet survival, B-thromboglobulin and platelet aggregate ratio in patients with coronary artery disease. Circulation II 58, #451, 1978.
38. Zielinsky A, Hirsh J, Hull R, Powers P, Turpie AGG, Han P: Evaluation of radioimmunoassay for Fragment E (FgE) in the diagnosis of venous thrombosis. Thrombosis and Hemostasis 42, #0054, 1979.
39. Kelton J, Neame PB, Walker I, Turpie AGG, McBride J, Han P, Nicholson W, Hirsh J: Thrombotic thrombocytopenic purpura: Mechanism for effectiveness of plasmapheresis. Thrombosis and Hemostasis 42, #0264, 1979.
40. Han P, Turpie AGG, Genton E, Gent M: The effect of antiplatelet drugs on plasma B-thromboglobulin in coronary artery disease. Thrombosis and Hemostasis 42, #0131, 1979.
41. Han P, Turpie AGG, Genton E: Plasma B-thromboglobulin measurement to differentiate types of thrombocytopenia. Thrombosis and Hemostasis 42, #6010, 1979.
42. Turpie AGG, Han P, Genton E, Butt RW, Zielinsky A: The effect of contrast media, 125-Iodine labelled fibrinogen, heparin and aspirin on plasma BTG concentration. Thrombosis and Hemostasis 42, #0721, 1979.
43. Turpie AGG: Intermittent pneumatic compression prophylaxis in neurosurgery. Third Annual Symposium on Vascular Surgery, New York, New York, November, 1979.
44. Turpie AGG: Diagnosis of venous thromboembolism. Third Annual Symposium on Vascular Surgery, New York, New York, November, 1979.
45. Turpie AGG: Treatment of venous thromboembolism. Third Annual Symposium on Vascular Surgery, New York, New York, November, 1979.
46. Han P, Turpie AGG, Butt RW, LeBlanc P: The use of B-thromboglobulin release to assess platelet damage during cardiopulmonary bypass. Hematology Society of Australia, Hobart, Tasmania, February, 1980.
47. Turpie AGG: Clinical effectiveness of drugs in venous occlusion and pulmonary embolism. Haematologist's point of view. Conference on Clinical Pharmacology and Therapeutics, London, England, August, 1980.
48. deBoer AC, Stewart A, Butt R, Turpie AGG, Genton E: 125I-fibrinogen dilute whole blood clot lysis time: the effect of intermittent pneumatic compression of the calves. Joint Meeting of the 18th Congress of the International Society of Blood Transfusion, Montreal, Canada, August, 1980.

49. Turpie AGG, Neame PB, Kelton JG, deBoer AC: Plasma betathromboglobulin concentration in thrombocytopenia and thrombocytosis. Joint Meeting of the 18th Congress of the International Society of Haematology and the 16th Congress of the International Society of Blood Transfusion, Montreal, Canada, August, 1980.
50. Duke RJ, Turpie AGG, Bloch RF, Devine EE, Derby IR, Kronby MH, Bayer NH: Clinical trial of low-dose heparin for the prevention of stroke progression. *Circulation* II 62: #56, November, 1980.
51. Turpie AGG, Genton E, Han P, deBoer AC, Gent M: Evaluation of gamma function calculation of platelet survival time (PST). *Circulation* II 62: #1060, November, 1980.
52. Turpie AGG, Genton E, Hull R, Hirsh J, deBoer AC, Hiscoe C, Johnston M, Gent M: Calf and thigh compression to prevent venous thrombosis (VT) in intracranial disease (ICD). *Circulation* II 62: #1300, November, 1980.
53. Turpie AGG, deBoer AC, Genton E, Duke RJ, Bloch RF, Devine EE, Zielinsky A: Plasma betathromboglobulin (BTG) and serum fragment E (FgE) in acute partial stroke. *Circulation* II 62: #447, November, 1980.
54. Zielinsky A, Hirsh J, Carter C, Hull R, Powers P, Turpie AGG, Straumanis G: An evaluation of the radioimmunoassay for Fragment E in the diagnosis of venous thrombosis in clinically symptomatic patients. *Circulation* II 62: #634, November, 1980.
55. Hull R, Hirsh J, Sackett DL, Taylor W, Carter C, Turpie AGG, Zielinsky A, Powers P, Gent M: Replacement of venography in suspected venous thrombosis by impedance plethysmography and 125I-fibrinogen leg scanning. *Circulation* II 62: #1298, November, 1980.
56. Turpie AGG, deBoer AC, Genton E, Butt R, Han P, Gunstensen J: Platelet survival time and betathromboglobulin in cardiac valve replacement. *Am J of Cardiology* 47, #498, 1981.
57. deBoer AC, Han P, Turpie AGG, Butt R, Gent M: The effect of antiplatelet drugs on platelet survival time and betathromboglobulin in coronary artery disease. *Thrombosis and Hemostasis* 46, #601, July, 1981.
58. Turpie AGG, deBoer AC, Sealey BJ, Butt R, Genton E: Betathromboglobulin and fibrinopeptide A in exercise-induced myocardial ischemia. *Thrombosis and Hemostasis* 46, #618, July, 1981.
59. deBoer AC, Turpie AGG, Butt RW, Genton E: The contribution of increased fibrinolysis induced by intermittent pneumatic compression of the legs in the prevention of deep vein thrombosis. *Thrombosis and Hemostasis* 46 #596, July, 1981.
60. Turpie AGG, deBoer AC, Han P, Butt R, Genton E: Plasma and urine betathromboglobulin concentration in deep vein thrombosis. *Thrombosis and Hemostasis* 46, #515, July, 1981.
61. deBoer AC, Turpie AGG, Butt R, Genton E: Thromboxane B2 and betathromboglobulin in symptomatic coronary artery disease. *Thrombosis and Hemostasis* 46, #844, July, 1981.

62. Kelton JG, Powers PJ, Turpie AGG, Carter CJ: Heparin associated thrombocytopenia is not a typical drug induced thrombocytopenia. *Thrombosis and Hemostasis* 46, #678, July, 1981.
63. Hull R, Carter CJ, Ockelford P, Hirsh J, Zielinsky A, Turpie AGG, Powers P: The use of non-invasive testing and venography for the diagnosis of acute recurrent deep vein thrombosis. *International Vascular Symposium, London, October, 1981.*
64. Turpie AGG, deBoer AC, Johnston RV, Butt R, Sealey BJ, Genton E: Plasma thromboxane B2 and urine betathromboglobulin in exercise-induced myocardial ischemia. *Canadian Cardiovascular Society, Montreal, 1981.*
65. Turpie AGG, Treatment of cerebrovascular disorders. *Microsymposium Nieuwe ontwikkelinger in de diagnostiek en behandeling van arteriele en veneuze thrombose. Bergwegziekenhuis Rotterdam, Holland, March, 1982.*
66. Hull R, Carter C, Ockelford P, Hirsh J, Turpie AGG, Powers P: Objective diagnosis of acute recurrent deep vein thrombosis by combined non-invasive testing and venography. *Annals of the Royal College of Physicians and Surgeons of Canada* 15, #132, 1982.
67. Turpie AGG, deBoer AC, Butt R, Genton E: Activation of platelets and blood coagulation in exercise-induced myocardial ischemia. *Annals of the Royal College of Physicians and Surgeons of Canada* 15, #134, 1982.
68. Turpie AGG, deBoer AC, Giroux M, Kinch D, Butt R, Gunstensen J, Gent M, E. Genton: Platelet survival and betathromboglobulin after heterograft mitral valve replacement. *thrombosis and Hemostasis* 50 (1), #63, 1983.
69. Doyle DJ, Turpie AGG, deBoer AC, Talbot C, McNamee J, Hirsh J, Gent M: Failure of suloctidil to prevent deep venous thrombosis in neurosurgical patients. *Thrombosis and Hemostasis* 50 (1), #248, 1983.
70. Turpie AGG, Butt R, Evaluation of a radioimmunoassay kit for fibrinopeptide A. *Blood* 62 (5) Suppl. 1, #1018, 1982.
71. Doyle DJ, Belbeck LW, McDonald S, Turpie AGG, Gunstensen J; Comparison of low-molecular weight heparin (Choay 222) with standard heparin for cardiopulmonary bypass in dogs. *Blood* 62 (5) Suppl 1, #1102, 1983.
72. Buchanan MR, Butt RW, Nazir D, Turpie AGG, Hirsh J: The regulation of platelet/endothelial cell adhesion by two arachidonic acid metabolites. *Thrombosis and Hemostasis* 50 (1), #190, 1983.
73. Hull R, Carter C, Turpie AGG, Jay R, Hirsh J, Kinch D, Raskob G: A randomized trial of sequential pneumatic limb compression in the prevention of venous thromboembolism following elective hip surgery. *Thrombosis and Hemostasis* 50 (1), #66, 1983.
74. Hull R, Carter C, Turpie AGG, Hirsh J, Jay R, Powers P, Raskob G, Dodd P: A randomized trial of diagnostic strategies for symptomatic deep vein thrombosis. *Blood* 62 (5) Suppl. 1, #1114, 1983.
75. Hull RD, Carter C, Turpie AGG, Hirsh J, Jay R, Powers P, Kinch D, Raskob G, Dodd P: A randomized trial of diagnostic strategies for symptomatic deep vein thrombosis. *Clinical and Investigative Medicine* 6 (Suppl 1), #117, 1983.

76. Jay R, Hull R, Carter C, Ockelford P, Buller H, Turpie AGG, Hirsh J: Outcome of abnormal impedance plethysmography results in patients with proximal vein thrombosis: frequency of return to normal. *Thrombosis and Hemostasis* 50 (1), #152, 1983.
77. Hull R, Carter C, Turpie AGG, Hirsh J, Jay R, Kinch D, Raskob G: A randomized trial of diagnostic strategies for symptomatic deep vein thrombosis. *Thrombosis and Hemostasis* 50 (1), #160, 1983.
78. Hull RD, Hirsh J, Carter C, Jay R, Coates G, Gill J, Turpie AGG: Pulmonary angiography, ventilation scanning and venography in patients with clinically suspected pulmonary embolism and abnormal perfusion scans. *Thrombosis and Hemostasis* 50 (1), #328, 1983.
79. Hull R, Carter C, Turpie AGG, Hirsh J, Jay R, Powers P, Dodd P, Gent M: A randomized trial of diagnostic strategies for symptomatic deep vein thrombosis. *Annals of the Royal College of Physicians and Surgeons* 16, #353, 1983.
80. Gent M (on behalf of the Study Group): An evaluation of suloctidil in the secondary prevention of cardiovascular events in patients surviving a thromboembolic stroke. Ninth International Joint Conference on Stroke and Cerebral Circulation, Tampa, February, 1984.
81. Doyle DJ, Cairns JA, Turpie AGG, McEwan P, Holder D, Steele M: Systemic urokinase in acute myocardial infarction: Dose schedules, lytic effect and correlation with peak creatine kinase. *Clinical and Investigative Medicine* 6 (Suppl 1), #71, 1983.
82. Doyle DJ, Cairns JA, Turpie AGG, Holder DA, McEwan MP: Intravenous urokinase (UK) and streptokinase (SK) in acute myocardial infarction (AMI). Evaluation by CK evolution and angiography. *Hemostasis* 14, #8, 1984.
83. Turpie AGG: The diagnosis and prevention of venous thromboembolism. Education Programme, XX Congress of the International Society of Hematology, Buenos Aires, Argentina, September, 1984.
84. Turpie AGG: Antiplatelet drugs in the prevention of postoperative deep vein thrombosis. Symposium - Drugs, Present and Future. XX Congress of the International Society of Hematology, Buenos Aires, Argentina, September, 1984.
85. Turpie AGG: Non-invasive diagnostic methods in thrombotic occlusive diseases. XX Congress of the International Society of Hematology, Buenos Aires, Argentina, September, 1984.
86. Turpie AGG: Enfermedad Tromboembolica. XXXIII Aniversario Del Hospital, Buenos Aires, Interzonal de Agudos Buenos Aires, Argentina, September, 1984.
87. Raskob G, Hull R, Leclerc J, Jay R, Hirsh J, Rosenbloom D, Johnston M, David M, Turpie AG, Gent M: Sustained therapeutic heparinization by subcutaneous administration for the primary treatment of acute venous thrombosis. *Circulation* 70 (Suppl II) #361, 1984.
88. Raskob G, Hull R, Leclerc J, Jay R, Hirsh J, Rosenbloom D, Johnston M, David M, Turpie AG, Gent M: Sustained therapeutic heparinization by subcutaneous administration for the primary treatment of venous thrombosis. *Clinical and Investigative Medicine (Suppl 10)* #40, 1984.

89. Raskob G, Hull R, Rosenbloom D, Leclerc J, Jay R, David M, Thomas M, Johnston M, Turpie AG, Gent M, Hirsh J: Lostistics of double-blinding a randomized trial of intravenous venous subcutaneous heparin for the treatment of venous thrombosis. *Controlled Clinical Trials*, 5:300, 1984.
90. Raskob G, Doyle D, Hull R, Turpie AGG, Hirsh J, David M, Jay R, Leclerc J, Gent M, Rosenbloom D. Sustained therapeutic anticoagulation with subcutaneous heparin for the primary treatment of venous thrombosis. *Clinical Pharmacology and Therapeutics* 35:268, 1984.
91. Turpie AGG: Antiplatelet drugs in ischemic heart disease, coronary artery bypass or peripheral arterial surgery. XVIIth International Congress of Internal Medicine, Kyoto, Japan, October, 1984.
92. Jay RM, Turpie AGG, Carter CJ, Hirsh J: Systemic fibrinolysis in venous thrombosis patients treated with recombinant tissue-type plasminogen activator. *Thrombosis and Hemostasis* 54, #01031, 1985.
93. Turpie AGG, Butt RW, Buchanan MR: The role of the lipoxxygenase pathway in the mechanism of action of Nafazatrom. *Thrombosis and Hemostasis* 43, #1436, 1985.
94. Turpie AGG: Venous anatomy: Deep vein thrombosis and misconception about the disease. Third Annual Seminar on Peripheral Vascular Disease and Hypertension. Toronto, August, 1985.
95. Turpie AGG, Jay RM, Carter CJ, Hirsh J: Systemic fibrinolysis in venous thrombosis patients treated with recombinant tissue-type plasminogen activator. *Clinical and Investigative Medicine* 8 (4), #166, 1985.
96. Turpie AGG, Jay RM, Carter CJ, Hirsh J: A randomized trial of recombinant tissue plasminogen activator for the treatment of proximal deep vein thrombosis. *Circulation II*: 72 (4), #770, 1985.
97. Turpie AGG, Duke RJ, Bloch RF, Trebilcock RG, Bayer N: A randomized controlled trial of intravenous heparin for the prevention of stroke progression in acute thrombotic stroke. *Circulation ii*: 72 (4) #536, 1985.
98. Turpie AGG: Thrombolytic therapy in venous and arterial diseases. Clinic Day in Internal Medicine, Essex Medical Society, Windsor, Ontario, November 20, 1985.
99. Duke RJ, Turpie AGG, Bloch RF, Trebilcock RG, Bayer NH: A randomized controlled trial of heparin in acute partial thrombotic stroke. 11th International Joint Conference on Stroke and Cerebral Circulation. San Francisco, February, 1986.
100. Turpie AGG: Current trends in treating thromboembolic disorders. Wellington County Medical Society, February 19, 1986.
101. Turpie AGG: Treatment of deep venous thrombosis. Medical College of Ohio, Department of Surgery, Toledo, Ohio, April 19, 1986.
102. Turpie AGG: Clinical trials with low-molecular weight heparin in venous thrombosis. *Thrombosis Research (Suppl VI)* #132, 1986.
103. Turpie AGG, Levine MN, Hirsh J, CARter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M: Randomized controlled trial of PK 10169 low molecular weight heparin (LMWH) for venous thrombosis prophylaxis after elective hip surgery. *Circulation* 74 (Supp II) #941, October, 1986.

104. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani HN, Hull RD, Gent M: A double blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep vein thrombosis in patients with thrombotic stroke. *Blood* 68 (Supp 1) #342, November, 1986.
105. Turpie AGG: Current uses of thrombolytic therapy. Presented at the American College of Physicians/Royal College of Physicians of Canada at the Ontario Annual Meeting, Toronto, March 7, 1987.
106. Turpie AGG: Current status of prophylactic anticoagulation: valve replacement, hip and knee surgery. 59th Annual Scientific Session, The New York Cardiological Society, April 25, 1987.
107. Turpie AGG: Anticoagulation in venous and arterial thromboembolism. Presented for Dupont, Kitchener, Ontario, May 12, 1987.
108. Turpie AGG: Thrombolytic therapy. Canadian Society of Laboratory Technologists. Hamilton, Ontario, June 21-26, 1987.
109. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani HN, Hull RD, Gent M: A double blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep vein thrombosis in patients with thrombotic stroke. XIth International Congress on Thrombosis and Haemostasis, Brussels, Belgium, July 6-10, 1987.
110. Powers PJ, Gent M, Jay R, Hirsh J, Levine M, Turpie G: Deep vein thrombosis prophylaxis in surgically treated fractured hip patients. XIth International Congress on Thrombosis and Haemostasis, Brussels, Belgium, July 6-10, 1987.
111. Turpie AGG, Gunstensen J, Hirsh J, Gent M: Optimal level of anticoagulation following tissue valve replacement: A randomized trial. *Circulation* 76 (Supp IV) #2061, October, 1987.
112. Turpie AGG, Bloch R, Duke R: Heparin in the treatment of thromboembolic stroke. New York Academy of Sciences, November 3-5, 1987.
113. Tratamiento Antitrombotico. Curso Educacional de Avances en Hemostasia Y Trombosis. Barcelona, Spain, March 3-5, 1988.
114. Turpie AGG: Current trends in antithrombotic therapy. 33rd Annual Scientific Assembly of the College of Family Physicians of Canada, Alberta Chapter, Banff, Alberta, March 6-11, 1988.
115. Turpie AGG, Robinson J, Mulji AS, Mishkel GJ, Sealey BJ, Doyle DJ, Cairns JA, Hirsh J, Gent M: Prevention of left ventricular mural thrombosis in acute myocardial infarction: A double-blind trial comparing high dose with low dose subcutaneous heparin. *Journal of the American College of Cardiology* 11 (2) Suppl A, 26A, 1988.
116. ISIS Collaborative Group: Results of a large randomised trial of intravenous streptokinase and oral aspirin in acute myocardial infarction. *Journal of the American College of Cardiology* 11 (2) Suppl A, 232A, 1988.
117. Turpie AGG: Antithrombotic effects of aspirin. Annual Towsley Lecture, Midland Hospital Centre, Midland, Michigan, April 11, 1988.
118. Turpie AGG: Current trends in thromboembolic disorders: prophylaxis and treatment. Halton Medical Society Presentation, Oakville, May 18, 1988.

119. Turpie AGG, Levine MN: The relationship between ex-vivo anti-factor Xa levels and efficacy and safety of low molecular weight heparin. Satellite Symposium - Xth International Congress on Thrombosis, Athens, Greece, May 22-27, 1988.
120. Turpie AGG, Hirsh J, Gent M, Julian D, Johnson J: A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control in the prevention of deep vein thrombosis in neurosurgical patients. Xth International Congress on Thrombosis, Athens, Greece, #269, 1988.
121. Turpie AGG: A randomized study of two intensities of warfarin for prosthetic heart valve surgery. Xth International Congress on Thrombosis, Athens, Greece, #77, 1988.
122. Turpie AGG: Current trends in anticoagulation. "One Day in Hematology 88", The College of Family Physicians of Canada, Saskatchewan Chapter, May 28, 1988.
123. Turpie AGG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA, Hirsh J, Gent M: Prevention of left ventricular mural thrombosis in acute transmural anterior myocardial infarction: A double blind trial comparing high dose with low dose subcutaneous calcium heparin. XXII Congress of the International Society of Hematology, Milan, Italy, August 28-September 2, 1988.
124. Turpie AGG: Platelet involvement in the pathogenesis of atherothrombotic disease. XXII Congress of the International Society of Hematology, La Ticlopidina Nella Prevenzione Degli Eventi Trombotici Maggiori Nella Malattia Vascolare Ischemica Symposium, Milan, Italy, August 28-September 2, 1988.
125. Turpie AGG: Recombinant tissue plasminogen activator (rt-PA) in pulmonary embolism and deep venous thrombosis. Special Symposium on Thrombolytic Therapy, Cardiology Symposium, Section of Cardiology and Department of Continuing Medical Education, University of Manitoba, September 9, 1988.
126. Turpie AGG: Premier Symposium Suisse sur l'heparine a bas poids moleculaire. Etude comparative contre Placebo de l'efficacite de l'Enoxaparine dans a prevention des thromboses veineuses profondes dans la chirurgie de la hanche. Berne, Switzerland, December 1, 1988.
127. Turpie AGG: What is thrombolytic therapy and why do we use it? Contemporary Management of Cardiovascular Disease - Heart and Stroke Foundation of Ontario, Toronto, December 15-16, 1988.
128. Turpie AGG: Thrombolytic therapy in venous thromboembolism. Joint Meeting of the Forum on Angiology of the Royal Society of Medicine and the British Society for Haemostasis and Thrombosis. London, England, March 21, 1989.
129. Turpie AGG: Profilaxis de la thrombosis venosa profunda con heparinas bajo peso molecular, en pacientes traumatologicos. Academia Nacional de Medicina, Buenos Aires, Argentina, April 4, 1989.
130. Turpie AGG: Prevencion de la thrombosis mural ventricular en pacientes con IAM anterior tras mural: un estudio doble ciego comparando heparina calcica en dosis altas o bajas. Academia Nacional de Medicina, Buenos Aires, Argentina, April 4, 1989.

131. Turpie AGG: Comparacion randomizada de dos intensidades de anticoagulacion oral luego del reemplazo valvular con protesis biologicas. Academia Nacional de Medicina, Buenos Aires, Argentina, April 4, 1989.
132. Turpie AGG: El uso en terapeutica de TVP de las heparinas de bajo peso molecular. Academia Nacional de Medicina, Buenos Aires, Argentina, April 5, 1989.
133. Turpie AGG: Nuevas drogas fibrinoliticas en el tratamiento de la embolia pulmonar. Academia Nacional de Medicina, Buenos Aires, Argentina, April 5, 1989.
134. Turpie AGG: CATS: Estudio Americano Canadiense sobre Ticlopidina. TASS: Estudio Ticlopidina-Aspirina en accidente cerebro vascular isquemico. 2° Simposio Educacional Reunion Satelite Grupo CAHT, Buenos Aires, Argentina, April 6, 1989.
135. Turpie AGG: Comparacion randomizada de dos intensidades de anticoagulacion oral luego del reemplazo valvular con protesis biologicas. 2° Simposio Educacional en Profilaxis Y Terapeutica Antitrombotica Reunion Cientifica Del Grupo Caht. Chateau Carreras, Cordoba, Argentina, April 7, 1989.
136. Turpie AGG: The Anti-Clotters in Heart Disease and Stroke. Continuing Medical Education - Telemedicine, April 19, 1989.
137. Turpie AGG: Anticoagulant therapy after acute myocardial infarction. Thrombosis and Antithrombotic Therapy: Direction for the '90s" symposium, Fort Lauderdale, Florida, April 13, 1989.
138. Turpie AGG: Prevention of post-operative venous thrombosis with low molecular weight heparin. V Congreso Nacional de la Sociedad Espanola de Trombosis y Hemostasia. Bilbao, Spain, May 4, 1989.
139. Turpie AGG: When time is muscle. Critically Speaking, Current Issues. Henderson General Hospital, Hamilton, June 1, 1989.
140. Turpie AGG: The Canadian American Stroke Study (CATS). Simposio Internacional Sobre Terapeutica Antiagregante Plaquetaria Nas Isquemias Cerebrovasculares. Academia Brasileira de Neurologia, Rio de Janeiro, Brazil, July 25, 1989.
141. Turpie AGG: The Ticlopidine Aspirin Stroke Study (TASS). Simposio Internacional Sobre Terapeutica Antiagregante Plaquetaria Nas Isquemias Cerebrovasculares. Academia Brasileira de Neurologia, Rio de Janeiro, Brazil, July 25, 1989.
142. Turpie AGG: The Canadian American Stroke Study (CATS). XII Congreso Interamericano de Cardiologia, Rio de Janeiro, Brazil, July 26, 1989.
143. Turpie AGG: Prevencion del Accidente Cerebrovascular Isquemico. Resultado de los Estudios CATS (The Canadian American Ticlodipine Aspirin Study). Symposium Internacional Sobre Terapeutica Antiplaquetaria, Sociedad Argentina Para el Estudio de la Trombosis. Buenos Aires, Argentina, July 28, 1989.
144. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M, Turpie AGG: Relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine to prevent deep vein thrombosis after hip replacement. XIIth Congress of the International Society on Thrombosis and Haemostasis. Tokyo, Japan, August 1989.

145. Turpie AGG: Clinical evaluation of International Normalized Ratio (INR) for control of oral anticoagulants. XIIth Congress of the International Society on Thrombosis and Haemostasis, Tokyo, Japan, August 1989.
146. Turpie AGG: Significance of CATS and TASS studies from USA and Canada in prevention of secondary cardiac and cerebral infarction. Academy of Medicine of Manila, Manila, Philippines, August 1989.
147. Turpie AGG: Significance of CATS and TASS studies from USA and Canada in prevention of secondary cardiac and cerebral infarction. Neurological Society of Thailand, Bangkok, Thailand, September 1, 1989.
148. Turpie AGG: Enoxaparin prophylaxis in elective hip surgery. Venous Thromboembolism: Managing the Risk. Rhone-Poulenc Symposium, Berlin, West Germany, October 5, 1989.
149. Turpie AGG: The Canadian American Ticloipdine Study (CATS) in thromboembolic stroke. Prevention and treatment of arterial thromboembolism: New aspects of Ticlopidine. Lancet (German Supplement) October 6, 1989.
150. Turpie AGG: TPA vs Heparin in deep venous thrombosis: results of a randomized controlled trial. American College of Chest Physicians, 55th Annual Scientific Assembly and XVI World Congress on Diseases of the Chest, Boston, Massachusetts, October 29, 1989.
151. Massel D, Turpie AGG, Gill JB, Cairns JA, Russett J: Development of neutralizing antibodies after 1.5 million units of streptokinase in the treatment of acute myocardial infarction. Clin and Invest Medicine 12 (5) #120, 1989.
152. Turpie AGG: Anticoagulant therapy in cardiac disease. Continuing Medical Education - Day in Medicine, Hamilton Convention Centre, November 1, 1989.
153. Massel D, Turpie AGG, Gill JB, Cairns JA, Russett J: Development of neutralizing antibodies after 1.5 million units of streptokinase in the treatment of acute myocardial infarction. Circulation 80 (4) Suppl, #1398 Abst 1989.
154. Turpie AGG: Side effects of antithrombotic therapy - optimal dosage. Stroke Prevention; A symposium. Montreal, Toronto, Halifax, Nov 27-30, 1989.
155. Turpie AGG: Deep vein thrombosis. Contemporary Management of Cardiovascular Disease. Heart and Stroke Foundation of Ontario. Toronto, Ontario, December 14-15, 1989.
156. Turpie AGG: The efficacy and tolerance of high-dose or low-dose heparin in the prevention of mural thrombosis. Prospects and Strategies in Cardiovascular Research II - Heparins in Cardiology Workshop, Second International Symposium, Antwerp, Belgium, February 19, 1990.
157. Turpie AGG: Prevention of cerebral emboli. Continuing Medical Education - Telemedicine Canada, March 2, 1990.
158. Turpie AGG: Ticlopidine in Recent Thromboembolic Stroke: The Canadian American Ticlopidine Study (CATS). J of Neurol 237:(2): 161, 1990.
159. Turpie AGG. Thrombolytic therapy in acute myocardial infarction. Wellington County Medical Society, Guelph, Ontario May 16, 1990.
160. Turpie AGG. New concepts in antithrombotic therapy. Residents Evening in Anticoagulant Therapy. DuPont Pharmaceuticals, Hamilton May 24, 1990.

161. Turpie AGG. Update in Thromboembolic Diseases. Kabi Pfrimmer S.A. Laboratories. Barcelona June 18-19, 1990.
162. Turpie AGG. Dilemma of the 90's - Stroke Prevention - When to Anticoagulate. Chinese Canadian Medical Society, Toronto, August 22, 1990.
163. Connolly SJ. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. Clinical and Investigative Medicine 13 (5): #251 Abst 1990.
164. Massel D, Turpie AGG, Cairns JA, et al. Persistence of neutralizing antibodies at one year following IV streptokinase for acute myocardial infarction. Clinical and Investigative Medicine 13 (5). #224 Abst 1990.
165. Massel D, Gill JB, Turpie AGG, Cairns JA. Thrombolysis does not increase the rate of cardiac catheterization in the first year post-MI. Clinical and Investigative Medicine 13 (5) #119 Abst 1990.
166. Turpie AGG: A symposium on modern anticoagulant therapy. The Heart and Stroke Foundation of Ontario. Hamilton October 24, 1990.
167. Connolly SJ (CAFA Study Group) Canadian Atrial Fibrillation Anticoagulation Study. Circulation 82 Suppl III, #0426, 1990.
168. Massel D, Turpie AGG, Cairns JA, Gill JB, O'Dell C, Russett, J: Persistence of neutralizing antibodies at 1 year following IV streptokinase for acute myocardial infarction. Circulation 82 (4) Suppl, #1007 Abst 1990.
169. Turpie AGG: Atrial fibrillation revisited. 17th Annual Day in Medicine, Hamilton, October 31, 1990.
170. Turpie AGG: Continuing Medical Education. Valvular Heart Disease -Its thromboembolic complications and their prevention. "Issues in Thromboembolism in the 1990's". Tampa, Florida, November 3, 1990.
171. Levine M, Hirsh J, Gent M, Turpie A et al: A randomized trial comparing Enoxaparine low molecular weight heparin with standard unfractionated heparin in patients undergoing elective hip surgery. Blood 76 (10):Suppl 1:513a #2043, Nov 15, 1990.
172. Turpie AGG: Continuing Medical Education. Prevention of thromboembolic stroke in non-valvular atrial fibrillation. Lambton County Medical Society, Sarnia, November 21, 1990.
173. Turpie AGG: Continuing Medical Education. Indications for Anticoagulation. Dept. of General Practice Rounds, November 27, 1990
174. Turpie AGG: Visiting Professor, Medical Grand Rounds, University of California, San Diego, November 30, 1990.
175. Turpie AGG: Review of Canadian Atrial Fibrillation Anticoagulation Study. University of California, San Diego, December 1, 1990.
176. Turpie AGG: Anticoagulation in prosthetic and natural valve disease. Contemporary management of Cardiovascular Disease 1990. Heart and Stroke Foundation of Ontario, Toronto, December 6, 1990.

177. Turpie AGG: The prevention of stroke in non-valvular atrial fibrillation. Lincoln County Academy of Medicine, St. Catharines, January 12, 1991.
178. Turpie AGG: The use of heparin in cardiology. Belgian Association for Cardiology, Brussels, Feb 1-2, 1991.
179. Turpie AGG: Current issues in Anticoagulation. The Leeds and Grenville Medical Society, Brockville, February 13, 1991.
180. Turpie AGG: Anticoagulant Therapy for Valve Disease. All Heart Symposium '91, UBC-Continuing Medical Education, Vancouver, February 22, 1991.
181. Turpie AGG: Fragmin in Australia. Fragmin Symposium, Hayman Island, Queensland, Australia, March 24, 1991.
182. Turpie AGG: Resultados del estudio ISIS 3. 4 Simposium Internacional, Nuevas Perspectivas Terapeuticas en Trombosis. Academia Nacional de Medicina, Buenos Aires, Argentina, April 9, 1991.
183. Turpie AGG: Terapeutica anticoagulante en la enfermedad coronaria isquemica. 4 Simposium Internacional, Nuevas Perspectivas Terapeuticas en Trombosis. Academia Nacional de Medicina, Buenos Aires, Argentina, April 10, 1991.
184. Turpie AGG: Trombosis mural ventricular en el IAM. 4 Simposium Internacional, Nuevas Perspectivas Terapeuticas en Trombosis. Academia Nacional de Medicina, Buenos Aires, Argentina, April 11, 1991.
185. Turpie AGG: Fibrilacion auricular: reduccion de riesgo de stroke. 4 Simposium Internacional, Nuevas Perspectivas Terapeuticas en Trombosis. Academia Nacional de Medicina, Buenos Aires, Argentina, April 11, 1991.
186. Turpie AGG: Estudios en prevencion de TVP y EP en el postoperatorio de cirugia traumatologica con heparina y heparinas de bajo peso molecular. 4 Simposium Internacional, Nuevas Perspectivas Terapeuticas en Trombosis. Academia Nacional de Medicina, Buenos Aires, Argentina, April 11, 1991.
187. Turpie AGG: Anticoagulant therapy for valvular heart disease. Directions for the '90's. Heart and Stroke Foundation of Ontario, May 1, 1991.
188. Turpie AGG: Atrial fibrillation - Strategies to reduce the rate of stroke. The Hong Kong Neurological Society and Australian Association of Neurologists Joint Scientific Meeting, Hong Kong, May 6-8, 1991.
189. Turpie AGG: Thrombolysis for acute non-myocardial conditions. 7th World Congress on Emergency and Disaster Medicine. Montreal, May 15, 1991.
190. Turpie AGG: Heparin and thrombolysis - ISIS-3 and other trials. Canadian ISIS-3 Thrombolysis Symposium. Toronto May 24-25, 1991.
191. Turpie AGG: How to use anticoagulant and fibrinolytic therapy in stroke. Toronto Neurology Update 1991, Toronto, May 31, 1991.
192. Turpie AGG: Prevention of stroke in atrial fibrillation. Continuing Medical Education - Health Care for the Elderly. Hamilton, June 5, 1991.
193. Turpie AGG: Results and implications of ISIS-3. Issues in reperfusion for the 1990's. The University of Calgary, Banff, June 9, 1991.

194. Turpie AGG: An evening in Thrombolytics. Port Colborne, June 12, 1991.
195. Turpie AGG, Levine MN, Powers P, Ginsberg JS, Jay R, Klimek M: A double blind randomized trial of ORG 10172 low molecular weight heparinoid versus unfractionated heparin in the prevention of deep vein thrombosis. *Thrombosis and Haemostasis* 65 (6) #303, 1991.
196. Turpie AGG: Lomoparan in the prevention of deep vein thrombosis in stroke patients. Satellite Symposium, ISTH, Amsterdam, Netherlands, July 6, 1991.
197. Turpie AGG: Risk factors and prophylaxis of DVT with a LMWH, Fraxiparine. Satellite Symposium, ISTH, Amsterdam, Netherlands, July 6, 1991.
198. Turpie AGG: Non-valvular atrial fibrillation: Risks and benefits of anticoagulant therapy. Essex County Medical Society, Windsor Ontario, July 10, 1991.
199. Turpie AGG: ISIS III: Resultados de SK vs APSAC vs TPA. XLVII Congresso da Sociedade Brasileira de Cardiologia. Sao Paulo, Brazil, September 15-19, 1991.
200. Turpie AGG: Update in Heparin Therapy. Haematological Association of Thailand, Bangkok, Thailand, September 27, 1991.
201. Turpie AGG: Advancement in heparin therapy - Singapore Haematological Society, Singapore, September 29, 1991.
202. Turpie AGG: Strategies in risk reduction for stroke in patients with ischaemic heart disease. Singapore Haematological Society, Singapore, September 29, 1991.
203. Turpie AGG: Role of low molecular weight heparin (Fraxiparine) in cardiology. An International Symposium. Hypertension and Coronary Heart Disease Beijing, China, October 1, 1991.
204. Turpie AGG: Ticlopidine in prevention of major ischemic vascular event. An International Symposium. Hypertension and Coronary Heart Disease, Beijing, China, October 1, 1991.
205. Turpie AGG: Strategies for the prevention of cardioembolic stroke. Chinese Society of Cardiology. Beijing, China, October 2, 1991
206. Turpie AGG: Advances in heparin therapy. Hong Kong Haematological Society, Hong Kong, October 4, 1991.
207. Turpie AGG, Gent M, Laupacis A, Latour Y, Wright D, Hoffman J, Gunstensen J, Basile F, Klimek M, Hirsh J: Reduction in mortality by adding acetylsalicylic acid (100 mg) to oral anticoagulants in patients with heart valve replacement. *Can J Cardiol* 7:95A (Suppl A): August 1991.
208. Turpie AG: La ticlopidina en la prevencion de accidentes vasculares isquemicos graves. XXIV Congreso Nacional Sociedad Venezolana de Cardiologia. Caracas, Venezuela, October 21, 1991.
209. Turpie AGG: Antithrombotic therapy in rheumatic heart disease. Heart and Stroke Foundation of Ontario Symposium, Hamilton, November 6, 1991.
210. Turpie AGG: Prevention of stroke in atrial fibrillation. Clinical Geriatric Traineeship. Continuing Medical Education. Hamilton, November 7, 1991.

211. Massel D, Turpie AGG, Cairns JA, Ofosu F, Buchanan M: Previous streptokinase (SK) therapy inhibits subsequent SK thrombolysis. *Circulation* 84 (4) Abstract #1858, 1991.
212. Turpie AGG: Ticlopidine in recent thromboembolic stroke (CATS) and after stroke precursors (TASS). XII International Congress on Haemostasis and Thrombosis, Buenos Aires, Argentina, November 19, 1991.
213. Turpie AGG: Risk factors of DVT. Clinical experience with Fraxiparine in the prophylaxis and treatment of DVT. XII International Congress on Haemostasis and Thrombosis, Buenos Aires, Argentina, November 21, 1991.
214. Turpie AGG: Anticoagulation update - What's new in the 90's. Cambridge Memorial Hospital Conjoint Clinical Meeting, Cambridge, November 28, 1991.
215. Turpie AGG: Thrombolysis in acute myocardial infarction: Preliminary Results of ISIS-3. X Biennial Cardiology Conference, Pakistan Cardiac Society, December 5-7, 1991.
216. Turpie AGG: Thrombolytic therapy in acute venous thrombosis. Department of Surgery, Northwestern University Medical School, Chicago, December 14, 1991.
217. Turpie AGG: Should I anticoagulate my patient with atrial fibrillation? Peterborough County Medical Society, Peterborough, Ontario, January 31, 1992.
218. Turpie AGG: Expanded Criteria for Thrombolysis. Newfoundland Society of Cardiology. Cornerbrook, Newfoundland, February 1, 1992.
219. Turpie AGG: The role of heparin. Newfoundland Society of Cardiology. Cornerbrook, Newfoundland, February 1, 1992.
220. Turpie AGG: Different indications for heparins in cardiology. Third International Congress in Cardiovascular Research. Antwerp, Belgium, February 17, 1992.
221. Turpie AGG: Modern anticoagulant therapy. Brantford General Hospital, Brantford, February 26, 1992.
222. Turpie AGG: Recent advances in antithrombotic therapy. St. Michael's Hospital, Toronto, March 3, 1992.
223. Turpie AGG: Coumadin: Use in patients undergoing hip surgery. Medical/Surgical Rounds, Scarborough General Hospital, March 4, 1992.
224. Turpie AGG: Non-valvular atrial fibrillation. Who to anticoagulate? How to anticoagulate? Scarborough Grace General, March 4, 1992.
225. Turpie AGG: Post-MI Anticoagulation. Jewish General Hospital, Montreal, March 5, 1992.
226. Turpie AGG: Post-MI Anticoagulation. Institute of Cardiology, Montreal, March 5, 1992.
227. Turpie AGG: Post-MI Anticoagulation. Sacre Coeur Hospital, Montreal, March 6, 1992.

228. Turpie AGG: The risk of stroke and the role of antithrombotic therapy. "A Close-up on the Evidence". York County Hospital, Medical Education Committee, Bradford, Ontario, March 11, 1992.
229. Turpie AGG: Antithrombotic therapy - Direction for the 90's. Medical Grand Rounds, Sunnybrook Health Science Centre, Toronto, March 24, 1992.
230. Turpie AGG: Antithrombotic therapy following heart valve replacement. Heart Valve Surgery Programme, Lake Louise, Alberta, March 27-29, 1992.
231. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. Reduction in mortality by adding aspirin (100 mg) to oral anticoagulants in patients with heart valve replacement. JACC 19 (3):103A, 1992.
232. Turpie AGG. Antiplatelet therapy in Cardiovascular disease. Joint Board for Postgraduate Medical Education, Riyadh, Saudi Arabia, April 26, 1992.
233. Turpie AGG. Antithrombotic therapy in ischaemic heart disease. Joint Board for Postgraduate Medical Education, Riyadh, Saudi Arabia, April 27, 1992.
234. Turpie AGG. Low molecular weight heparin, mode of action and clinical evaluation. Joint Board for Postgraduate Medical Education, Riyadh, Saudi Arabia, April 27, 1992.
235. Turpie AGG. Antithrombotic therapy in stroke. Joint Board for Postgraduate Medical Education, Riyadh, Saudi Arabia, April 27, 1992.
236. Turpie AGG. The prevention of systemic embolism in mechanical heart valve replacement. Thrombosis and Its Management. Leon Poller Retirement Symposium, Manchester, England, May 7-8, 1992.
237. Turpie AGG: New approach in the management of stroke. Asian/Pacific Congress on Bleeding Disorders and Transfusion Medicine, Bangkok Thailand, May 10-15, 1992.
238. Turpie AGG. Thrombosis update. Asian Pacific Congress on Bleeding Disorders and Transfusion Medicine. Bangkok Thailand, May 10-15, 1992.
239. Turpie AGG: Risk factors and management of deep vein thrombosis in surgery - New approach with low molecular weight heparin. Kuala Lumpur Medical Society, Kuala Lumpur, Malaysia, May 16, 1992.
240. Turpie AGG: Recent advances in antithrombotic therapy. Manila Academy of Medicine, Manila Philippines, May 18, 1992.
241. Turpie AGG: Recent advances in antithrombotic therapy. Cebu City Medical Society, Cebu City Philippines, May 18, 1992.
242. Turpie AGG: Recent advances in antithrombotic therapy. Davao City Medical Society, Davao City Philippines, May 19, 1992.
243. Turpie AGG. Antiplatelets/Antithrombins/Antibodies. Reperfusion 1992: Emergency. Univ. of British Columbia, May 23-24, 1992.
244. Turpie AGG. Final results of the ISIS-3 Study. Instituto de Cardiologia, Buenos Aires, Argentina, June 19, 1992.
245. Turpie AGG. New advances in ischemic cardiopathy with antiplatelet drugs and LMWH. Instituto de Cardiologia, Buenos Aires, Argentina, June 19, 1992.

246. Turpie AGG. Aspirin, the ageless remedy: Comparison with oral anticoagulants. Rounds in Emostasi E Trombosi, Istituto di Clinica Medica 2, Pavia Italy, September 7, 1992.
247. Turpie AGG. Anticoagulant Therapy - Directions for the 90's. Ospedali Riuniti di Bergamo, Bergamo Italy, September 8, 1992.
248. Samama MM, Forbes C, Turpie AGG, Lowe G: Treatment of venous thromboembolism. 16th World Congress of the International Union of Angiology, Paris September 16, 1992.
249. Turpie AGG: Antithrombotic therapy following heart valve replacement. Hopital Tenon, Service de Cardiologie, September 17, 1992.
250. Turpie AGG: Anticoagulant Therapy. Update on Drugs - Coumadin. Geriatric Medicine for the Practising Physician. Ontario Association of Medical Directors of Homes for Senior Citizens. Toronto, September 21, 1992.
251. Turpie AGG: Anticoagulation: How I would do it. 3rd Annual Cardiovascular therapeutics related to anticoagulant therapy. The Heart and Stroke Foundation. Hamilton, October 14, 1992.
252. Turpie AGG: Thromboembolism - Diagnosis and Treatment. Grey-Bruce Medical Society, October 15, 1992.
253. Gill JB, Fondevila CG, Brister SJ, Turpie AGG et al: Contrast media induces thrombin generation during PTCA. Canadian Cardiovascular Society, Ottawa, October 22, 1992.
254. Turpie AGG: Antithrombotic therapy following heart valve replacement. Canadian Cardiovascular Society, Ottawa, October 23, 1992.
255. Turpie AGG: Antithrombotic therapy following heart valve replacement. Controversies in Antithrombotic Therapy. The Thrombosis Interest Group, Ottawa, October 23, 1992.
256. Turpie AGG: Thrombophlebitis - Long term treatment. American College of Chest Physicians. 58th Scientific Assembly, Chicago, October 26, 1992.
257. Turpie AGG: Anticoagulation. 19th Annual Day in Medicine, CME, Hamilton, November 4, 1992.
258. Turpie AGG: Therapeutic anticoagulation. The Ontario College of Family Physicians. Toronto, November 12, 1992.
259. Turpie AGG: Interchange Forum: Developments in prophylactic therapy for venous thromboembolic disease. Dallas, November 13, 1992.
260. Turpie AGG: Clinical update on antithrombotic therapy. The University of Arizona College of Medicine, New Orleans, November 14, 1992.
261. Ginsberg JS, Hirsh J, Gent M, McKinnon B, Turpie AGG et al. A phase II study of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 86 (4) ppI-409, 1992.
262. Turpie AGG: Combined antiplatelet therapy and full dose anticoagulation in patients with artificial heart valves. American Heart Association, New Orleans, November 1992.

263. Turpie AGG: V.T.E.D. Diagnosis: Which investigations? I.S.E.R.V.D. 1st Congress, San Diego, November 23, 1992.
264. Turpie AGG: V.T.E.D. Treatment: Treatment in the 90's? I.S.E.R.V.D. 1st Congress, San Diego, November 24, 1992.
265. Turpie AGG: Pulmonary thromboembolism. Contemporary Management of cardiovascular disease. Toronto, December 11, 1992.
266. Turpie AGG: Low molecular weight heparin and heparinoids and anticoagulation. American College of Physicians, Indiana Chapter, Indianapolis, Indiana Feb. 20, 1993.
267. Turpie AGG: DVT and PE in trauma patients. Multi-disciplinary Trauma Series, Hamilton, Feb. 23, 1993.
268. Turpie AGG: Should I anticoagulate my patient with atrial fibrillation. Special Education Seminar, Huronia Medical Association, Midland, February 24, 1993.
269. Turpie AGG: Antithrombotic Update: Direction for the 90's. Continuing Medical Education, North York Branson Hospital, Toronto, March 4, 1993.
270. Turpie AGG: Thrombin Inhibitors. ISIS Collaborators Meeting; American College of Cardiology, Anaheim, California, March 16, 1993.
271. Turpie AGG: Anticoagulation in the 90's. Belleville General Hospital, Grand Rounds, March 25, 1993.
272. Turpie AGG, Stanton E: The use of heparin in ischemic heart disease "Unanswered Questions", Medical Grand Rounds, St. Joseph's Hospital, Hamilton, April 14, 1993.
273. Turpie AGG: The use of low molecular weight heparins in orthopaedic surgery. University of Manitoba, Faculty of Medicine, April 19, 1993.
274. Turpie AGG: The use of low molecular weight heparins in Cardiology. Visiting Professor, Department of Cardiology, University of Manitoba, April 20, 1993.
275. Turpie AGG: Short and long-term management of lower extremity venous thrombosis. The Anticoagulation Forum. Monterey, California, April 23, 1993.
275. Turpie AGG: Prevention of recurrent Stroke. Columbia University, New York, New York, April 24, 1993.
276. Turpie AGG: Clinical experience with Orgaran in deep vein thrombosis prophylaxis in high risk patients. "Clinical use of the new antithrombotic Orgaran in high risk situations" Symposium, Oss, The Netherlands, April 29, 1993.
277. Turpie AGG: Prevention of stroke in atrial fibrillation. Continuing Medical Education, McMaster University, Burlington, Ontario, May 5, 1993.
278. Turpie AGG: Update on thrombolytic therapy in acute myocardial infarction. Ontario College of Pharmacists, Toronto, Ontario, May 6, 1993.
279. Turpie AGG: Oral anticoagulation: New indications and old indications revisited. Anticoagulation for the 90's Symposium. Springfield, Illinois May 8, 1993.

280. Turpie AGG: Chairman - New Concepts in Stroke, Pathophysiology and Prevention. 2nd International Conference on Stroke, Geneva, Switzerland, May 12-15, 1993.
281. Turpie AGG: Venous Thromboembolism. Clinical Advances in Venous Thrombo-Embolic Disease Symposium, McMaster University Faculty of Health Sciences Symposium, Queen's Landing Inn, Niagara on the Lake, May 15, 1993.
282. Turpie AGG: Trials with Heparin. European Atherosclerosis Society Meeting, Capri, Italy, May 16-19, 1993.
283. Turpie AGG: DVT - Diagnosis, Prevention and Treatment. Grand Rounds, St. Mary's General Hospital, Kitchener, Ontario, May 27, 1993.
284. Turpie AGG: Thromboembolic disease in joint replacement. 48th Annual Meeting of the Canadian Orthopaedic Association, 27th Annual Meeting of the Canadian Orthopaedic Research Society, Montreal, Quebec, June 1, 1993.
285. Turpie AGG: Prevention of deep vein thrombosis after orthopedic surgery. Orthopedic Rounds, Buffalo General Hospital, June 2, 1993.
286. Turpie AGG: Platelet dysfunction during cardiopulmonary bypass. Blood Conservation '93. Department of Anaesthesia of the University of Ottawa. Halifax, Nova Scotia, June 8, 1993.
287. Turpie AGG: Diagnosis of venous thromboembolism and pulmonary embolism. Thrombosis Forum, XVII World Congress on Diseases of the Chest, Amsterdam, June 15, 1993.
288. Turpie AGG: Controversies in the diagnosis and treatment of venous thromboembolism. Thrombosis Forum, XVII World Congress on Diseases of the Chest, Amsterdam, June 17, 1993.
289. Turpie AGG: Prophylaxis and treatment of DVT and pulmonary embolism with heparin/Coumadin, and update on usage of low molecular weight heparin. The Credit Valley Hospital, Medicine Rounds, Mississauga, June 29, 1993.
290. Turpie AGG (on behalf of the Thrombosis Interest Group). Control of anticoagulant therapy: A cross Canada survey. *Thromb Haemost* 69 (6):667, 1993.
291. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsburg J, Geerts W, Neemeh J, Leclerc J, Powers P, Piovella F, Skingley P. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis (DVT). *Thromb Haemost* 69 (6):982, 1993.
292. Fondevila CG, Gill JB, Brister SJ, Turpie AGG, Holder DA, Ofosu FA, Buchanan MR. Contrast media induces thrombin generation during PTCA. *Thromb Haemost* 69 (6):1014, 1993.
293. Powers P, Gent M, Klimek M, Levine M, Geerts W, Neemeh J, Turpie AGG, Jay R, Leclerc J, Ginsberg J, Hirsh J. A randomized double-blind trial comparing a low-molecular weight heparinoid, Orgaran, with aspirin in the prevention of venous thromboembolism following surgery for hip fracture. *Thromb Haemost* 69 (6):1116, 1993.
294. Levine MN, Hirsh J, Gent M, Turpie AGG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomized trial comparing the activated thromboplastin time with the heparin assay to monitor heparin therapy in patients with acute venous

- thromboembolism requiring large daily doses of heparin. *Thromb Haemost* 69 (6):1122, 1993.
295. Lensing AWA, Doris I, McGrath F, Prandoni P, Ginsberg J, Turpie A, Hirsh J. Color doppler vs real-time ultrasonography in the diagnosis of postoperative asymptomatic DVT. *Thrombosis and Haemostasis* 69 (6):1361, 1993.
 296. Oberhardt BJ, Gresalfi J, Fearington T, Goslen G, Turpie AG, Massel D. Rapid determination of resistance to SK in thrombolytic therapy patients using a simple in vitro dry chemistry test. *Thromb Haemost* 69 (6):1654, 1993.
 297. Turpie AGG: Hirulog: A new direct thrombin inhibitor. Potential role in the prevention of deep vein thrombosis. *ISTH Satellite Symposium, New York City, N.Y. July 10, 1993.*
 298. Turpie AGG: Stroke and Cardiac Patients: Preventing vascular events and MI's. *Consultation on Stroke. Kommunikom Publications, 1993.*
 299. Turpie AGG: Anticoagulation in the 90's. *Grand Rounds, Jefferson Hospital, Pittsburg PA, July 27, 1993.*
 300. Turpie AGG: Anticoagulation in the 90's. *Grand Rounds, St. Frances Hospital, Pittsburg, PA, July 28, 1993.*
 301. Turpie AGG: The clinical use of low molecular weight heparin. *Medical Grand Rounds, McMaster University, August 5, 1993.*
 302. Turpie AGG: Preventing thromboembolic complications from prosthetic heart valves. *4th Annual Thrombosis, Thromboembolism and Thrombolysis Symposium, Yale University, August 20, 1993.*
 303. Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular weight heparin: Enoxaparin). *Detroit Medical Society, Detroit Michigan, August 25, 1993.*
 304. Turpie AGG: Venous thromboembolism prophylaxis in orthopaedic surgery. *SICOT '93, Seoul Korea, August 30, 1993.*
 305. Turpie AGG: Prophylaxis and treatment of DVT and Pulmonary Embolism: Update on low molecular weight heparin. *Grand Rounds, Peel Memorial Hospital, September 17, 1993.*
 306. Massel D, Turpie AGG, Oberhardt BJ, Gresalfi NJ, Fearington T, Goslen G: Estimation of resistance of streptokinase: A preliminary report of a rapid bedside test. *The Canadian Journal of Cardiology* 9 (Suppl E) Abstract #279, 1993.
 307. Turpie AGG: Deep vein thrombosis: Diagnosis and Treatment. *Thrombosis: New Perspectives in Diagnosis and Treatment Symposium, Robert Wood Johnson Medical School, New Brunswick, New Jersey, October 1, 1993.*
 308. Turpie AGG: Diagnosis and treatment of deep vein thrombosis. *Current Concepts in Venous Thromboembolic Disorders Symposium, Episcopal Hospital, Philadelphia, PA, October 2, 1993.*
 309. Turpie AGG: Valvular Heart Disease. "Thrombosis and its Management" *Triennial Symposium, McMaster University, Hamilton, Ontario, October 6, 1993.*

310. Turpie AGG: Heparin in acute coronary ischaemia. Medical Grand Rounds, Hamilton Civic Hospitals, Hamilton, Ontario, October 8, 1993.
311. Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular weight heparin: Enoxaparin). Pulmonology Conference, Kansas University Medical Centre, Kansas City, MO, October 12, 1993.
312. Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular weight heparin: Enoxaparin). Noon Conference, Kansas University Medical Centre, Kansas City, MO, October 12, 1993.
313. Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular weight heparin: Enoxaparin). Orthopaedic Conference, Research Hospital, Kansas City, MO, October 12, 1993.
314. Turpie AGG: Low molecular weight heparin; advancement in antithrombotic therapy. Medical Rounds, Lincoln General Hospital, Lincoln NE, October 12, 1993.
315. Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular weight heparin: Enoxaparin). Grand Rounds, Research Hospital, Kansas City, MO, October 13, 1993.
316. Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular weight heparin: Enoxaparin). Orthopedic Surgery Grand Rounds, Research Hospital, Kansas City, MO, October 13, 1993.
317. Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular weight heparin: Enoxaparin). Orthopedic Surgery Grand Rounds, Truman Medical Center, Kansas City, MO, October 14, 1993.
318. Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular weight heparin: Enoxaparin). Thursday Conference, St. Joseph Hospital, Kansas City, MO, October 14, 1993.
319. Turpie AGG: Deep venous thrombosis. Medical Grand Rounds, Grant Medical Center, Columbus, Ohio, November 2, 1993.
320. Turpie AGG: Prevention of deep vein thrombosis and pulmonary embolism following total joint replacement: New advances with low molecular weight heparin. The Southern Tier Orthopedic Society, Binghamton, New York, November 15, 1993.
321. Turpie AGG: New advances in the prophylaxis of deep vein thrombosis and pulmonary embolism. The Medical Symposia, Atlanta Georgia, November 16, 1993.
322. Turpie AGG: Prophylaxis and treatment of DVT and pulmonary embolism: Update on low molecular weight heparin. Grand Rounds, The Wellesley Hospital, November 17, 1993.
323. Turpie AGG: Anticoagulants in Haemodialysis. Nephrology Association of Thailand. Chiang Mai, Thailand, November 23, 1993.
323. Turpie AGG: Low molecular weight heparin. Its benefits in clinical practice. Heart Association of Thailand, Bangkok, Thailand, November 25, 1993.
324. Turpie AGG: New progress in antiplatelet therapy. International Scientific Meeting of Haematologists from South-East Asian Countries. Medan, Indonesia, December 2, 1993.

325. Turpie AGG: State-of-the-art Lecture. Low molecular weight heparin. Its benefits in clinical practice. International Scientific Meeting of Haematologists from South-East Asian Countries. Medan, Indonesia, December 2, 1993.
327. Turpie AGG: An Overview of antiplatelet in cardiology and neurology. Indonesian Heart Association, Jakarta, Indonesia, December 4, 1993.
328. Turpie AGG: Recent experience with the use of Ticlopidine in cardiology and neurology. Indonesian Heart Institute, Jakarta, Indonesia, December 4, 1993.
329. Turpie AGG: Deep vein thrombosis and pulmonary embolism in surgery. Philippines College of Surgeons, Plenary Lecture. Manila, Philippines, December 8, 1993.
330. Turpie AGG: New progress in antiplatelet therapy. International Scientific Meeting of Haematologists from South-East Asian Countries. Medan, Indonesia, December 2, 1993.
331. Turpie AGG: State-of-the-art Lecture. Low molecular weight heparin. Its benefits in clinical practice. International Scientific Meeting of Haematologists from South-East Asian Countries. Medan, Indonesia, December 2, 1993.
332. Turpie AGG: Thrombolytics - Prevention of deep vein thrombosis. Medical Grand Rounds, St. Alphonsus Regional Medical Center, Boise Idaho, December 10, 1993.
333. Turpie AGG: Thrombolytics - Prevention of deep vein thrombosis. Idaho Orthopedic Association, Boise Idaho, December 10, 1993.
334. Turpie AGG: The role of low molecular weight heparin in the management of thromboembolic disease. Medical Grand Rounds. St. Vincent Hospital, Indianapolis, Indiana, December 13, 1993.
335. Turpie AGG: The role of low molecular weight heparin in the management of thromboembolic disease. Medical Grand Rounds. Lutheran Hospital of Indiana, Fort Wayne, Indiana, December 14, 1993.
336. Turpie AGG: New insights on aortic disease, valvular heart disease and anticoagulation therapy. New Perspectives on the Marfan Syndrome: An Anniversary Celebration. Stanford University Medical Centre, January 8, 1994.
337. Turpie AGG: Advances in antithrombotic therapy: role of low molecular weight heparins. Sutter Community Hospital Noon Conference, San Francisco, CA, February 11, 1994.
338. Turpie AGG, Gent M: Comparison of warfarin and ASA in patients with bioprosthetic heart valves. 19th Int'l Joint Conference on Stroke and Cerebral Circulation. American Heart Association, February 18, 1994.
339. Turpie AGG: Venous thromboembolism. Advances in prophylaxis and treatment. Medical Grand Rounds, Baylor University Medical Centre, Dallas, Texas, February 22, 1994.
340. Turpie AGG: Venous thromboembolism. Advances in prophylaxis and treatment. Medical Grand Rounds, Presbyterian Hospital, Dallas, Texas, February 23, 1994.

341. Turpie AGG: Venous thromboembolism. Advances in prophylaxis and treatment. Medical Grand Rounds, South Western Medical School, Dallas, Texas, February 23, 1994.
342. Turpie AGG: Antithrombotic Therapy; A major contributor to stroke prevention in patients with NVAf. The Ukrainian Medical Association of Toronto, Toronto, March 9, 1994.
343. Turpie AGG: Advances in antithrombotic therapy: role of low molecular weight heparin. Medical-Surgical Grand Rounds, New Britain General Hospital, New Britain, CT. March 24, 1994.
344. Turpie AGG: Advances in antithrombotic therapy: role of low molecular weight heparin. Surgical Grand Rounds, Hartford General Hospital, Hartford, CT. March 25, 1994.
345. Turpie AGG: Antithrombotic therapy following heart valve replacement. Cardiac Surgery Fellows Symposium, Minneapolis, Minnesota, April 9, 1994.
346. Turpie AGG: Anticoagulants: Current usage and future prospects. First McGill Conference on Thrombolysis: Montreal, April 15, 1994.
347. Turpie AGG: Atrial Fibrillation. Practical approach to antithrombotic therapy in the 1990's. Sunnybrook Health Science Centre, Toronto, June 1, 1994.
348. Turpie AGG: Advances in antithrombotic therapy: role of low molecular weight heparin. Medical Grand Rounds, Cedar Sinai Hospital, Los Angeles, California, June 9, 1994.
349. Turpie AGG: The role of low molecular weight heparin. Kaiser Foundation Hospital, Medicine Grand Rounds, Honolulu, Hawaii, July 6, 1994.
350. Turpie AGG: Current advances in therapy: The role of low molecular weight heparin. Straub Clinic & Hospital, Honolulu, Hawaii, July 7, 1994.
351. Turpie AGG: Optimizing Oral Anticoagulant Rx. Canadian Therapeutics Update, Niagara-on-the-Lake, July 17, 1994.
352. Turpie AGG: Hirudin, Low MW Heparin. Canadian Therapeutics Update, Niagara-on-the-Lake, July 17, 1994.
353. Turpie AGG: Coagulation tests in the diagnosis and management of arterial and venous thrombosis. American College of Clinical Chemists, New Orleans, Louisiana, July 19, 1994.
354. Turpie AGG: Pathophysiology of thromboembolic diseases. American College of Clinical Chemists, New Orleans, Louisiana, July 19, 1994.
355. Gawad YA, Skea D, Takahashi M, Tanser PH, Stanton EB, Sayles MJ, Turpie AG et al. Development and evaluation of an assay specific for human anti-streptokinase antibodies (IgG). Clin Chem 40 (6): 991, 1994.
356. Turpie AGG: Coagulation tests in the diagnosis and management of arterial and venous thrombosis. American Association for Clinical Chemistry, New Orleans, Louisiana, July 19, 1994.
357. ISIS-3 Collaborative Group. Mortality in relation to female sex in ISIS-3. Circulation 88 (4) II: #1178, 1994.

358. ISIS Collaborative Group: ISIS-4: Randomised study of oral captopril in over 50,000 patients with suspected acute myocardial infarction. *Circulation* 88 (4) II: #2113, 1994.
359. ISIS Collaborative Group: ISIS-4: Randomised study of oral isosorbide mononitrate in over 50,000 patients with suspected acute myocardial infarction. *Circulation* 88 (4) II: #2115, 1994.
360. Turpie AGG: Anticoagulation in cardiovascular diseases. XVI Congress of the European Society of Cardiology, Berlin, Germany, September 10, 1994.
361. Turpie AGG: Thrombolysis in venous thrombosis and pulmonary embolism. XIIIth Int'l Congress on Fibrinolysis, Leuven, Belgium, September 19, 1994.
362. Turpie AGG: Thrombogenesis and Atherosclerosis. 39th Annual Scientific Meetings of the Royal College of Pathologists of Australia, October 4, 1994.
363. Turpie AGG: Hyper-coagulability. Pathology Professional Activities Committee, 39th Annual Scientific Meetings of the Royal College of Pathologists of Australia, October 6, 1994.
364. Turpie AGG: Haemostatic risk factors in thrombosis. Plenary Lecture, 39th Annual Scientific Meetings of the Royal College of Pathologists of Australia, October 6, 1994.
365. Turpie AGG: The effectiveness of thromboembolic prophylaxis in the general surgical patient. New insights into the Etiology and Prevention of Postsurgical DVT. Temple University School of Medicine, Chicago, October 8, 1994.
366. Turpie AGG: Prevention of deep vein thrombosis and pulmonary embolism. Continuing Medical Education, St. James Hospital, Chicago, Il, October 10, 1994.
367. Turpie AGG: Prevention of deep vein thrombosis and pulmonary embolism - The role of low molecular weight heparin. Continuing Medical Education, St. Anthony Hospital, Chicago Il, October 12, 1994.
368. Turpie AGG: Cardiomyopathy and mitral prosthesis malfunction. 5th Annual Cardiovascular Therapeutics Related to Anticoagulant Therapy, Hamilton, October 19, 1994.
369. Turpie AGG: Curso de actualizacion en tromboembolismo pulmonar: Hospital Britanico de Buenos Aires, Buenos Aires, Argentina, October 22, 1994.
370. Turpie AGG: Antiagregantes en la prevencion primaria y secundaria del Stroke. III Congreso Interdisciplinario de Enfermedades Encefalovasculares (Stroke), Buenos Aires, Argentina, October 24, 1994
371. Turpie AGG: Queda algo por decir acerca de la fibrilacion auricular. Jornadas Rioplanteneses de Cardiologia, Buenos Aires, Argentina, October 25, 1994.
372. Turpie AGG: Advances in antithrombotic therapy: The role of low molecular weight heparin. Illinois Scientific Meeting, American College of Physicians, October 28, 1994.
373. Turpie AGG: New anticoagulant agents. Contemporary Management of Cardiovascular Diseases. Heart and Stroke Foundation of Ontario. December 9, 1994.

374. Turpie AGG: Low dose ASA therapy with coumadin. Coagulation Dilemmas in the Treatment of Cardiovascular Disease, Mercy Heart Institute, February 26, 1995.
375. Turpie AGG: Oral anticoagulants and aspirin in the prevention of thromboembolism in patients bearing prosthetic heart valves. Simposio Sulla Terapia Anticoagulante. Rome, Italy, March 11, 1995.
376. Turpie AGG: Low molecular weight heparin and prevention of thromboembolic disease. Brotman Medical Staff Foundation, 33rd Annual Scientific Seminar. Century City, CA, March 25, 1995
377. Turpie AGG: Chairman, International Symposium on Thrombosis and LMWH. The Royal College of Physicians of Thailand, Pattaya, Thailand, April 21, 1995.
378. Turpie AGG: Venous thromboembolism: Consensus statements and management strategies. The Royal College of Physicians of Thailand, Pattaya, Thailand, April 21, 1995.
379. Turpie AGG: Overview of antithrombotic therapy in Cardiology. The Royal College of Physicians of Thailand, Pattaya, Thailand, April 21, 1995.
380. Turpie AGG. Venous thromboembolism: Appropriate assessment and interventions. CONA Meeting, Calgary April 1995.
381. Turpie AGG: Overview of antithrombotic therapy in Cardiology. Hong Kong College of Cardiology. April 24, 1995.
382. Turpie AGG: Adjuvant and long-term therapies: Anticoagulants. McMaster Symposium, Hamilton, April 29, 1995.
383. Turpie AGG: Assessing venous thromboembolic risk and initiating appropriate interventions. New Insights in the Prevention of Venous Thromboembolism in Joint Replacement. Calgary, April 30, 1995.
384. Turpie AGG: Overview of antithrombotic therapy in Cardiology. Hong Kong College of Cardiology, Hong Kong, April 24, 1995.
385. Turpie AGG: Management of perioperative anticoagulant therapy. Haemostatic problems in adult cardiac surgery. Mechanisms and Management Symposium Proceedings. May 1995.
386. Turpie AGG: Anticoagulation in cardiovascular disease. Cardiology Update, McMaster University, Hamilton, May 10, 1995.
387. Turpie AGG: Antithrombotic Therapy: Role of low molecular weight heparin. St Francis Hospital and Medical Centre, Topeka, Kansas 66606-1609, May 11, 1995.
388. Turpie AGG. Emerging concepts in the clinical use of low molecular weight heparins. US Pharmacist Educational Symposia, University of Georgia College of Pharmacy, June 4, 1995.
389. Turpie AGG. Clinical perspective on heparin, hirudin and other antithrombin drugs. XVth Congress of the International Society on Thrombosis and Hemostasis. Satellite Meeting, Eilat, Israel, June 17.95.
390. van Riel AM, Henkens CMA, Koopman MMW, Turpie AGG et al: Low molecular weight heparin (LMWH) and compression stockings in the prevention of venous

- thromboembolism (VTE) in neurosurgery. XVth Congress of the International Society on Thrombosis and Hemostasis, Jerusalem, June 12, 1995 #285.
391. Cogo A, Lensing AWA, Koopman MMW Turpie AGG et al: Compression ultrasound for the diagnostic management of clinically suspected deep vein thrombosis. XVth Congress of the International Society on Thrombosis and Hemostasis, Jerusalem, June 12, 1995 #758.
392. Hirsh J, Levine M, Gent M, Turpie AGG. Out patient low molecular weight heparin versus in-hospital standard heparin for the treatment of venous thrombosis. XVth Congress of the International Society on Thrombosis and Haemostasis, Jerusalem, June 12, 1995, #733.
393. Turpie AGG: Advances in antithrombotic therapy: Novel agents. Wright Schultz Plenary Lecture. XVth Congress of the International Society on Thrombosis and Haemostasis, Jerusalem, June 15, 1995.
394. Turpie AGG. Venous Thromboembolism: Appropriate assessment and interventions. Hospital Pharmacy Practice, June 1995.
395. Turpie AGG: LMWH in unstable angina. XVII Congress of the European Society of Cardiology, Amsterdam, August 20, 1995.
396. Turpie AGG: The role of aspirin in patients with heart valve prostheses. XVII Congress of the European Society of Cardiology, Amsterdam, August 20, 1995.
397. Turpie AGG: HOT LINE III. FRIC Investigators. XVII Congress of the European Society of Cardiology, Amsterdam, August 20, 1995.
398. Baird M, Toal CB, Klinke WP, Kostuk WJ, Belanger L, Turpie AG. A randomized, double-blind multi-centre study of the effects of nifedipine (GITS) in patients with chronic stable angina. Canadian Journal of Cardiology 11 (Supple E):132E, August 1995.
399. Turpie AGG, Ruddy TD, Sussex BA et al. Low molecular weight heparin (Dalteparin) in unstable coronary artery disease (FRIC). Canadian Journal of Cardiology 11 (Suppl E):110E, August 1995.
400. Yusuf S, Michaelis W, Hua A, Turpie AGG et al. Effects of oral anticoagulants on mortality, reinfarction and stroke after myocardial infarction. Canadian Journal of Cardiology 11 (Suppl E):111E, August 1995.
401. Davies RF, Butt R, Foris K for the Canadian Zatebradine in Angina Research Group. Effect of zatebradine and diltiazem on ischaemia during ambulatory monitoring. Canadian Journal of Cardiology 11 (Suppl E):132E, August 1995.
402. Turpie AGG: Rationale and use of low molecular weight heparin. "Deep venous thrombosis and pulmonary embolism: An update on diagnosis, prophylaxis and management" Symposium. Medical College of Pennsylvania and Hahnemann University, Philadelphia, Pennsylvania, October 14, 1995.
403. Turpie AGG: New therapeutic opportunities for heparin: What does low molecular weight offer? Towards 2000: New pathways for the clinical management of acute ischemic syndromes. CCS Satellite Symposium, October 24, 1995.
404. Turpie AGG: Newer Clinical use of heparin and low molecular weight heparins. Heparin and Related Drugs Session, The Sixth IBC International Symposium, Washington, October 23, 1995.

405. Turpie AGG: Successors to heparin; new antithrombotic agents. Duke University Medical Center symposium at the AHA, November 14, 1995.
406. Turpie AGG. Management of perioperative anticoagulant therapy. pp 18-19, 1995.
407. Turpie AGG: Antithrombotic therapy following heart valve replacement. Cardiac Surgery Fellows Symposium. March 28-31, 1996.
408. Turpie AGG: Nhung nghien cuu ve thuoc tan soi huyet. Sixth Vietnam National Congress of Cardiology. Ho Chi Minh City, April 27, 1996.
409. Turpie AGG: The Prevention IV Conference. American Heart Association, Tucson, Arizona, May 1, 1996.
410. Turpie AGG. Carotid disease: Medical approach. International Multidisciplinary Vascular Disease Symposium. Winnipeg, May 15, 1996.
411. Turpie AGG: Platelets and Thrombosis: Platelet Inhibitors. International Multidisciplinary Vascular Disease Symposium. Winnipeg, May 15, 1996.
412. Turpie AGG: Anticoagulation for DVT: LMWH: HIT. International Multidisciplinary Vascular Disease Symposium. Winnipeg, May 17, 1996.
413. Turpie AGG: State of the art treatment of thrombotic disorders. Clinical Chemistry 42 (6):S78, 1996.
414. Turpie AGG. Advances in antithrombotic therapy and the expanding role of low molecular weight heparin. The University of Illinois at Chicago. July 19, 1996.
415. Turpie AGG. Clinical aspects of thrombolytic therapy in AMI. The 2nd Great Wall International Symposium and Exhibition on Interventional Cardiology (GWISIC '96), October 7, 1996.
416. Turpie AGG. Use of low molecular weight heparin and hirudin in unstable coronary disease. The 2nd Great Wall International Symposium and Exhibition on Interventional Cardiology (GWISIC '96), October 7, 1996.
417. Turpie AGG. Advances in antithrombotic therapy: The expanding role for low molecular weight heparins. Columbian Society of Internal Medicine, Bogota, Columbia, October 11, 1996.
418. Turpie AGG. Antithrombotic therapy in cardiac disease: New horizons. Columbian Society of Internal Medicine, Bogota, Columbia, October 11, 1996.
419. Wells P, Ginsberg J, Anderson D, Hirsh J, Turpie A et al. The use of a clinical model in a prospective management study of patients with suspected pulmonary embolism (PE). Haemostasis 26 (3) #8, 1996.
420. Turpie AGG. Management of venous thromboembolism. Haemostasis 26 (3) #291, 1996.
421. Ginsberg J, Wells P, Anderson D, Hirsh J, Turpie A et al. The value of the Simplified D-dimer in a prospective management study of patients with suspected pulmonary embolism (PE). Haemostasis 26 (3) #316, 1996.
422. Scazziota A, Altman R, Rouvier J, Gurfinkel E, Turpie GG, Glancszpigel R. Low versus high dose aspirin plus oral anticoagulant in heart valves prostheses. Final Report. Haemostasis 26 (3) #560, 1996.

423. Turpie AGG. Low molecular weight heparins: A major breakthrough in heparin therapy. The 2nd International Antithrombotic Therapy Symposium. Proceedings 10-12, 1996.
424. Turpie AGG. Calf vein thrombosis: To treat or not to treat. Thrombosis Forum 2 (2):6-8, October 1996
425. Turpie AGG (for the FRIC Study Group). Low molecular weight heparin (LMWH) in the initial and prolonged treatment of unstable coronary artery disease: The Fragmin in unstable Coronary heart disease study (FRIC). Canadian Cardiovascular Society Meeting, Montreal, October 31, 1996.
426. Klein W for the FRIC Study Group. Low molecular weight heparin in the initial and prolonged treatment of unstable coronary artery disease - the fragmin in unstable coronary heart disease study (FRIC). European Heart J 17:306, 1996
427. Ray JG, Turpie AGG. Current antithrombotic therapy following heart valve replacement in Canada and the United States. Canadian Cardiovascular Society Meeting, Montreal, October 31, 1996.
428. Cohen M, Demers C, Gurfinkel E, Fromell G, Langer A, Turpie AGG (ESSENCE Group). Primary endpoint analysis from the ESSENCE Trial: Enoxaparin vs unfractionated heparin in unstable angina and non-Q wave infarction. Circulation 94 (8) #3240, 1996.
429. Turpie AGG, Cruickshank MK, Latour Y, Laupacis A, Gent M, Hirsh J. Double blind comparison of aspirin with warfarin following bioprosthetic heart valve replacement. Circulation 94 (8) #3802, 1996.
430. Turpie AGG. Introduction. Presentations in Focus. ASH Meeting, Dec 7-10, 1996.
431. Turpie AGG. Arterial thrombosis - new treatment approaches. Vienna, February, 1997.
432. Turpie AGG: Venous Thrombosis Prophylaxis in Stroke. European Stroke Conference, Amsterdam 1997.
433. Turpie AGG: Unstable Coronary Disease: The rationale for low molecular weight heparin. Uppsala, 1997.
434. Turpie AGG. Arterial thrombosis - New treatment approaches. Annals of Haematology 1996; 74 (Suppl II):373.
434. Goodman S, Langer A, Demers C, Turpie A et al. One year follow-up of the ESSENCE trial (Enoxaparin vs heparin in unstable angina/non Q wave myocardial infarction): Sustained clinical benefit. Can J Cardiol 14: (Supp F) 122F, 1998.
434. Turpie AGG, Gent M, Cruickshank M, Kovacs M. et al. Randomized comparison of moderate (INR 3.0-3.5) with low intensity (INR 2.0-2.5) anticoagulant therapy in patients with prosthetic heart valves treated with aspirin (100 mg/dah). Can J Cardiol 14: (Supp F) 123F, 1998.
434. Turpie AGG. Cardiac Update: Low molecular weight heparin. American College of Chest Physicians. Toronto, Nov 12, 1998.

435. Cohen Marc, Demers Christine, Gurfinkel Enrique, Fromell Gregg, Langer Anatoly, Turpie A.G.G. (ESSENCE Group). Management of acute ischemic coronary syndromes in the next millenium - Review of recent clinical trials, ESSENCE and TIMI 11A-B Trials. *Annals of Haematology* 1996; 74 (Suppl II):372.
436. Cohen M, Demers C, Fromell GJ, Califf RM, Turpie AGG, Gurfinkel E, Langer A, Fox KA. Hemorrhage incidence with low molecular weight heparin vs unfractionaed heparin in patients with unstable angina or non-Q-wave myocardial infarction. Anaheim, March 16-19, 1997.
437. Turpie AGG. Antithrombotic therapy following heart valve replacement. *Cardiac Surgery Symposium*. Minneapolis April 4, 1997.
438. Kearon C (for the LAFIT Investigators). Two years of warfarin versus placebo following three months of anticoagulation for a first episode of idiopathic venous thromboembolism. XVIth Congress of the International Society on Thrombosis and Haemostasis. Florence June 6-12, 1997.
439. Ageno W, Turpie AGG. Randomized comparison of anticoagulant control by a computer generated system with a manual system. *Thrombosis and Haemostasis (Supplement)* #PS2858, June 1997.
440. Cohen M, Turpie AGG, Demers C et al. Blind comparison of enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary arery disease ESSENCE trial. *Thrombosis and Haemostasis (Supplement)* #SC1528, June 1997.
441. Lowe GDO, Haverkate F, Thompson SG, Bertina RM, Turpie AGG, Mannucci PM. Prediction of deep vein thrombosis after elective hip surgery by preoperative haemostatic tests: The ECAT DVT Study. *Thrombosis and Haemostasis (Supplement)* #OC742, June 1997.
442. Fox KAA, Cohen M, Demers C, Gurfinkel E. Fromell G, Bigonzi F, Premmereur J, Langer A, Goodman S, Califf R, Turpie AGG* for the ESSENCE Group. A double blind comparison of Enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary artery disease "THE ESSENCE TRIAL". *Heart* 77 (Suppl 1) #58, 1977.
443. Turpie AGG. Current clinical considerations in venous thromboembolic disease: The role of low molecular weight heparin. Lafayette, IN, July 14, 1997.
444. Turpie AGG. Advances in antithrombotic therapy: The role of low molecular weight heparins. St. Vincent Hospital, Grand Rounds, Indianapolis, IN, July 15, 1997.
445. Wells PS, Ginsberg J, Anderson DR, Hirsh J, Turpie AGG et al. The value of bilateral venous compression ultrasonography in patients with suspected pulmonary embolism (PE). *Clin Invest Med* 20:#201, 1997.
446. Buchanan MR, Brister SJ, Turpie AGG. Ticlopidine as an alternate antiplatelet agent for aspirin nonresponders. *Canadian Cardiovascular Society*, Winnipeg October 5-9, 1997.
447. Cohen M, Fox K. Turpie AGG, Demes C. Gurfinkel E, Langer A, Califf R, Fromell G, Bigonzi F on behalf of the ESSENCE Group. Patient populations and clinical practices: inter-region differences observed in the international ESSENCE trial. *European Heart Journal* 18 (Abstract Supplement) P1046, 1997.

448. Bozovich G, Gurfinkel E, Duronto E, Colorio C, Cohen M, Mautner B on behalf of the ESSENCE Investigators. Relationship between acute thrombotic markers and silent ischaemic events in patients with unstable angina or non-Q wave myocardial infarction. *European Heart Journal* 18 (Abstract Supplement) #2647, 1997.
449. Ageno W, Johnson J, Nowacki B, Siguenza M, Turpie AGG. Management of the initial phase of warfarin treatment: Retrospective analysis of post-operative heart valve replacement patients compared with nonsurgical patients. *Blood* 1997 90 (10): #3199
450. Turpie AGG. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A & 11B. A meeting for Canadian investigators in the ESSENCE trial. June 28, 1997.
451. Hommel M (for the FISS bis investigators Group). Fraxiparine in ischaemic Stroke Study (Fiss bis). *Cerebrovasc Dis* 8 (suppl 4):19, 1998.
452. Ageno W, J Nowacki B, Turpie AGG. Accuracy and clinical utility of anticoagulation induction using a computer generated system compared with manual dosing in hospitalized patients. *Thrombosis Research* 91 (Suppl 1) #156, 1998
453. Ageno W, Johnson J, Nowacki B, Sloane D, Turpie AGG. The role of coagulation factors II, V, VII and X in the response to oral anticoagulants in patients following heart valve replacement. *Thrombosis Research* 91 (Suppl 1) #158, 1998
453. Zighetti ML, Cattaneo M, Turner RM, Thompson SG, Lowe GDO, Haverkate F, Bertina RM, Turpie AGG, Mannucci PM on behalf of the ECAT DVT Study Group. Fasting plasma homocysteine levels do not predict the occurrence of deep vein thrombosis after elective hip replacement. *Thrombosis Research* 91 (Suppl 1) #30, 1998
454. Turpie AGG, Gent M. Randomized comparison of moderate (INR 3.0-3.5) with low intensity (INR 2.0-3.5) anticoagulant therapy in patients with prosthetic heart valves treated with aspirin. *Circulation* 98 (17) #4026, 1998.
455. Holper EM, Antman EM, McCabe CH, Turpie AGG et al. A simple, readily available method for risk stratification of patients with unstable angina or non-Q myocardial infarction: A TIMI 11B Substudy. *Circulation* 98 (17) #2594, 1998.
455. Antman EM, McCage CH, Premmreur, Gurfinkel E, Bernink PJLM, Turpie AGG: Enoxaparin for the acute and chronic management of unstable angina/non-Q wave myocardial infarction: Results of TIMI 11B. *Circulation* 98 (17) #2649, 1998.
456. Turpie AGG: Antiplatelet agents: Current status and future perspectives. *ISCVS, Gold Coast, Australia, October* #109, 1998.
457. Turpie AGG: The role of low molecular weight heparin in arterial disease and following arterial interventions. *ISCVS, Gold Coast, Australia, October* #110, 1998.
458. Turpie AGG: Thrombophilia update: Guidelines for investigation and treatment. *ISCVS, Gold Coast, Australia, October* 112, 1998.
459. Turpie AGG: Pharmacology of the low molecular weight heparins. *Am Heart Journal (Supp)* 135 (6):S329, 1998.
460. Turpie AGG. Reducing stroke risk - what can family physicians do? *29th Heart and Stroke Clinical Update. Toronto, Ontario, December 10, 1998.*

462. Turpie AGG. Update on Antiplatelet Drugs. Joseph Brant Memorial Hospital, Medical Grand Rounds, December 15, 1998.
463. Bath PM for the TAIST Investigators. Tinzaparin in acute ischaemic stroke trial (TAIST). XVII Congress of ISTH. August 1999.
464. Turpie AGG. Looking forward in DVT treatment. ISTH Satellite Symposium, August 1999.
465. Turpie AGG, Samama M, Cohen A, Darmon J, Desjardins L, Eldor A, Janbon C, Leizorovicz A, N'Guyen, Olsson C-G, Weisslinger N. prophylaxis of venous thromboembolism in acute medical patients with enoxaparin: An international, randomized double-blind, placebo-controlled trial. *Circulation* 1999; 100 (18) Abst #3264.
466. Cohen M, Antman E, Gurfinkel E, Turpie A, Furst J, Bigonzi F, Radley D. The benefit of enoxaparin in Q-wave myocardial infarction: A sub-study of the TIMI 11B and ESSENCE meta-analysis. *Circulation* 1999; 100 (18) Abst #4182.
467. Antman E, Gurfinkel E, Turpie A, Bernink P, Salein D, Bayes de Luna A, Fox K, Lablanche J-M, Radley D, Furst J, Braunwald E. Treatment benefit of enoxaparin in unstable angina/non-Q wave myocardial infarction is maintained at one year followup in TIMI 11B. *Circulation* 1999; 100 (18) Abt #2621.
468. Turpie AGG. New Role for low molecular weight heparins in unstable angina-Basis and Clinical Experience. Donnerstag, May 18, 2000.
469. Turpie AGG, Johnson J. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin (dalteparin). *Can J Cardiol* 16 (Suppl F) September 2000.
470. Turpie AGG, Johnson J. Temporary discontinuation of oral anticoagulants. Role of low molecular weight heparin (Dalteparin). *Circulation* 2000 #3983..
471. Cohen M, Antman EM, Gurfinkel EP, Turpie AGG, Furst J, Bigonzi F, Radley D. The benefit of enoxaparin in Q-wave myocardial infarction: A Substudy of the TIMI 11B and ESSENCE meta-analysis. *Circulation* 2000 #2992.
472. Treatment benefit of enoxaparin in unstable angina/non-Q wave myocardial infarction is maintained at one year followup in TIMI 11B. *Circulation* 2000 #106863.
473. Batchelor WB, Radley D, Cohen M, Turpie Alexander G.G., Langer, A, Goodman S. A comparison of the impact of practice patterns on the outcomes of patients with acute coronary syndromes in the USA and Canada: Post Hoc analysis of ESSENCE and TIMI 11B. *JACC* 37 (2) Suppl A, Feb 2001: 863-5 p 359.
474. Turpie AGG, Bauer KA, Eriksson B, Lassen MR. Pentasaccharide significantly reduces venous thromboembolism after orthopedic surgery compared with low molecular weight heparin. *Am Coll of Chest Physicians*, 2001.
475. Bauer KA, Turpie AGG, Eriksson B, Lassen M. Superiority of pentasaccharide over low molecular weight heparin for venous thromboembolism prophylaxis is independent of age, gender and obesity. *Am Coll of Chest Physicians*, 2001.
476. Peters PC, Turpie AGG, Bauer KA, Eriksson B, Lassen MR. The first synthetic factor Xa inhibitor, Arixtra/Xantidar (pentasaccharide), shows superiority over low molecular weight heparin in prevention of venous thromboembolism after orthopedic surgery. *Am Coll of Chest Physicians*, 2001-05-15

477. Turpie AGG, Bauer KA, Eriksson B, Lassen MR, Hawkins DW on behalf of the Pentasaccharide Orthopedic Prophylaxis Studies Investigators. Pentasaccharide superiority over low-molecular-weight heparin for prevention of venous thromboembolism after major orthopedic surgery is independent of age. Am Soc of Consultant Pharmacists (ASCP), 2001.
478. Inverso SM, Antman EM, Spinler SA for the ESSENCE and TIMI11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B Studies. ACC, 2001.
479. Turpie AA, Bauer KA, Eriksson B, Lassen MR, Peters PC. Pentasaccharide (Fondaparinux): A novel factor Xa inhibitor that is superior to low-molecular-weight heparin for the prevention of venous thromboembolism after orthopaedic surgery. American Assoc of Hip and Knee Surgery. Dallas, Texas, November 9, 2001.
480. Turpie AGG. Pentasaccharide significantly reduces venous thromboembolism after orthopedic surgery compared with low-molecular-weight heparin. ACCP, Nov 2001.
481. Lassen MR, Eriksson BI, Bauer KA, Turpie AGG. Pentasaccharide (Fondaparinux), Aristra® versus enoxaparin for the prevention of venous thromboembolism (VTE) in major orthopedic surgery: subgroup analyses on efficacy. Blood 98 (11) Abstract #1117, 2001.
482. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson G-G, Turpie AGG. Benefit of enoxaparin in medical patients: a subgroup analysis. Blood 98 (11) Abstract #119, 2001.
483. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Effect on efficacy and safety of the timing of the first pentasaccharide (Fondaparinux, Aristra®) administration in the prevention of venous thromboembolism (VTE) after major orthopedic surgery. Blood 98 (11) Abstract #119, 2001.
484. Eriksson B, Bauer KA, Lassen MR, Turpie AGG. Current management of venous thromboembolism prophylaxis after major orthopedic surgery in North America and Europe: lessons from the pentasaccharide (Fondaparinux, Arixa®) database. Blood 98 (11) Abstract #1133, 2001.
485. Bauer A, Eriksson BI, Lassen MR, Turpie AGG. Relevance of systemic venographic outcomes in venous thromboembolism (VTE) prophylaxis studies: lessons from the pentasaccharide (Fondaparinux, Arixa®) clinical program. Blood 98 (11) abstract #1144, 2001.
486. Kearon C, Ginsberg JS, Anderson DR, Kovacs M, Wells P, Julian J, MacKinnon B, Demers C, Douketis J, Turpie AG, van Nguyen P, Green D, Kassis J, Kahn S, Solymoss S, Desjardins L, Geerts W, Weitz J, Hirsh J, Gent M. Sofast Investigators. Four weeks versus 12 weeks of anticoagulation for a first episode of venous thromboembolism (VTE) provoked by a transient risk factor: A randomized double-blind trial. Blood 98 (11): Abst#1879,2001.
487. Turpie AGG. Highlights from Presentations of the Medenox Study. Thromboprophylaxis: an emerging field. Manila, The Philippines. May 29, 2000.
488. Turpie AGG. Overview of the clinical results of pentasaccharide in major orthopedic surgery. Haematologica 86 (Supp II) Nov. 2001.
489. Eriksson BI, Turpie AGG, Lassen MR, Bauer KA, Comparison of the first synthetic Factor Xa inhibitor, Fondaparinux sodium, with low molecular weight heparin in the prophylaxis of venous thromboembolism following major orthopaedic surgery. 7th Congress of the European Association of Hospital Pharmacists, March 20-22, 2001.

490. Turpie Alexander G.T. Setting a standard for venous thromboembolism prophylaxis. Am J Heath - Syst Pharm 58 (Suppl 2):S-18-S23, 2001.
491. Turpie AGG. Low molecular weight heparins, novel anticoagulants and strategies. Am College of Cardiology, March 2002.
492. Turpie AGG. Meet the Experts Meeting. Am College of Cardiology, March 2002.
493. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery. An overview of efficacy and safety results. International Union of Angiology, New York, April 8/02
494. Turpie AGG. Fondaparinux in the prevention of venous thromboembolism after major orthopaedic surgery. The Official Journal of the International Society of Cardiovascular Pharmacotherapy 16 (Supp 1) 2002 #016.
495. Leizorovicz for the PREVENT Study Group. Evaluation of the benefits of dalteparin for thromboprophylaxis in acutely ill medical patients. 9th Int'l Symposium on Thromboembolism, Seville, June7-8,2002.
496. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Efficacy and Safety of Fondaparinux in the thromboprophylaxis of venous thromboembolism (VTE) following major orthopaedic surgery according to the recommendations for use in the United States (USA). The Hematology Journal, 3: (Suppl 1) June 2002, Abstract #1229.
497. Turpie AGG, Bauer KA, Eriksson B, Lassen MR. Consistency of fondaparinux superiority for venous thromboembolism prevention in orthopedic surgery according to different composite efficacy endpoints. Chest 122 (4) 59S. October 2002 Supplement.
498. Muntz JE, Turpie AGG, Bauer KA, Eriksson B, Lasdsen MR. Role of the duration of fondaparinux prophylaxis in preventing venous thromboembolism following major orthopedic surgery. Chest 122 (4) 59S. October Supplement, 2002.
499. Cohen AT, Alikhan R, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson C-G, Turpie AGG. Prevention of venous thromboembolism in medical patients with enoxaparin: A subgroup analysis of the MEDENOX Study. ICT, Bologna October 2002.
500. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Role of the duration of fondaparinux prophylaxis in preventing venous thromboembolism following major orthopedic surgery. AAPM&R. Orlando, Florida, Nov. 22, 2002.
501. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism following hip fracture surgery. Blood 100 (11):304, 2002.
502. The MATISSE Investigators. Fondaparinux (Arixtra) in comparison to (low molecular weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism - The Matisse clinical outcome studies. Blood 100 (11):302, 2002.
503. Levine MN, Lee AY, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles F, Julian JA, Haley S, Kovacs M, Gent M and the CLOT Investigators. A randomised trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Blood 100 (11): #298, 2002.

504. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Effect of age on the benefit-risk ratio of fondaparinux thromboprophylaxis in patients undergoing major orthopedic surgery. *Blood* 100 (11): 1066, 2002.
505. Cohen AT, Alikhan R, Arcelus J, Haas S, Spyropoulos, Tapson V, Turpie AGG. Venous thromboembolism risk assessment in medical patients. *Blood* 100 (11): 1074, 2002.
506. Hull R, Schellong S, Tapson V, Yusen R, Monreal M, Samama MM, Turpie AGG. Extended thromboprophylaxis in acutely ill medical patients with prolonged immobilisation: The EXCLAIM Study. *Blood* 100 (11): 3988, 2002.
507. Kovacs M, Kahn S, Solymoss S, Anderson D, Desjardins L, Rodger M, Turpie A, Bates S, Douketis J, Kearon C, Wells P. Prospective multicentre trial of bridging therapy with dalteparin for patients who require temporary discontinuation of OAC for prosthetic valves or high risk atrial fibrillation. *Blood* 100 (11):559, 2002.
508. Kearon C, Ginsberg JS, Kovacs M, Anderson DR, Wells P, Julian J, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AGG, Geerts WH, Solymoss S, van Nguyen P, Demers C, Kahn S, Kassis J, Rodger M, Hambleton J, Gent M for the ELATE Investigators. Low intensity (INR 1.5-1.9) versus conventional intensity (INR 2.0-3.0) anticoagulation for extended treatment of unprovoked VTE: a randomised double blind trial. *Blood* 100 (11): 562, 2002.
509. Piovella F, Turpie AG, Planes A, Gallus A, Wang CJ, Lee WC, Lee K, Perdriset G, Rouillon A for the AIDA Steering Committee. AIDA-Assessment of the incidence of deep vein thrombosis in Asia following major orthopaedic surgery: Rationale and study design. 6th Congress of the European Federation of National Associations of Orthopaedics and Traumatology. Helsinki Finland, July 4-10, 2003, #P6108.
510. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Elastic stockings do not influence superior efficacy of fondaparinux over enoxaparin for thromboprophylaxis in orthopaedic surgery. 6th Congress of the European Federation of National Associations of Orthopaedics and Traumatology. Helsinki Finland, July 4-10, 2003, #P1062.
511. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Effect on efficacy and safety of the timing of the first fondaparinux administration for the thromboprophylaxis in orthopaedic surgery. 6th Congress of the European Federation of National Associations of Orthopaedics and Traumatology. Helsinki Finland, July 4-10, 2003, #P1063.
512. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Management of orthopedic surgery patients in North America, Europe and other countries: Lessons from the fondaparinux database. 6th Congress of the European Federation of National Associations of Orthopaedics and Traumatology. Helsinki Finland, July 4-10, 2003, #P1064.
513. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux is superior to enoxaparin for thromboprophylaxis in orthopedic surgery irrespective of patients or surgery characteristics. 6th Congress of the European Federation of National Associations of Orthopaedics and Traumatology. Helsinki Finland, July 4-10, 2003, #P1066.
514. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism following hip fracture surgery. 6th Congress of the European Federation of National Associations of Orthopaedics and Traumatology. Helsinki Finland, July 4-10, 2003, #P1067.

515. Turpie AGG, Leizorovicz A, Cohen AT, Olsson C-G, Vaitkus PT, Goldhaber SZ for the PREVENT medical thromboprophylaxis study group. A randomised, multicentre, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 patients hospitalised with acute medical illnesses. 10th Int'l Symposium on Thromboembolism, London June 13-14, 2003.
516. Spyropoulos AC, Turpie AGG, Dunn A, Spandorfer J for the REGIMEN Investigators. Clinical outcomes with the use of unfractionated heparin or low molecular weight heparin as perioperative bridging therapy in patients on long-term oral anticoagulants: rationale, objectives, design and interim analysis of a large, long-term multicenter study (REGIMEN). ISTH, Birmingham, July 2003.
517. Turpie AGG, Colwell CW Jr. Bauer KA, Eriksson BI, Lassen MR. Efficacy of fondaparinux for thromboprophylaxis in high-risk patients.
518. Turpie AG, Colwell CW, Bauer K, Eriksson BI, Lassen MR. Fondaparinux reduces long-term risk of venous thromboembolism after surgery for hip fracture. Chest 124 (4 Suppl): 132S, 2003.
519. Turpie AG, Colwell CW, Bauer K, Eriksson BI, Lassen MR. Efficacy of fondaparinux for thromboprophylaxis in high-risk patients undergoing hip fracture surgery. Chest 124 (Suppl 4):240S, 2003.
520. Cohen AT, Leizorovicz A, Turpie AG, Olsson C-G, Vaitkus PT, Goldhaber SZ. The PREVENT Medical Thromboprophylaxis Study Group. Thromboprophylaxis with dalteparin for the prevention in acutely ill medical patients with respiratory failure. Chest 124 (Suppl 4):132S, 2003.
521. Turpie AGG, Leizorovicz A, Cohen AT, Olsson CG, Vaitkus PT, Goldhaber SZ. Dalteparin for the prevention of venous thromboembolism in acutely ill medical patients: A randomised placebo-controlled trial in 3,706 hospitalized patients. Can J of Cardiol 19 (Suppl A) Abstract #861, 2003.
522. Turpie Alexander G, Colwell, Clifford W, Bauer K, Eriksson Bengt I, Lassen, Michael R. Fondaparinux reduces long-term risk of venous thromboembolism after surgery for hip fracture. Chest 124, #4, Suppl, October 2003, pp 132S.
523. Turpie Alexander G, Colwell Clifford W, Bauer Kenneth, Eriksson Bengt I, Lassen Michael R. Efficacy of fondaparinux for thromboprophylaxis in high-risk patients undergoing hip fracture surgery. Chest 124, #4 Suppl, October 2003, pp. 240S.
524. Cohen AT, Davidson B L, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG, Cariou RG, Egberts JfM, Lensing AWA. Fondaparinux for the prevention of VTE in acutely ill medical patients. Blood 102 (11) #42, 2003.
525. Vaitkus PT, Leizorovicz A, Goldhaber SZ, Olsson C-G, Cohen AT, Weitz JI, Turpie AG. Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood 102 (11) #575, 2003.
526. Piovella F, Wang C-J, Lu H, Lee K, Lee LH, Lee WC, Turpie AG, Gallus A, Planes A et al. Deep vein thrombosis in Asia after major orthopedic surgery. An epidemiological study with mandatory bilateral venography and central independent adjudication. Blood 102: (11) #733, 2003.
527. Anderson FA, Tapson VF, Decousus H, Spyropoulos AC, Turpie AGG, FitzGerald G for the IMPROVE Investigators. IMPROVE, a multinational observational cohort study of practices

in prevention of venous thromboembolism in acutely ill medical patients: A comparison with clinical study patient populations. Blood 102: (11) #1146, 2003.

528. Leizorovicz A, Cohen AT, Turpie AG, Olsson C-G, Vitkus PT, Weitz JI, Goldhaber SZ. Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood 102 (11) #1153, 2003.

529. Spyropoulos AC, Turpie AGG, Dunn A, Jacobson A, Douketis for the REGIMEN Investigators. Registry of patients on chronic oral anticoagulant therapy requiring (Low molecular weight) heparin for an elective surgical intervention or procedure (REGIMEN): Rationale, design and interim analysis of a large, long-term, multicenter cohort study. Blood 102 (11) #1161, 2003.

530. Becker F, Leizorovicz A, Olsson C-G, Cohen AT, Vaitkus PT, Turpie AG, Weitz JI, Goldhaber SZ. Venous ultrasound: An alternative to venography for evaluation of dalteparin prophylaxis in 3706 medically ill hospitalised patients. Blood 102 (11) #1165, 2003.

531. Panju A, Kahn S, Geerts W, Pineo G, Desjardins L, Turpie A, Glezer S, Sebaldt R. Utilization of venous thromboprophylaxis in acutely ill medical patients in Canada: results from the Canadian Registry (CURVE). Blood 102 (11) #1813, 2003.

532. Hull R, Tapson VF, Schellong S, Yusen RD, Monreal M, Samama MM, Turpie AGG, Wildgoose P, Cort S. The EXCLAIM study: extended thromboprophylaxis with enoxaparin in acutely ill medical patients with restricted mobility. Blood 102 (11) #4208, 2003.

533. Tapson VF, Decousus H, Piovella F, Zotz RB, Allegrone J, Anderson FA for the IMPROVE Investigators. A multinational observational cohort study in acutely ill medical patients of practices in prevention of venous thromboembolism: findings of the International medical prevention registry on venous thromboembolism (IMPROVE). Blood 102 (11) #1154, 2003.

534. Kucher N, Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vaitkus PT, Goldhaber SZ for the PREVENT Medical Thromboprophylaxis Study Group. Obesity does not attenuate the effectiveness of low-dose dalteparin in preventing venous thromboembolism. ACC New Orleans, March 2004.

535. Turpie AGG. The diagnosis and treatment of DVT and PE. Lake Louise, April 2004. Turpie AGG. New Anticoagulants: Will they alter how we treat patients. Lake Louise, April 2004.

536. Turpie AGG. New anticoagulants: will they alter how we treat patients. Lake Louise, April 2004.

537. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG, Cariou RG, Egberts JFM, Lensing AWA. ARTEMIS Investigators (London, UK, Seattle WA, USA, Bedford Park, SA Australia, Hoersholm Denmark, Warsaw Poland, Hamilton Ontario, Canada, Chilly Mazarin, France, OSS, The Netherlands). Thromboprophylaxis with fondaparinux acutely ill medical patients aged 75 years or more. 21st World Congress of the Int'l Union of angiology, May 22-26, 2004.

538. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG, Cariou RG, Egberts JFM, Lensing AWA. ARTEMIS Investigators (London, UK, Seattle WA, USA, Bedford Park, SA Australia, Hoersholm Denmark, Warsaw Poland, Hamilton Ontario, Canada, Chilly Mazarin, France, OSS, The Netherlands). Thromboprophylaxis with fondaparinux in acutely ill medical patients with moderate renal impairment. 21st World Congress of the Int'l Union of angiology, May 22-26, 2004.
539. Turpie AGG. Future in ACS. 21st World Congress of the Int'l Union of Angiology, May 22-26, 2004.
540. Turpie AGG. VTE prophylaxis: clinical benefits of new antithrombotics. Int'l Society on Thrombosis and Haemostasis. Venice, June 17-19, 2004.
541. Turpie AGG. Preventing VTE in medical patients - clinical evidence to support a role for LMWH. Int'l Society on Thrombosis and Haemostasis. Venice, June 17-19, 2004.
542. Fiessinger JN on behalf of the TAIPAID study Group. S18886, a new specific oral TP receptor antagonist, is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease. European Society of Cardiology, Munich 2004.
543. Davidson B, Turpie AGG, Colwell C, Kwong LM. Early vs delayed initiation of fondaparinux prophylaxis to prevent postoperative pulmonary embolism: A clinical endpoint study. Chest 126 (4) October 2004 (783S abstr)
544. Anderson FA for the Improve Investigators. A multinational comparison of prophylaxis practices for venous thromboembolism during medical intensive care: findings from IMPROVE. Chest 126 (4) October 2004 (784S abstr).
545. Fitzgerald G, Tapson V, Spyropoulos AC, Froehlich JB, Decousus H, Bergmann J-F, Bhong BH, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanella R, Pini M, Piovella F, Turpie AG, Zoltz RB, Anderson FA for the IMPROVE investigators. Does obesity influence physician practices in provision of prophylaxis for venous thromboembolism? Lessons from IMPROVE. Chest 126 (4) October 2004 (785 abstr).
546. Dunn AS, Spyropoulos AC, Sirko SP, Turpie AG. PROspective Perioperative Enoxaparin Cohort Trial: a Multicenter Cohort Study of Perioperative Bridging with Enoxaparin in Patients Requiring Interruption of Long-term Oral Anticoagulant Therapy (PROSPECT). ASH, San Diego, December 2004.
547. Turpie AGG for the PROVE Investigators. A prospective registry on venous thromboembolic events: The PROVE registry. ASH, San Diego Abstr #923, December 2004.
548. Tapson VF, Decousus H, Bergmann J-F, Eriksson BI, Froehlich, Kakkar AK, Merli GJ, Monreal M, Spyropoulos AC, Turpe AGG, Zoltz RB, Fitzgerald F, Anderson FA for the IMPROVE investigators. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous thromboembolism prophylaxis practices in acutely ill medical patients. ASH, San Diego, Abst #1762, Dec. 2004
549. Piovella F, Wang Ching-Jen, Lu Housan, Lee Kenneth, Lee Lai Heng, Lee Lee Won Chui, Turpie AGG, Gallus A Planes A, Passera R, Roillon A, The AIDA Investigators. High rate of deep vein thrombosis in Asia after major orthopedic surgery: The AIDA Study final results. ASH, San Diego, Abst 2580, Dec. 2004.

550. Spyropoulos AC, Turpie AGG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ for the REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular weight heparin as bridging therapy in patients on long-term oral anticoagulants: results from the REGIMEN Registry. ASH, San Diego, Abstr #709, Dec. 2004.
551. Cohen AT, Alikhan R, Arcelus JI, Bergmenn J-F, Haas S, Merli GJ, Spyropoulos AC, Tapson VF, Turpie AGG. Identification of medical patients who should receive venous thromboembolism prophylaxis. ASH, San Diego, Abstr #1786, Dec 2004.
552. Dunn AS, Spyropoulos AC, Spyropoulos AC, Sirko SP, Turpie AGG. Perioperative bridging therapy with enoxaparin in patients requiring interruption of long-term oral anticoagulant therapy: a multicenter cohort study. ASH, San Diego, Abstr #1786, Dec 2004.
553. Turpie AGG, Douketis JD. Enoxaparin is effective and safe as bridging anticoagulation in patients with a mechanical prosthetic heart valve who require temporary interruption of warfarin because of surgery or an invasive procedure. ASH, San Diego, Abstr #703, Dec 2004.
554. Cohen AT, Gallus AS, Davidson BL, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA. Benefit of fondaparinux in medical patients: a subgroup analysis. ASH, San Diego, Abstr #4079, Dec 2004.
555. Kearon C, Ginsberg JS, Julian J, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie G, McCarty D, MacKinnon B, Hirsh J, Gent M, FIDO Investigators. Fixed dose, weight-adjusted, unfractionated heparin (UFH) given subcutaneously (sc) without laboratory monitoring for acute treatment of venous thromboembolism (VTE): Randomized comparison with low molecular weight heparin (LMWH). ASH, San Diego, Abstr #707, Dec 2004.
556. Spyropoulos AC, Dunn AS, Turpie AGG, Kaatz S, Spandorfer J, Douketis J, Jacobson A, Frost FJ for the REGIMEN Investigators, Lovelace Medical Centre, Albuquerque, NM. Perioperative bridging therapy with unfractionated heparin or low molecular weight heparin in patients with mechanical heart valves on long-term oral anticoagulants: Results from the REGIMEN Registry. JACC 45 #3 (Suppl A): 1016-47, 2005.
557. Eriksson BI, Borris LC, Dahl OE, Haas SK, Huisman MV, Kakkar AK, Kalebo P, Misselwitz F, Muhlhofer EM for the ODIXa-HIP Study Investigators. Prevention of venous thromboembolism with an oral, direct factor Xa inhibitor - Bay 59-7939 - in Elective Hip Replacement: a dose-ranging study. Oral presentation at the XXth ISTH, Sydney, Australia, 6-12 August, 2005.
558. Turpie AGG, Fisher WD, Bauer K, Kwiong L, Gent M, Misselwitz F for the ODIXa-Knee Investigators. An oral, Direct Factor Xa Inhibitor - Bay 59-7939 - for prophylaxis against venous Thromboembolism after total knee replacement: a dose-ranging study. Oral presentation at the XXth ISTH, Sydney, Australia, 6-12 August, 2005.
559. Zotz RB, Decousus H, Monreal M, Chong BH, Pavanello R, Pini M, Turpie AGG, Huang W, Anderson Jr. FA for the IMPROVE Investigators. J Thromb Haemost 3 (Suppl 1), 2005.
560. Turpie AGG for the PROVE Investigators. The PROVE Registry: A Prospective Registry on venous Thromboembolic Events. J Thromb Haemost 3 (Suppl 1), 2005.

561. Turpie AGG for the PROVE Investigators. A comparison of patients with DVT in Asia and Europe/Australia: Findings from the PROVE Registry. *J Thromb Haemost* 3 (Suppl 1), 2005.
562. Julian J, Kearon C, Solymoss S, Douketis J, Ockelford P, Jackson S, Turpie AGG, McCarty D, MacKinnon B, Hirsh J, Gent M, Ginsberg JS for the FIDO Investigators. Heparin levels with subcutaneously (sc) low molecular weight heparin (LMWH) and Unfractionated heparin (UFH): results from a randomised trial. *J Thromb Haemost* 3 (Suppl 1), 2005.
563. Kearon C, Ginsberg JS, Julian J, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AGG, McCarty D, MacKinnon B, Hirsh J, Gent M (for the FIDO Investigators). *J Thromb Haemost* 3 (Suppl 1), 2005.
564. Spyropoulos AC, Turpie AGG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ for the REGIMEN Investigators. low molecular weight heparin or unfractionated heparin as bridging therapy in patients on long-term oral anticoagulants: results from the REGIMEN Registry. *J Thromb Haemost* 3 (Suppl 1), 2005.
565. Kwong LM, Colwell CW, Turpie AGG, Davidson BL. Self-injection of fondaparinux (Arixtra) in the prophylaxis against venous Thromboembolism after major orthopedic surgery is well accepted, effective and save: data from the FLEXTRA Trial. *J Thromb Haemost* 3 (Suppl 1), 2005.
566. Turpie AG, Bauer K, Caprini J, Comp P, Gent M, Muntz J on behalf of the APOLLO investigators. Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC along in the prevention of VTE after major abdominal surgery: Results of the APOLLO study. *J Thromb Haemost* 3 (Suppl 1), 2005.
567. O'Donnell MJ, Kearon C, Johnson J, Turpie ID, Zondag M, Robinson M, Turpie AGG. Predictors of mid-interval low molecular weight heparin anti-Xa levels. *J Thromb Haemost* 3 (Suppl 1), 2005.
568. O'Donnell MJ, Kearon C, Johnson J, Turpie ID, Zondag M, Robinson M, Turpie AGG. Residual anticoagulant activity following bridging low molecular weight heparin: prevalence and risk factors. *J Thromb Haemost* 3 (Suppl 1), 2005.
569. Turpie AGG, Douketis J. Bridging anticoagulation with enoxaparin is effective and safe in patients with a mechanical heart valve (MHV) who require temporary interruption of vitamin K antagonist (VKA) therapy. *J Thromb Haemost* 3 (Suppl 1), 2005.
570. Tapson VF, Spyropoulos AC, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Pavanello R, Turpie AGG, Fitzgerald G, Anderson Jr. FA for the IMPROVE investigators. Does body weight influence physician practices for providing venous Thromboembolism prophylaxis to acutely ill medical patients: Findings from IMPROVE. *J Thromb Haemost* 3 (Suppl 1), 2005.
571. Piovela F, Wang CJ, Lee LH, Lee WC, Turpie AG, Gallus A, Planes A, Passera R for the AIDA Investigators. Long-term outcomes after deep vein thrombosis in Asia. The AIDA-extension study. *J Thromb Haemost* 3 (Suppl 1), 2005.
572. Piovela F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, Turpie AG, Gallus A, Planes A, Passera R, Rouillon A for the AIDA Investigators. High rate of deep vein thrombosis in Asia after major orthopedic surgery: an epidemiological study with mandatory bilateral venography and central independent adjudication. *J Thromb Haemost* 3 (Suppl 1), 2005.

573. Kwong LM, Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. The benefit-to-risk ratio of fondaparinux thromboprophylaxis in patients undergoing major orthopedic surgery is independent of age. *J Thromb Haemost* 3 (Suppl 1), 2005.
574. Turpie AGG for the PROVE Investigators. Clinical history, risk factors and use of VTE prophylaxis in patients with symptomatic DVT in China. *J Thromb Haemost* 3 (Suppl 1), 2005.
575. Turpie AGG for the PROVE Investigators. A characterization of patients with symptomatic DVT in India. *J Thromb Haemost* 3 (Suppl 1), 2005.
576. Turpie AGG, Fisher WD, Bauer K, Kwong L, Gent M, Misselwitz F for the ODIXa-KNEE Investigators. An oral, direct factor Xa inhibitor - BAY 59-7939 - for prophylaxis against venous Thromboembolism after total knee replacement: a dose ranging study. *J Thromb Haemost* 3 (Suppl 1), 2005.
577. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turie AGG, Egberts JFM, Lensing AWA for the ARTEMIS Investigators. Thromboprophylaxis with fondaparinux in acutely III medical patients aged 75 years or more, or with moderate renal impairment. *J Thromb Haemost* 3 (Suppl 1), 2005.
578. Cohen AT, Gallus AG, Davidson BL, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA for the ARTEMIS Investigators. Benefit of fondaparinux in medical patients: A subgroup analysis. *J Thromb Haemost* 3 (Suppl 1), 2005.
579. Anderson FA Jr., Decousus H, Fitzgerald G, Bergmann JR, Froehlich JB, Nakamura M, Spyropoulos AC, Zotz RB, Spender F, Turpie AGG for the IMPROVE Investigators. Observed rates of clinically apparent venous Thromboembolism and death due to pulmonary embolism among unselected hospitalised acutely ill medical patients compared to rates predicted from clinical trials. *J Thromb Haemost* 3 (Suppl 1), 2005.
580. Davidson BL, Turpie AGG, kwong LM, Colwell CW Jr. for the FLEXTRA Investigators. *J Thromb Haemost* 3 (Suppl 1), 2005.
581. Douketis Jd, Johnson JA, Turpie AG. Low molecular weight heparin qs bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. *Perspect Vasc Surg Endovasc Ther* June 17(2):176, 2005.
582. Eriksson BI, Turpie AGG. An oral, direct factor Xa inhibitor for thromboprophylaxis after orthopaedic surgery; pooled results. *AAOS*, March 2005.
581. Bauer K, Caprini J, Comp P, Gent M, Muntz J, Turpie AGG. Combined pharmacologic and mechanical prophylaxis for the prevention of VTE after major abdominal surgery: Results of the APOLLO Study. *ASCRS*, Dec 1, 2005.
582. Turpie AGG, Bauer KA, Borris L, Dahl OE, Fraser WD, Gent M, Haas S, Menno, Huisman MV, Kakker AK, Kalebo P, Kwong LM, Homering M, Misselwitz F, Eriksson B. Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa inhibitor: Pooled results of two phase IIb lclinical trials. *Blood* 106 (11), 2005, #277.
583. Schellong SM, Beyer J, Halbritter K, Schmidt B, Turpie AGG, Eriksson BI, Misselwitz F, Kalebo P. VENUS - a study to validate centrally adjudicated venous ultrasound against venography after major orthopaedic surgery. *Blood* 106 (11), 2005, #281.

584. Monreal M, Zotz RB, Decousus H, Chong BH, Merli G, Pavanello R, Pini M, Turpie AGG, Huand W, Anderson FA. Influence of perceived risk factors for bleeding on venous thromboembolism prophylaxis practices in acutely ill medical patients: findings from IMPROVE. *Blood* 106 (11), 2005. #917
585. Eriksson BI, Turpie AGG, Lassen MR, Prins MH, Agnelli G, Gaillard ML, Meems B (Intr by Jawed Fareed). YM150, an oral direct factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study. *Blood* 106 (11), 2005. #1865
586. Piovella F, Anderson FA, Decousus H, Fitzgerald G, Bergmann J-F, kakkar AK, Spyropoulos AC, Zotz RB, Spencer FA, Turpie AGG for the IMPROVE investigators. Rates of clinically apparent venous thromboembolism and death resulting from pulmonary embolism among unselected hospitalised acutely ill medical patients versus rats predicted from clinical studies. *Blood* 106 (11), 2005 #1620.
587. Turpie AGG, Bauer KA, Caprini JA, Comp PP, Gent M, Muntz JE. Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of venous thromboembolism after major abdominal surgery: The randomised APOLLO study. *Blood* 106 (11), 2005 #279.
588. Caprini j, Bauer K, Comp P, Gent M, Muntz J, Turpie AGG for the APOLLO investigators. Combined pharmacologic and mechanical prophylaxis for the prevention of VTE after major abdominal surgery: results of the APOLLO study. ASCRS, 2005.
589. Turpie AGG. Is it time to rethink the management of venous thromboembolic disease - evidence-based approached. ASH, Atlanta, 2005.
590. Piovella F, Wang C-J, Lee LH, Lee WC, Turpie AG, Gallus A, Planes A, Passera R. Long-term outcomes of post-surgical deep vein thrombosis in Asia: The AIDA-Extension Study. ASH, December, 2005.
591. Colwell CW, Kwong LM, Turpie AGG. Timing of the first dose of fondaparinux for thromboprophylaxis after major orthopaedic surgery: The FLEXTRA Trial. AAOS, 2006.
592. Turpie AGG. New anticoagulant drugs in venous and arterial thrombosis. Haematologica reports. La Thuile Italy, March 26-April 1, 2006.
593. Caprini J, Bauer K, Comp P, Gent M, Muntz J, Turpie AGG on behalf of the Apollo Investigators. Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC along in the prevention of VTE after major abdominal surgery: An analysis of higher risk patients. ASCRS June 2006.
594. Colwell CW, Kwong LM, Turpie AGG. Timing of the first dose of fondaparinux for thromboprophylaxis after major orthopaedic surgery: The FLEXTRA Trial.

BOOK CHAPTERS

1. Clinical Pharmacology (Dilling) Formulary, 21st Edition. Ed. S. Alstead, 1963.
2. Clinical Pharmacology (Dilling) Revision, 22nd Edition. Ed. S. Alstead and J.G. Macarthur, 1964.
3. Clinical Pharmacology and Therapeutics. "The British Encyclopedia of Medical Practice, Medical Progress", 1964.
4. Clinical Pharmacology and Therapeutics. "The British Encyclopedia of Medical Practice, Medical Progress", 1967.
5. Clinical Pharmacology and therapeutics. "The British Encyclopedia of Medical Practice, Medical Progress", 1968.
6. Platelets: Haemostasis and Thrombosis. "Recent Advances in Haematology", Eds. A. Goldberg and M.C. Brain, 1971.
7. Ancrod - A new anticoagulant. "Human Blood Coagulation," 4th Edition, Eds. R. Biggs and R.G. McFarlane, 1972.
8. The Oesophagus. "Integrated Gastroenterology", Eds. I.A. Gillespie and T.J. Thomson, 1972.
9. Ancrod - a new anticoagulant. "Human Blood Coagulation", 4th Edition (Revised), Eds. R. Biggs and R.G. McFarlane, 1973.
10. Nonpharmacologic prophylaxis against venous thrombosis: Prevention of venous thrombosis in neurosurgical patients with intermittent calf compression. "Venous Thromboembolism: Prevention and Management", Chapter 10, Eds. J.L. Madden and M. Hume, 1976.
11. The role of platelets in thrombosis. "The Detection and Treatment of Thromboembolism", Eds. C.D. Forbes and N. MacKay, 1977.
12. The use of antiplatelet agents in the prevention of arterial thrombosis. "The Detection and Treatment of Thromboembolism", Eds. C.D. Forbes and N. MacKay, 1977.
13. Platelet Suppressant Therapy. "Venous and Arterial Thrombosis", Eds. J. Joist and L.A. Sherman, 1979.
14. Thromboembolic Cerebral Vascular Diseases "Clinical Textbook on Thrombosis", W.B. Saunders Company, 1980.
15. Genton E, Turpie AGG: Venous thromboembolism associated with gynaecological surgery. Symposium on Operative Gynaecology. W. DroegemueLLer (Eds), Clinical Obstetrics and Gynaecology 23:209-242, 1980.
16. Antithrombotic effects of drugs which suppress platelet function: Their potential in preventing growth of tumor cells. "Interaction of Platelets and Tumor Cells" Alan R. Liss Inc. New York, pp 31-62, 1982.
17. Blood tests for the diagnosis of thromboembolism "Cardiology" Eds. E.I. Chazov, V.N. Smirnov, R.G. Oganov, Plenum Publishing, pp 417-422, 1984.

18. Doyle DJ, Turpie AGG, Cairns JA, Holder DA, McEwan MP: Systemic lytic effects and coagulation changes with intravenous thrombolytic therapy in evolving myocardial infarction. "Progress in Fibrinolysis VII" Davidson JF, Donati MB, Coccheri (Eds) Churchill Livingstone, 1985.
19. Venous Thromboembolism "Current Therapy in Hematology-Oncology" Bayliss TM, Brain MC, Cherniack RM (Eds) B.C. Decker, 1987.
20. Thrombosis prevention and treatment in spinal cord injured patients, "Spinal Cord Rehabilitation", Bloch RF, Basbaum M (Eds), Williams and Wilkins, 212-240, 1986.
21. Antiplatelet drugs in ischemic heart disease, coronary artery bypass or peripheral artery surgery. "Internal Medicine Today and Tomorrow", Oda T, Hamaguchi A, Homma M, Kawai C (Eds), 403-407, 1986.
22. Thrombolytic therapy in venous thromboembolism "Tissue Plasminogen Activator in Thrombolytic therapy" Sobel BE, Collen D, Grossbard EB (Eds), Marcel Dekker, Inc. New York and Basel, 1987.
23. Thrombolytic therapy in venous thromboembolism "Thrombose - diagnostiek, preventie en behandelings anno" J.W. ten Cate (Ed), 1986.
24. Thrombolysis in deep vein thrombosis "Thrombolysis in Cardiovascular Disease" Julian D, Kubler W, Norris RM, Swan HJC, Collen D, Verstraete M (Eds), 397-408, 1989.
25. Oczkowski WJ, Turpie AGG: Antithrombotic treatment of cerebrovascular disease "Antithrombotic Therapy" Bailliere's Clinical Haematology (International Practice and Research) J. Hirsh (ed): 3 (3) 781-813, 1990.
26. Turpie AGG, LeClerc JR: Prophylaxis of venous thromboembolism. in "Venous Thromboembolic Disorders" Lea & Febiger Publishers, LeClerc J (Ed), 303-345, 1990.
27. Hirsh J, Levine M, Turpie AGG: Prevention de la maladie thrombo-embolique. "Embolie pulmonaire et thrombose veineuse profonde" Simonneau G, Huet Y (Ed), 167-178, 1991.
28. Turpie AGG: Principals of thromboprophylaxis in Pregnancy and after Gynaecological Surgery. "Haemostasis and Thrombosis in Obstetrics and Gynaecology". Greer IA, Turpie AGG, Forbes CD (eds). Chapman and Hall 1991 pp 305-315.
29. Turpie AGG: Thrombolytic therapy in acute venous thrombosis. "Technologies in Vascular Surgery". Yao JST, Pearce WH (eds). W.B. Saunders Company 1992 pp 504-511.
30. Turpie AGG: La terapia trombolitica nella trombosi venosa "Trombolisi Yearbook" G. Agnelli (ed). Excerpta Medica 1992 pp 143-153.
31. Turpie AGG: Antithrombotic therapy following heart valve replacement. "Thrombosis and its Management" Poller L, Thomson JM (eds). Churchill Livingstone 1992 pp 182-187.
32. New concepts in stroke pathophysiology and prevention. Sanofi Winthrop Symposium to the Second International Stroke Conference N.M. Bornstein, A.G.G. Turpie (ed), Geneva, May 15, 1993.
33. Turpie AGG: La terapia trombolitica nella trombosi venosa "Trombolisi Yearbook 1994" G. Agnelli (ed). Excerpta Medica 1994 pp 141-155.

34. Prins MH, Turpie AGG: Diagnosis and treatment of venous thromboembolism. "Haemostasis and Thrombosis" Bloom AL, Forbes CD, Thomas DP, Tuddenham EG (ed). Churchill Livingstone 1994 pp 1381-1414.
35. Ginsberg JS, Murmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, Levine MN, Panju AA, Powers P, Stevens P, Turpie AGG et al. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. "Prevention of Venous Thrombosis" M.T. Nurmohamed (ed). Haveka BV, Amsterdam, The Netherlands, 1994.
36. Turpie AGG. Orgaran (ORG 10172): A low molecular weight heparin. "Prevention of Venous Thromboembolism" Bergqvist D, Comerota AJ, Nicolaidis AN, Scurr JH (ed). Med-Orion Publishing 1994 pp 173-180.
37. Turpie AGG. Oral anticoagulants and antiplatelet drugs. "Prevention of Venous Thromboembolism" Bergqvist D, Comerota AJ, Nicolaidis AN, Scurr JH (ed). Med-Orion Publishing 1994 pp 173-180.
38. Turpie AGG. Thrombolytic therapy in venous thrombosis. Thrombolysis Yearbook, 1994 pp 151-166.
39. Prins MH, Turpie AGG. Management of venous thromboembolism. "A Textbook of Vascular Medicine". Tooke E, Lowe G (ed). Arnold Publishing, 1995, pp 515-537.
40. Turpie AGG. Neurosurgery and stroke patients. "Venous Thromboembolism: An Evidence-Based Atlas". Hull R, Raskob G, Pineo G (eds). Futura Publishing Co., 1996, pp 63-66.
41. Turpie AGG. Danaparoid. "Cardiovascular Drug Therapy" Messerli FH (editor) Saunders Publishing, 1996, pp 1505-1510.
42. Turpie AGG. Enoxaparin (Lovenox). "Cardiovascular Drug Therapy" Messerli FH (editor) Saunders Publishing, 1996, pp 1511-1517.
43. Turpie AGG. La Terapia trombolitica nella trombosi venosa. "Trombolisi Yearbook, 1997", G. Agnelli (ed), 1996 pp 165-183.
44. Turpie AGG. Valvular heart disease and heart valve prostheses. "Oral Anticoagulants", L. Poller, J. Hirsh (eds), 1997 pp 143-148.
45. Turpie AGG. La terapia trombolitica nella trombosi venosa. "Trombolisi Yearbook", G. Agnelli (ed), 1998 pp 181-201.
46. Ageno W, Turpie AGG. Heparinoids. "Cardiovascular Thrombosis", M. Verstraete, V. Fuster, E. Topol (ed), 1998 pp 221-234.
47. Turpie AGG. Secondary prevention of deep vein thrombosis and pulmonary embolism. "Cardiovascular Thrombosis", M. Verstraete, V. Fuster, E. Topol (ed), 1998 pp 683-689.
48. Turpie AGG. Antithrombotic therapy after heart valve replacement. "Evidence Based Cardiology" S. Yusuf, J.A. Cairns, A.J. Gamm, E.L. Fallen, B.J. Gersh (ed), 1998 pp 905-911.
49. Turpie AGG. Venous Thromboembolism. "Therapeutic Choices". Chapter 31; pp 249-255, 1998.
50. Turpie AGG et al. Acute Coronary Syndromes. International Cardiology Forum. Monograph Series, 2000.

51. Turpie AGG. Venous thromboembolism. Therapeutic Choices. Chapter 31;273-280, 2000.
52. Turpie AGG, Ageno W. Antithrombotic therapy after heart valve replacement. "Evidence Based Cardiology" S. Yusuf, J.A. Cairns, A.J. Gamm, E.L. Fallen, B.J. Gersh (ed), 2002 pp 832-836.
53. Turpie AGG. Venous thromboembolism. Therapeutic Choices. Chapter 31:358-369, 2003.
54. Turpie AG, Ageno W. Venous thromboembolism: Pathophysiology and diagnosis. In Therapeutic Strategies in Thrombosis. Chapter 17, 2006.